00017101552025FYfalsehttp://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2025#SellingGeneralAndAdministrativeExpenseP5YP1Yhttp://fasb.org/us-gaap/2025#AssetImpairmentChargeshttp://fasb.org/us-gaap/2025#AssetImpairmentChargesP1YP1YP1Yhttp://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2025#LongTermDebtAndCapitalLeaseObligationsCurrenthttp://fasb.org/us-gaap/2025#LongTermDebtAndCapitalLeaseObligationsCurrenthttp://fasb.org/us-gaap/2025#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2025#LongTermDebtAndCapitalLeaseObligationsP5Yhttp://fasb.org/us-gaap/2025#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2025#InterestIncomeExpenseNonoperatingNet39298iso4217:USDxbrli:sharesiso4217:USDxbrli:shareseye:storeeye:storeBrandeye:corporationxbrli:pureeye:installmenteye:officereye:segment00017101552024-12-292026-01-0300017101552025-06-2800017101552026-02-2000017101552026-01-0300017101552024-12-280001710155eye:ProductSalesMember2024-12-292026-01-030001710155eye:ProductSalesMember2023-12-312024-12-280001710155eye:ProductSalesMember2023-01-012023-12-300001710155eye:ServicesAndPlansMember2024-12-292026-01-030001710155eye:ServicesAndPlansMember2023-12-312024-12-280001710155eye:ServicesAndPlansMember2023-01-012023-12-3000017101552023-12-312024-12-2800017101552023-01-012023-12-300001710155us-gaap:CommonStockMember2022-12-310001710155us-gaap:AdditionalPaidInCapitalMember2022-12-310001710155us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001710155us-gaap:RetainedEarningsMember2022-12-310001710155us-gaap:TreasuryStockCommonMember2022-12-3100017101552022-12-310001710155us-gaap:CommonStockMember2023-01-012023-12-300001710155us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-300001710155us-gaap:TreasuryStockCommonMember2023-01-012023-12-300001710155us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-300001710155us-gaap:RetainedEarningsMember2023-01-012023-12-300001710155us-gaap:CommonStockMember2023-12-300001710155us-gaap:AdditionalPaidInCapitalMember2023-12-300001710155us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-300001710155us-gaap:RetainedEarningsMember2023-12-300001710155us-gaap:TreasuryStockCommonMember2023-12-3000017101552023-12-300001710155us-gaap:CommonStockMember2023-12-312024-12-280001710155us-gaap:AdditionalPaidInCapitalMember2023-12-312024-12-280001710155us-gaap:TreasuryStockCommonMember2023-12-312024-12-280001710155us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-312024-12-280001710155us-gaap:RetainedEarningsMember2023-12-312024-12-280001710155us-gaap:CommonStockMember2024-12-280001710155us-gaap:AdditionalPaidInCapitalMember2024-12-280001710155us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-280001710155us-gaap:RetainedEarningsMember2024-12-280001710155us-gaap:TreasuryStockCommonMember2024-12-280001710155us-gaap:CommonStockMember2024-12-292026-01-030001710155us-gaap:AdditionalPaidInCapitalMember2024-12-292026-01-030001710155us-gaap:TreasuryStockCommonMember2024-12-292026-01-030001710155us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-292026-01-030001710155us-gaap:RetainedEarningsMember2024-12-292026-01-030001710155us-gaap:CommonStockMember2026-01-030001710155us-gaap:AdditionalPaidInCapitalMember2026-01-030001710155us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-030001710155us-gaap:RetainedEarningsMember2026-01-030001710155us-gaap:TreasuryStockCommonMember2026-01-030001710155us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2026-01-030001710155us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-12-280001710155eye:February2022RepurchaseProgramMember2022-02-232022-02-230001710155eye:February2022RepurchaseProgramMember2022-02-230001710155eye:February2022RepurchaseProgramMember2023-01-012023-12-300001710155eye:February2024ShareRepurchaseMember2023-12-300001710155eye:February2024ShareRepurchaseMember2024-02-230001710155eye:February2024ShareRepurchaseMember2023-12-312024-12-280001710155eye:February2024ShareRepurchaseMember2024-12-292026-01-030001710155eye:February2024ShareRepurchaseMember2026-01-030001710155eye:March2026ShareRepurchaseMemberus-gaap:SubsequentEventMember2026-03-020001710155eye:TheCARESActMember2026-01-030001710155eye:TheCARESActMember2024-12-280001710155eye:SupplyVendorsTopThreeMemberus-gaap:SupplierConcentrationRiskMembereye:ContactLensesInventoryMember2024-12-292026-01-030001710155eye:SupplyVendorsTopOneMemberus-gaap:SupplierConcentrationRiskMembereye:GlassesLensesInventoryMember2024-12-292026-01-030001710155eye:SupplyVendorsTopTwoMemberus-gaap:SupplierConcentrationRiskMembereye:FramesInventoryMember2024-12-292026-01-030001710155us-gaap:BuildingMember2026-01-030001710155srt:MinimumMemberus-gaap:EquipmentMember2026-01-030001710155srt:MaximumMemberus-gaap:EquipmentMember2026-01-030001710155srt:MinimumMembereye:InformationSystemsHardwareAndSoftwareMember2026-01-030001710155srt:MaximumMembereye:InformationSystemsHardwareAndSoftwareMember2026-01-030001710155us-gaap:FurnitureAndFixturesMember2026-01-030001710155srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2026-01-030001710155srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2026-01-030001710155eye:OtherPropertyAndEquipmentUnderLeaseArrangementMember2026-01-030001710155us-gaap:InterestRateSwapMember2025-12-230001710155srt:MinimumMember2024-12-292026-01-030001710155srt:MaximumMember2024-12-292026-01-030001710155eye:CustomerManagedCarePayorsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-12-292026-01-030001710155us-gaap:EmployeeSeveranceMember2024-12-292026-01-030001710155us-gaap:EmployeeSeveranceMember2023-12-312024-12-280001710155us-gaap:EmployeeSeveranceMember2023-01-012023-12-300001710155srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2024-12-292026-01-030001710155srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2024-12-292026-01-030001710155us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMembereye:WalmartMSAAndACLensMember2024-12-292026-01-030001710155us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMembereye:WalmartMSAAndACLensMember2023-12-312024-12-280001710155us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMembereye:WalmartMSAAndACLensMember2023-01-012023-12-300001710155eye:ProductSalesMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMembereye:WalmartMSAAndACLensMember2023-12-312024-12-280001710155eye:ProductSalesMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMembereye:WalmartMSAAndACLensMember2023-01-012023-12-300001710155eye:ServicesAndPlansMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMembereye:WalmartMSAAndACLensMember2023-12-312024-12-280001710155eye:ServicesAndPlansMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMembereye:WalmartMSAAndACLensMember2023-01-012023-12-300001710155us-gaap:TradeAccountsReceivableMember2026-01-030001710155us-gaap:TradeAccountsReceivableMember2024-12-280001710155eye:OtherReceivablesMember2026-01-030001710155eye:OtherReceivablesMember2024-12-280001710155us-gaap:LandAndBuildingMember2026-01-030001710155us-gaap:LandAndBuildingMember2024-12-280001710155us-gaap:EquipmentMember2026-01-030001710155us-gaap:EquipmentMember2024-12-280001710155eye:InformationSystemsHardwareAndSoftwareMember2026-01-030001710155eye:InformationSystemsHardwareAndSoftwareMember2024-12-280001710155us-gaap:FurnitureAndFixturesMember2024-12-280001710155us-gaap:LeaseholdImprovementsMember2026-01-030001710155us-gaap:LeaseholdImprovementsMember2024-12-280001710155us-gaap:ConstructionInProgressMember2026-01-030001710155us-gaap:ConstructionInProgressMember2024-12-280001710155eye:OwnedAndHostStoreBrandsMember2026-01-030001710155eye:OwnedAndHostStoreBrandsMember2024-12-280001710155eye:TrademarksAndTradenamesEyeglassWorldMembereye:OwnedAndHostStoreBrandsMember2024-12-292026-01-030001710155eye:TrademarksAndTradenamesAmericasBestContactsAndEyeglassesMembereye:OwnedAndHostStoreBrandsMember2026-01-030001710155eye:TrademarksAndTradenamesEyeglassWorldMembereye:OwnedAndHostStoreBrandsMember2026-01-030001710155eye:TrademarksAndTradenamesEyeglassWorldMember2023-12-312024-12-280001710155eye:TrademarksAndTradenamesAmericasBestContactsAndEyeglassesMember2026-01-030001710155eye:TrademarksAndTradenamesAmericasBestContactsAndEyeglassesMember2024-12-280001710155eye:TrademarksAndTradenamesEyeglassWorldMember2026-01-030001710155eye:TrademarksAndTradenamesEyeglassWorldMember2024-12-280001710155eye:ContractsAndRelationshipsFredMeyerMember2026-01-030001710155eye:ContractsAndRelationshipsFredMeyerMember2024-12-280001710155us-gaap:OtherIntangibleAssetsMember2026-01-030001710155us-gaap:OtherIntangibleAssetsMember2024-12-280001710155eye:ContractsAndRelationshipsFredMeyerMember2024-06-302024-09-280001710155eye:ConvertibleSeniorNotesDueIn2025Memberus-gaap:ConvertibleDebtMember2026-01-030001710155eye:ConvertibleSeniorNotesDueIn2025Memberus-gaap:ConvertibleDebtMember2024-12-280001710155eye:FirstLienTermLoanADueJuly132028Memberus-gaap:LoansPayableMember2026-01-030001710155eye:FirstLienTermLoanADueJuly132028Memberus-gaap:LoansPayableMember2024-12-280001710155eye:ConvertibleSeniorNotesDueIn2025Memberus-gaap:ConvertibleDebtMember2020-05-310001710155eye:ConvertibleSeniorNotesDueIn2025Memberus-gaap:ConvertibleDebtMember2023-01-012023-12-300001710155eye:ConvertibleSeniorNotesDueIn2025Memberus-gaap:ConvertibleDebtMember2023-12-300001710155eye:ConvertibleSeniorNotesDueIn2025Memberus-gaap:ConvertibleDebtMember2023-12-312024-12-280001710155eye:ConvertibleSeniorNotesDueIn2025Memberus-gaap:ConvertibleDebtMember2024-12-292026-01-030001710155eye:CreditAgreementMember2023-06-132023-06-130001710155eye:CreditAgreementMembersrt:MinimumMember2023-06-132023-06-130001710155eye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-132023-06-130001710155eye:DebtCovenantTermOneMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-130001710155us-gaap:SecuredOvernightFinancingRateSofrMembereye:DebtCovenantTermOneMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-132023-06-130001710155us-gaap:BaseRateMembereye:DebtCovenantTermOneMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-132023-06-130001710155eye:DebtCovenantTermTwoMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-130001710155us-gaap:SecuredOvernightFinancingRateSofrMembereye:DebtCovenantTermTwoMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-132023-06-130001710155us-gaap:BaseRateMembereye:DebtCovenantTermTwoMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-132023-06-130001710155eye:DebtCovenantTermThreeMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-130001710155us-gaap:SecuredOvernightFinancingRateSofrMembereye:DebtCovenantTermThreeMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-132023-06-130001710155us-gaap:BaseRateMembereye:DebtCovenantTermThreeMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-132023-06-130001710155eye:DebtCovenantTermFourMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-130001710155us-gaap:SecuredOvernightFinancingRateSofrMembereye:DebtCovenantTermFourMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-132023-06-130001710155us-gaap:BaseRateMembereye:DebtCovenantTermFourMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-132023-06-130001710155us-gaap:RevolvingCreditFacilityMemberus-gaap:OtherAssetsMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2026-01-030001710155eye:TermLoanMemberus-gaap:OtherNoncurrentLiabilitiesMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2026-01-030001710155eye:CreditAgreementMemberus-gaap:LineOfCreditMember2023-01-012023-12-300001710155eye:TermLoanMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2024-08-090001710155eye:TermLoanMembereye:CreditAgreementMemberus-gaap:LineOfCreditMember2024-12-280001710155us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2026-01-030001710155eye:TwoThousandSeventeenOmnibusIncentivePlanMember2026-01-030001710155eye:TwoThousandSeventeenOmnibusIncentivePlanMember2024-06-120001710155eye:TwoThousandFourteenStockIncentivePlanForKeyEmployeesOfNationalVisionHoldingsIncMember2026-01-030001710155eye:StockIncentivePlansMember2024-12-292026-01-030001710155eye:AssociateStockPurchasePlanMember2026-01-030001710155us-gaap:EmployeeStockOptionMember2024-12-292026-01-030001710155us-gaap:EmployeeStockOptionMember2023-12-312024-12-280001710155us-gaap:EmployeeStockOptionMember2023-01-012023-12-300001710155eye:RestrictedStockUnitsAndPerformanceSharesMember2024-12-292026-01-030001710155eye:RestrictedStockUnitsAndPerformanceSharesMember2023-12-312024-12-280001710155eye:RestrictedStockUnitsAndPerformanceSharesMember2023-01-012023-12-300001710155eye:AssociateStockPurchasePlanMember2024-12-292026-01-030001710155eye:AssociateStockPurchasePlanMember2023-12-312024-12-280001710155eye:AssociateStockPurchasePlanMember2023-01-012023-12-300001710155eye:RestrictedStockUnitsAndPerformanceSharesMember2026-01-030001710155eye:StockOptionServiceBasedMember2024-12-292026-01-030001710155eye:StockOptionServiceBasedMember2024-12-280001710155eye:StockOptionServiceBasedMember2023-12-312024-12-280001710155eye:StockOptionServiceBasedMember2026-01-030001710155eye:StockOptionServiceBasedMember2023-01-012023-12-300001710155eye:StockOptionPerformanceBasedMember2024-12-292026-01-030001710155eye:StockOptionPerformanceBasedMember2024-12-280001710155eye:StockOptionPerformanceBasedMember2023-12-312024-12-280001710155eye:StockOptionPerformanceBasedMember2026-01-030001710155eye:StockOptionPerformanceBasedMember2023-01-012023-12-300001710155us-gaap:RestrictedStockUnitsRSUMember2024-12-280001710155us-gaap:PerformanceSharesMember2024-12-280001710155us-gaap:RestrictedStockUnitsRSUMember2024-12-292026-01-030001710155us-gaap:PerformanceSharesMember2024-12-292026-01-030001710155us-gaap:RestrictedStockUnitsRSUMember2026-01-030001710155us-gaap:PerformanceSharesMember2026-01-030001710155us-gaap:RestrictedStockUnitsRSUMember2023-12-312024-12-280001710155us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-300001710155us-gaap:PerformanceSharesMember2023-12-312024-12-280001710155us-gaap:PerformanceSharesMember2023-01-012023-12-300001710155us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-12-292026-01-030001710155eye:AssociateStockPurchasePlanMember2024-12-292026-01-030001710155stpr:TX2023-12-312024-12-280001710155stpr:TX2023-01-012023-12-300001710155us-gaap:DomesticCountryMember2026-01-030001710155us-gaap:StateAndLocalJurisdictionMember2026-01-030001710155eye:OwnedAndHostStoreBrandsMember2024-12-292026-01-030001710155us-gaap:TransferredAtPointInTimeMember2024-12-292026-01-030001710155us-gaap:TransferredAtPointInTimeMember2023-12-312024-12-280001710155us-gaap:TransferredAtPointInTimeMember2023-01-012023-12-300001710155us-gaap:TransferredOverTimeMember2024-12-292026-01-030001710155us-gaap:TransferredOverTimeMember2023-12-312024-12-280001710155us-gaap:TransferredOverTimeMember2023-01-012023-12-300001710155eye:ProductProtectionPlanArrangementMember2024-12-280001710155eye:EyeCareClubArrangementMember2024-12-280001710155eye:ProductProtectionPlanArrangementMember2024-12-292026-01-030001710155eye:EyeCareClubArrangementMember2024-12-292026-01-030001710155eye:ProductProtectionPlanArrangementMember2026-01-030001710155eye:EyeCareClubArrangementMember2026-01-030001710155eye:ProductProtectionPlanArrangementMember2023-12-300001710155eye:EyeCareClubArrangementMember2023-12-300001710155eye:ProductProtectionPlanArrangementMember2023-12-312024-12-280001710155eye:EyeCareClubArrangementMember2023-12-312024-12-2800017101552026-01-042026-01-0300017101552027-01-032026-01-0300017101552028-01-022026-01-030001710155eye:FederalDistrictCourtForTheNorthernDistrictOfCaliforniaMember2025-10-102025-10-100001710155eye:NorthernDistrictOfGeorgiaFederalCourtMember2023-01-270001710155eye:StockholderDerivativeComplaintMemberus-gaap:SubsequentEventMember2026-02-112026-02-110001710155eye:StockholderDerivativeComplaintMember2025-10-032025-10-0300017101552024-12-172024-12-170001710155us-gaap:InterestRateSwapMember2025-12-310001710155us-gaap:InterestRateSwapMember2024-12-292026-01-030001710155eye:InterestRateCollarMember2023-12-312024-12-280001710155eye:InterestRateCollarMember2023-01-012023-12-300001710155us-gaap:InterestRateSwapMemberus-gaap:AccruedLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2026-01-030001710155us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2026-01-030001710155us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2026-01-030001710155eye:StockOptionsRestrictedStockUnitsRSUsAndConvertibleNotesMember2024-12-292026-01-030001710155eye:StockOptionsRestrictedStockUnitsRSUsAndConvertibleNotesMember2023-12-312024-12-280001710155eye:StockOptionsRestrictedStockUnitsRSUsAndConvertibleNotesMember2023-01-012023-12-300001710155us-gaap:OperatingSegmentsMembereye:ProductSalesMembereye:OwnedAndHostStoreBrandsMember2024-12-292026-01-030001710155us-gaap:OperatingSegmentsMembereye:ProductSalesMembereye:OwnedAndHostStoreBrandsMember2023-12-312024-12-280001710155us-gaap:OperatingSegmentsMembereye:ProductSalesMembereye:OwnedAndHostStoreBrandsMember2023-01-012023-12-300001710155us-gaap:OperatingSegmentsMembereye:ServicesAndPlansMembereye:OwnedAndHostStoreBrandsMember2024-12-292026-01-030001710155us-gaap:OperatingSegmentsMembereye:ServicesAndPlansMembereye:OwnedAndHostStoreBrandsMember2023-12-312024-12-280001710155us-gaap:OperatingSegmentsMembereye:ServicesAndPlansMembereye:OwnedAndHostStoreBrandsMember2023-01-012023-12-300001710155us-gaap:OperatingSegmentsMembereye:OwnedAndHostStoreBrandsMember2024-12-292026-01-030001710155us-gaap:OperatingSegmentsMembereye:OwnedAndHostStoreBrandsMember2023-12-312024-12-280001710155us-gaap:OperatingSegmentsMembereye:OwnedAndHostStoreBrandsMember2023-01-012023-12-300001710155us-gaap:CorporateNonSegmentMember2024-12-292026-01-030001710155us-gaap:CorporateNonSegmentMember2023-12-312024-12-280001710155us-gaap:CorporateNonSegmentMember2023-01-012023-12-300001710155us-gaap:MaterialReconcilingItemsMember2024-12-292026-01-030001710155us-gaap:MaterialReconcilingItemsMember2023-12-312024-12-280001710155us-gaap:MaterialReconcilingItemsMember2023-01-012023-12-300001710155eye:EyeglassesAndSunglassesMember2024-12-292026-01-030001710155eye:EyeglassesAndSunglassesMember2023-12-312024-12-280001710155eye:EyeglassesAndSunglassesMember2023-01-012023-12-300001710155eye:ContactLensesMember2024-12-292026-01-030001710155eye:ContactLensesMember2023-12-312024-12-280001710155eye:ContactLensesMember2023-01-012023-12-300001710155eye:AccessoriesAndOtherMember2024-12-292026-01-030001710155eye:AccessoriesAndOtherMember2023-12-312024-12-280001710155eye:AccessoriesAndOtherMember2023-01-012023-12-300001710155eye:ExamMember2024-12-292026-01-030001710155eye:ExamMember2023-12-312024-12-280001710155eye:ExamMember2023-01-012023-12-300001710155eye:ProductProtectionPlansMember2024-12-292026-01-030001710155eye:ProductProtectionPlansMember2023-12-312024-12-280001710155eye:ProductProtectionPlansMember2023-01-012023-12-300001710155eye:EyecareClubsMember2024-12-292026-01-030001710155eye:EyecareClubsMember2023-12-312024-12-280001710155eye:EyecareClubsMember2023-01-012023-12-300001710155us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-280001710155us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-300001710155us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001710155us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-292026-01-030001710155us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-312024-12-280001710155us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-300001710155us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2026-01-030001710155srt:ParentCompanyMember2026-01-030001710155srt:ParentCompanyMember2024-12-280001710155srt:ParentCompanyMember2024-12-292026-01-030001710155srt:ParentCompanyMember2023-12-312024-12-280001710155srt:ParentCompanyMember2023-01-012023-12-300001710155srt:ParentCompanyMember2023-12-300001710155srt:ParentCompanyMember2022-12-3100017101552025-09-282026-01-030001710155eye:L.ReadeFahsMember2025-09-282026-01-030001710155eye:L.ReadeFahsMember2026-01-030001710155eye:AlexWilkesMember2025-09-282026-01-030001710155eye:AlexWilkesMember2026-01-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________________________________________
FORM 10-K
_______________________________________________________________________
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended January 3, 2026
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____
Commission file number 001-38257
_______________________________________________________________________
National Vision Holdings, Inc.
(Exact name of registrant as specified in its charter)
_______________________________________________________________________
| | | | | | | | |
| Delaware | | 46-4841717 |
| (State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
2435 Commerce Ave,
Building 2200
Duluth, Georgia 30096
(Address of principal executive offices)
(770) 822‑3600
(Registrant’s telephone number, including area code)
_______________________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | EYE | Nasdaq |
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | | | | | | | |
| Large accelerated filer | ☒ | | Accelerated filer | ☐ | |
| Non-accelerated filer | ☐ | | Smaller reporting company | ☐ | |
| | | | Emerging growth company | ☐ | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing
reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by
any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of June 28, 2025, the last day of the registrant’s most recently completed second quarter, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $1.3 billion (based upon the closing sale price of the common stock on last trading date of the quarter on the Nasdaq).
Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date
| | | | | | | | |
| Class | | Outstanding at February 20, 2026 |
| Common Stock, $0.01 par value per share | | 79,437,185 |
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant's definitive Proxy Statement for its 2026 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended January 3, 2026.
NATIONAL VISION HOLDINGS, INC. AND SUBSIDIARIES
Table of Contents
| | | | | | | | | | | |
| | | Page |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS | 3 |
RISK FACTORS SUMMARY | 3 |
PART I | 5 |
| Item 1. | Business | 5 |
| Item 1A. | Risk Factors | 16 |
| Item 1B. | Unresolved Staff Comments | 38 |
| Item 1C. | Cybersecurity | 38 |
| Item 2. | Properties | 39 |
| Item 3. | Legal Proceedings | 40 |
| Item 4. | Mine Safety Disclosures | 40 |
PART II | 41 |
| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 41 |
| Item 6. | Reserved | 42 |
| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 42 |
| Item 7A. | Quantitative and Qualitative Disclosures About Market Risk | 59 |
| Item 8. | Financial Statements and Supplementary Data | 61 |
| Item 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 102 |
| Item 9A. | Controls and Procedures | 102 |
| Item 9B. | Other Information | 104 |
| Item 9C. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 104 |
PART III | 104 |
| Item 10. | Directors, Executive Officers and Corporate Governance | 104 |
| Item 11. | Executive Compensation | 106 |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 106 |
| Item 13. | Certain Relationships and Related Transactions, and Director Independence | 106 |
| Item 14. | Principal Accountant Fees and Services | 106 |
PART IV | 107 |
| Item 15. | Exhibits and Financial Statement Schedules | 107 |
| Item 16. | Form 10-K Summary | 109 |
| | Signatures | 110 |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K (this “Form 10-K”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts included in this Form 10-K, including statements concerning our plans, objectives, goals, beliefs, business strategies, future events, business conditions, results of operations, financial position, business outlook, business trends and other information, may be forward-looking statements.
Words such as “believes,” “expects,” “may,” “will,” “should,”, “could,” “seeks,” “intends,” “plans,” “estimates,” “anticipates,” or variations of such words or similar expressions are intended to identify forward-looking statements. The forward-looking statements are not historical facts, or guarantees of future performance and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements.
There are a number of risks, uncertainties and other important factors, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking statements contained in this Form 10-K. These risks and uncertainties include, but are not limited to, those described below in the “Risk Factors Summary,” in Part I. Item 1A. “Risk Factors” and elsewhere in this Form 10-K and those described from time to time in our future reports to be filed with the Securities and Exchange Commission (the “SEC”).
We caution you that the risks, uncertainties and other factors referenced above may not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct or (iv) our strategy, which is based in part on this analysis, will be successful. All forward-looking statements in this Form 10-K, apply only as of the date of this Form 10-K or as of the date they were made and, except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
RISK FACTORS SUMMARY
The following is only a summary of the principal risks that may materially adversely affect our business, financial condition, results of operations or liquidity. The following should be read in conjunction with the more complete discussion of the risk factors we face, which are set forth in the section entitled “Risk Factors” in this Form 10-K.
Risks Related to Our Business and Operations
•Market volatility, an overall decline in the health of the economy, global macroeconomic conditions and other factors may affect consumer spending or behavior, which could materially harm our sales, profitability and financial condition.
•We may not be successful in implementing our strategic initiatives, or in anticipating the impact of important strategic initiatives, and our plans for implementing such initiatives may be altered or delayed due to various factors, which may have an adverse impact on our business and financial results.
•The optical retail industry is highly competitive, and if we do not compete successfully, our business may be materially adversely impacted.
•Our success depends substantially on the value of our owned brands, and failure to maintain, protect, and enhance their value could have a material negative impact on our business, financial condition, and results of operations.
•Our success depends upon our marketing, advertising and promotional efforts. If we are unable to implement them successfully or efficiently, or if our competitors are more effective than we are, we may experience a material adverse effect on our business, financial condition and results of operations.
•If we fail to open and operate new stores in a timely and cost-effective manner or fail to successfully enter new markets, our financial performance could be materially adversely affected.
•Our growth is dependent on our ability to increase sales in existing stores and to successfully reinvest in existing stores.
•If we are unable to successfully implement our pricing strategies, it could have a material adverse impact on our business.
•Failure to recruit and retain vision care professionals for in-store roles or to provide remote care offerings could adversely affect our business, financial condition and results of operations.
•We are a value-based provider and our business model relies on value-based inputs. Factors such as wage rate increases, inflation, cost increases, increases in the price of raw materials and energy prices could have a material adverse effect on our business, financial condition and results of operations.
•We require significant capital to fund our expanding business. If we are unable to maintain sufficient levels of cash flow from our operations, we may not be able to execute or sustain our growth strategy or we may require additional financing, which may not be available to us on satisfactory terms or at all.
•Our growth strategies could strain our existing resources and cause the performance of our existing stores to suffer.
•We are subject to risks associated with leasing substantial amounts of space, including future increases in occupancy costs.
•Our e-commerce and omni-channel business faces distinct risks, and our failure to successfully manage those risks could have a negative impact on our profitability.
•If we fail to retain our existing senior management team, attract qualified new personnel or successfully implement our succession plans, such failure could have a material adverse effect on our business, financial condition and results of operations.
•Our operating results and inventory levels fluctuate on a seasonal basis.
•Catastrophic events, including changing climate and weather patterns leading to severe weather and natural disasters, may cause significant business interruptions and expenditures.
•Certain technological advances, greater availability of, or increased consumer preferences for, vision correction alternatives to prescription eyeglasses or contact lenses, or future drug development for the correction of vision-related problems may reduce the demand for our products and materially adversely impact our business and profitability.
•Our profitability and cash flows may be materially adversely affected if we are not successful in managing our inventory balances and inventory shrinkage.
•We depend on our distribution centers and optical laboratories. The loss of, or disruption in the operations of, one or more of these facilities may adversely affect our ability to process and fulfill customer orders and deliver our products in a timely manner, or at all, and may result in quality issues, which would materially adversely affect our reputation, our business and our profitability.
•If the performance of our Host brands declines or we are unable to maintain or extend our operating relationships with our Host partners, our business, profitability and cash flows may be adversely affected and we may be required to incur impairment charges.
•Sustainability issues, including those related to climate change, could have a material adverse effect on our business, financial condition and results of operations.
Risks Related to Our Dependence on Third Parties
•Our future operational success depends on our ability to develop, maintain and extend relationships with managed vision care companies, vision insurance providers and other third-party payors.
•We rely on third-party coverage and reimbursement, including government programs, for an increasing portion of our revenues, the future reduction of which could materially adversely affect our results of operations.
•We face risks associated with vendors from whom our products and certain services are sourced and are dependent on a limited number of suppliers.
•Our ability to source merchandise and services outside of the U.S. could be adversely impacted by changes in U.S. or international laws, including the imposition of tariffs by the U.S. and the resulting consequences.
•We rely heavily on our information technology systems, as well as those of our vendors, for our business to effectively operate and to safeguard confidential information; any significant failure, inadequacy, interruption or security breach could materially adversely affect our business, financial condition and operations.
Risks Related to Our Legal and Regulatory Environment
•We are subject to extensive state, local and federal vision care and healthcare laws and regulations and failure to adhere to such laws and regulations would materially adversely affect our business.
•We are subject to managed vision care laws and regulations and the failure to comply with such laws and regulations could have a materially negative impact on our business, financial condition or results of operations.
•We are subject to rapidly changing and increasingly stringent laws, regulations, contractual obligations, and industry standards relating to privacy, data security and data protection. The restrictions and costs imposed by these laws and other obligations, or our actual or perceived failure to comply with them, could subject us to liabilities that materially adversely affect our business, operations and financial performance.
•We could be materially adversely affected by product liability, product recall or personal injury issues.
•Failure to comply with laws, regulations and enforcement activities or changes in statutory, regulatory, accounting and other legal requirements could materially negatively impact our business, financial condition or results of operations.
•Adverse judgments or settlements resulting from legal proceedings relating to our business operations could materially adversely affect our business, financial condition and results of operations.
•We may not be able to adequately protect our intellectual property, which could harm the value of our brand and materially adversely affect our business.
Risks Related to Our Indebtedness
•We have a significant amount of indebtedness which could adversely affect our business and financial position, including by limiting our business flexibility and preventing us from meeting our debt obligations.
•A change in interest rates may adversely affect our business.
•Our credit agreement contains restrictions that limit our flexibility in operating our business.
Risks Related to Ownership of Common Stock
•Our stock price may be volatile or may decline regardless of our operating performance.
•Because we have no current plans to pay cash dividends on our common stock, investors may not receive any return on investment unless they sell their common stock for a price greater than that which they paid for it.
•We are a holding company with no operations of our own and, as such, we depend on our subsidiaries for cash to fund all of our operations and expenses, including future dividend payments, if any.
•Anti-takeover provisions in our organizational documents could delay or prevent a change of control.
•Our Board of Directors is authorized to issue and designate shares of our preferred stock in additional series without stockholder approval.
•Our certificate of incorporation provides, subject to limited exceptions, that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain stockholder litigation matters, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, associates or stockholders.
•If securities or industry analysts do not publish research or reports about our business or if they downgrade our stock or our sector, our stock price and trading volume could decline.
PART I
Item 1. Business
National Vision Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries are referred to here as “we,” “our,” “us,” “the Company,” or “National Vision.” National Vision Holdings, Inc. conducts substantially all of its activities through its indirect, wholly-owned subsidiary, National Vision, Inc. (“NVI”), and NVI’s subsidiaries.
We operate under one reportable segment, our Owned & Host segment, which includes our two owned brands, America’s Best Contacts and Eyeglasses (“America’s Best”) and Eyeglass World, as well as our Host brands, Vista Optical locations within select Fred Meyer stores and Vista Optical locations on select military bases. See Part II. Item 8. Note 15. “Segment Reporting” for more information.
Our Strategy & Transformation
We are one of the largest optical retailers in the United States (“U.S.”) and a leader in the value segment of the U.S. optical retail industry. We believe that vision is central to quality of life and that people deserve to see their best to live their best. Our mission is to help people by making quality eye care and eyewear more affordable and accessible. We achieve this by providing eye exams, eyeglasses and contact lenses to consumers across the nation. Our range of quality product offerings at multiple price points makes us an attractive destination for consumers of all income levels. As of January 3, 2026, our 2025 fiscal year end, we reach our customers through a diverse portfolio of 1,250 retail stores across four brands, our associated omni-channel consumer websites, and our dedicated e-commerce consumer website, DiscountContacts.com.
Historically, our business model primarily targeted lower-income consumers with a go-to-market strategy focused on merchandise and messaging of the lowest price. We evolved our operating model in light of the impact of Covid to address changing consumer and doctor preferences, including the introduction of cutting edge remote telehealth capabilities, which are now installed in over 800 of our locations. We believe this differentiator greatly improves our ability to provide consistent access to patient care across our network of stores. In fiscal 2024, we began implementing transformation initiatives designed to accelerate long-term growth and strengthen profitability, including new additions to our executive leadership team, continued expansion of exam capacity, and new traffic-driving initiatives.
In 2025, we embarked on the next phase of our transformation, focused on the rapid modernization of our business in the context of contemporary consumer needs and wants. Our strategy is focused around creating a more joyful consumer experience with refreshed merchandising, updated marketing and brand assets, new in-store technologies to support the customer journey, and an updated pricing architecture, all of which allow us to better serve our existing customers and expand our target consumer demographics. During 2025, as an embodiment of our transformation, we refreshed the National Vision and America’s Best brand identities. We also introduced a new America’s Best brand promise, “Every Eye Deserves Better,” which better reflects our customer mix. These consumer-facing strategies are paired with an increased focus on cost optimization and operating margin expansion, all of which are intended to drive the outcome of a stronger core business and improved operating results.
Our strategic framework is based on data-driven insights and analytics to inform our initiatives. We believe that we have tremendous opportunity across four growth vectors where we are under-indexed versus the category:
•Target Customer Segments. Focus on expanding with customers such as those who use managed vision care, progressive wearers, and Outside Rx customers
•Target Product Categories. Enhancing our product offerings to meet customer demand in areas such as premium lens coatings, transitions, advanced materials, and more premium and luxury frames
•Enhanced Customer Experience. Creating joyful in‑store experiences, personalizing shopping journeys, elevating clinical care, seamless doctor-to-retail handoffs, and implementing digital enhancements
•New Store Growth. Expect to open approximately 30 to 35 new stores per year in near term, primarily comprised of America’s Best stores, while we invest in our strategic initiatives and expect to reaccelerate to approximately 60 per year beginning 2028, totaling approximately 240 new stores through 2030
Our Business
We reach customers through a portfolio of brands, which consists of our leading brand, America’s Best, along with our emerging brands, which include Eyeglass World and our Host brands. Across all of our brands we are modernizing our approach to enhance the customer and patient experience in ways we believe will increase customer retention and drive lifetime loyalty.
All of our brands leverage our highly efficient centralized laboratory network and distribution system, which helps us minimize production and distribution costs. As one of the largest purchasers of eyeglass frames, eyeglass lenses and contact lenses in the U.S., we also benefit from centralized procurement efforts and purchasing economies of scale.
During fiscal 2025, we opened 33 new stores, and we plan to open approximately 30 to 35 new stores in fiscal 2026, primarily comprised of America’s Best stores. Since 2006, we have opened over 1,100 stores in the aggregate, including 1,072 stores under our America’s Best and Eyeglass World retail brands. Our new store model generally targets a store size between 2,500 to 4,500 square feet and an average new store cash investment of approximately $0.4 million to $0.6 million, in furniture, fixtures, leaseholds and equipment for new stores, net of tenant incentives. Our new store model targets sales in the fifth year of operation in the range of $1.5 million to $1.7 million, with at least 55% of year five sales targeted in the first full year of operation. Our new store model targets vary for America’s Best and Eyeglass World stores to reflect differences by brand, markets and geography. The majority of our owned stores have achieved profitability during the second year of operation and have paid back invested capital in three to five years.
Our America’s Best Brand. The America’s Best brand promise, “Every Eye Deserves Better,” launched in 2025 and signifies our commitment to attainable and accessible high-quality eye care and delivering outstanding customer experiences for our customers and patients. America’s Best is committed to providing the best value in the markets in which it operates, starting with our customers and patients and determining personalized value based on their lifestyle needs. In our 1,057 America’s Best stores, vision care services are provided by optometrists employed either by us or by independent professional corporations or similar entities. By leveraging our efficient centralized laboratory network, America’s Best stores minimize processing costs and drive significant economies of scale. America’s Best stores are primarily located in high-traffic strip centers next to other value-focused retailers.
Our Eyeglass World Brand. Historically, this brand has been positioned as an eyeglass superstore with a broad selection of designer brands and price points and offers a highly personalized level of service. In our 122 Eyeglass World locations offer eye exams provided by optometrists employed either by us or by independent professional corporations or similar entities, and have on-site laboratories that enable stores to quickly fulfill certain customer orders and make repairs on site. Lens orders that are not completed in store are completed by our centralized laboratory network. These stores are primarily located in freestanding or in-line locations near high-foot-traffic shopping centers.
Throughout fiscal 2025, we focused on strengthening Eyeglass World’s operational foundation, implementing new sales training and enhanced operations to improve the customer and patient experience. In the second half of fiscal 2025, we
initiated a brand positioning review of Eyeglass World as part of its transformation and expect to refresh the brand later in fiscal 2026.
Our Host Brands. We have two Host brands consisting of 53 Vista Optical locations on military bases and 18 Vista Optical locations within select Fred Meyer stores as of January 3, 2026. These brands combine a broad selection of products and attentive customer service with the convenience of one-stop shopping. These brands also utilize our centralized laboratories and provide eye exams principally by independent optometrists in nearly all locations.
Our Omni-Channel and E-Commerce Platforms. We offer our customers an engaging digital shopping experience through an established platform of omni-channel store websites, and our dedicated e-commerce consumer website, DiscountContacts.com. Our omni-channel store websites augment our America’s Best, Eyeglass World and Vista Optical in military brands and provide a customer experience that extends across our in-store, mobile and e-commerce channels. We offer a range of services to customers, including eyeglass purchasing, online scheduling and appointment reminders, contact lens purchasing, “buy-in-store and ship-to-home” capabilities and online frame browsing, among others. Our omni-channel offerings work in concert with these brands to enhance the overall quality of the customer experience. In fiscal 2026, we expect to move our e-commerce consumer websites to a new platform integrated with our new Customer Relationship Management (“CRM”) system to enable a more modern and seamless customer experience.
In the aggregate, sales from our omni-channel and e-commerce platforms, which include “buy-in-store and ship-to-home” transactions, represented approximately 7% of net revenue in each of fiscal year 2025 and 2024.
Our Industry and Competition
We operate in the highly fragmented and growing U.S. optical retail industry, which is defined by The Vision Council to include the sale of exams, frames, lenses, contact lenses, plano sunglasses and readers. According to The Vision Council, the size of the U.S. optical retail industry is estimated to be $69.5 billion in 2025. We believe the industry’s continued growth and its resilience to economic cycles is due in large part to the medical, non-discretionary and recurring nature of eye care purchases.
The majority of eyewear purchases are driven by need, with two primary drivers of demand: (i) diminishing eyesight with increasing age, causing new customers to buy corrective eyewear, and (ii) a steady and consistent replacement cycle as customers replace or purchase new eyewear for a variety of reasons, including changes in prescriptions, fashion trends and necessity (e.g., lost or broken eyewear).
The need for eyesight correction is diagnosed through eye tests and eye exams.
We anticipate that there are several key secular growth trends that will continue to contribute to the stability and growth of the U.S. optical retail industry:
•Aging Population. According to The Vision Council, approximately 80% of adults in the U.S. use some form of vision correction, and there is a significant increase in the use of vision correction above age 45, with further increases above age 55. Given that eyesight deteriorates progressively with age, aging of the U.S. population should result in incremental sales of eyecare and eye exams, and eyewear and related accessories.
•Managed Vision Care Adoption. According to The Vision Council, approximately 70% of consumers reported having some sort of vision care coverage in 2025. With our national scale and evolving product assortment, we believe we are well-positions to allow these customers to maximize the value of their benefit.
•Increased Usage of Computer and Mobile Screens. The U.S. population has experienced a dramatic increase in the amount of time spent viewing electronic screens, and according to the most recent data reported by The Vision Council in 2022, about 90% of American adults reported using digital devices for more than three hours per day with approximately 80% reporting experiencing symptoms of digital eye strain. This is anticipated to result in an increase of vision correction needs.
•Consistent Replacement Cycle. According to the most recent data reported by The Vision Council in 2025, glasses wearers purchase new glasses approximately every two years. Approximately 80% of contacts wearers purchase contact lenses at least once per year. An estimated 51 million people in the United States wear contact lenses that are typically disposable, replaced on a daily, weekly, or monthly basis, driving frequent repurchase.
•Growing Focus on Health and Wellness. The optical retail industry is poised to continue to benefit from an increasing societal focus on health and wellness. Consumers want personalized solutions that allow them to make informed decisions about their health. Additionally, rising healthcare costs are driving a growing emphasis on preventative healthcare. Eye exams can detect a host of physical ailments, such as hypertension or diabetes, and are one of the most inexpensive and effective forms of detection for many of these conditions.
•Momentum in Smart Eyewear. The optical industry is experiencing increased consumer interest in smart eyewear, an emerging category that can integrate vision correction with features such as AI-enablement, hands-
free communication, and seamless integration with smartphones. By appealing to tech‑savvy consumers, smart eyewear can draw new customers into optical retail while also increasing the average ticket size, as these products typically command higher prices than traditional frames and lenses.
The optical retail industry is highly competitive. Competition is generally based upon brand name recognition, price, convenience, selection, service and product quality.
We operate within the value segment of the U.S. optical retail industry, which emphasizes price and affordability. We compete with independent optical retailers who comprise nearly half of the industry, mass merchants and warehouse club stores, specialty retail chains, and independent eye care practitioners and opticians. In the broader optical retail industry, we also compete with large national retailers, both in physical retail locations and online.
We also compete with online sellers of contact lenses and eyewear. The online sale of contact lenses has steadily increased in particular since the passage of the Fairness to Contact Lens Consumers Act. See “Government Regulation” below for more detail. We expect to continue to face competition in the future as companies increasingly employ emerging technologies in the optical retail industry, including, for example, online vision exams.
In our managed care business, we also compete with other managed care payors, several of which are vertically integrated, with substantial retail networks. As a provider under managed care contracts, we may have access to new customers while better serving our existing customers who are covered by managed care by filing claims directly with the payor and collecting only the applicable co-pay amount from these customers. Competition in our managed care business is based on many factors, including price and the density of the provider network. We have, in the past, and may, in the future, experience heightened challenges to be admitted as a provider to these networks or to maintain our status in them.
Our Products and Services
Within our store brands, we primarily offer two products and one service: eyeglasses, contact lenses and eye exams.
Our diverse frame product portfolio encompasses many brand names and thousands of stock keeping units (“SKUs”). Our stores typically stock well-known frame brands, secondary frame brands, direct import and private label frames. Offerings include both brand name designers, like Ray-Ban, Coach and Calvin Klein, and private label options at attractive prices for value-seeking consumers across income demographics. Our brand-name frame offerings are manufactured by market leaders and we partner with several overseas factories to direct source our private label products. During fiscal 2025, we began to enhance our product offering in areas where we are underdeveloped relative to the optical retail category. We added frames at higher price points and enhanced our portfolio offering with premium products to meet consumer demand while remaining the destination for value. We also introduced innovative products such as Ray-Ban Meta smart glasses.
We also offer a broad portfolio of lenses, including single vision, bifocal, and progressive lenses, with a variety of treatments to enhance vision. We have opportunities to evolve our lens mix by increasing our focus on products and technologies such as advanced‑material lenses, premium lens options, specialized coatings, or photochromic lenses (e.g., Transitions). While we offer these solutions today, we remain underpenetrated relative to the category, and elevating our execution and customer education can unlock meaningful growth. Our sales associates play a key role in educating customers about higher‑quality, thinner, and other value‑added lens options that carry higher margins through one-on-one consultative-selling. As a result, a significant number of America’s Best customers and Eyeglass World customers who purchase eyeglasses choose upgraded lenses and/or frames.
In our America’s Best and Eyeglass World stores, we also offer contact lenses from all major contact lens manufacturers, including our own private label brands (Sofmed and Natural Eyes HydraWear, made by CooperVision), along with a variety of eyewear accessories.
Collectively, our broad product offerings deliver consistent financial results and reduce our reliance on any individual product, style or trend.
Eye exam services are provided by optometrists employed by us, or by professional corporations or similar entities owned by eye care practitioners with whom we have contractual arrangements or by independent optometrists who sublease in our store locations. In addition, as part of our efforts to provide quality, accessible eye care, we have deployed a telehealth solution in certain locations that allows optometrists working remotely to provide eye exam services to patients. Through this remote medicine platform, patients still visit our stores for eye care services, but instead of seeing the optometrists in person, the patients are connected with optometrists licensed in their state through video conferencing technology. The optometrists work with trained optometric technicians to collect preliminary data, and then the optometrists control the optometric equipment remotely to conduct the refractions and eye health examinations while communicating with the patients in real time via 2-way synchronous audio and visual connection. As of January 3, 2026, this technology has been enabled in over 800 of our America’s Best locations. We believe remote medicine not only helps provide quality, accessible eye care to more patients, but also helps address constraints in exam capacity from optometrist availability in store. As part of the rollout, we have also invested in the transition to an electronic health record (“EHR”) platform in nearly all America’s Best locations.
The disposable nature of contact lenses means that customers must replenish their contacts frequently and, in order to refill their prescriptions, contact lens users must have a current prescription. For a prescription to be current, customers generally need to have an eye exam every one or two years, depending on the state in which they reside. America’s Best offers its Eyecare Club programs primarily to its contact lens customers. As of January 3, 2026, the Eyecare Club had approximately 1.3 million active members. Eyecare Club members receive two eye exams per year and 10% off all contact lenses and eyeglasses for the duration of the three-year membership, as well as other periodic benefits and discounts, for a one-time fixed payment. The multiyear nature of these memberships, which customers pay in full at the time they join, facilitates repeat traffic to America’s Best stores for exams and contact lens purchases and builds customer loyalty.
See Note 8. “Revenue from Contracts with Customers” in our audited consolidated financial statements included in Part II. Item 8. of this Form 10-K for additional information.
Our Customers
Increasingly, we are using consumer insights and data to drive our strategy and deliver an expanded view of our customer. Historically, we have primarily targeted price-driven consumers, but data shows our customer base leans toward middle income and mirrors broad U.S. demographics. Our customers are pragmatic buyers, who appreciate value regardless of their income level; style leaders, who want more premium products and may have their own prescription in hand; and wellness shoppers with vision benefits, who are looking for great clinical experiences or may have more advanced eye care needs. As we evolve to better attract and serve these customers who are already shopping with us, we believe we have significant runway for growth.
We are keenly focused on expanding our penetration within three key, high-value customer segments:
•Managed Care. Managed Care customers use vision insurance benefits provided through a managed care plan to pay for their eye exam or eyewear purchase. Our managed care business relates to vision care programs and associated benefits provided by stand-alone vision insurance entities, healthcare plans and government programs. National Vision participates as a provider of both vision care and related vision product solutions, including eyeglasses and contact lenses, and primarily participates in private managed care programs.
While our managed care business has continued to grow, we are underpenetrated in the managed care market relative to the broader optical retail industry. In 2025, our managed care business represented 42% of our revenues from continuing operations. We believe we have a clear path to bring the percentage of revenues from managed care payors to 50%. According to The Vision Council, approximately 70% of consumers reported having some sort of vision care coverage in 2025. With our national scale and evolving product assortment, we believe we are well-positioned to win with this growing customer segment by allowing them to maximize the value of their vision insurance benefits.
•Outside Rx. Outside Rx customers already have a prescription from another provider and come to one of our retail locations or omni-channel web sites to purchase eyeglasses or contact lenses. We believe that we are well positioned to win with Outside Rx customers, including by tailoring marketing messaging to better reach these consumers and evolving adjusting selling techniques and product mix to better serve them in the store.
•Progressive Wearers. Progressive Wearers are customers who rely on progressive, “no‑line” bifocal lenses, and represent a high‑value segment due to their need for more advanced, premium lens solutions.
Our Sales and Marketing
We developed our marketing and sales strategy based on the knowledge we have of our customers. Our brands are positioned to stand for great value and great service, both of which resonate with our target consumers and leave a lasting impression that is distinct from the competition.
During fiscal 2025, we began a transformation of our sales strategy, which starts with our customers and patients and determines personalized value based on their lifestyle needs. To accomplish this, we are investing in sales associate training to transform the selling approach from a more transactional approach focused on price to a more consultative approach designed to provide the best value. We also continue to invest in digital tools, using technology to complement the selling experience wherever possible, to personalize the customer experience and showcase products and features.
In fiscal 2025, we launched a new customer experience platform to centrally manage all customer data, communications and analytics, which replaced our previous CRM system. Our CRM system is used to collect customer demographic data. With this information and the third-party data that we use to supplement the customer information, we enhance our customer relationships with communications based on their individual vision needs and interests to help improve existing customer retention. We believe our new CRM system will allow us to build dynamic, omnichannel customer journeys based on individual behaviors and preferences in order to maximize customer engagement and increase customer retention through personalized experiences across our brands. In fiscal 2026, we expect to move our e-commerce consumer websites to a new platform integrated with our new CRM system to enable a more modern and seamless customer experience. We believe these investments, along with maintenance of our existing information technology capabilities, will provide the flexibility and capacity to accommodate our future growth plans.
In addition to our CRM system, digital advertising is a critical component of our media mix, as we believe both of these programs generate a high rate of return. Potential customers gain awareness of our brands through paid and organic digital efforts via content, video and social media that lead them to our websites.
We believe that video is a key channel for connecting with our customers. A significant portion of America’s Best and Eyeglass World’s advertising investments are on awareness-driving video advertisements, network television and digital platforms, which we leverage broadly across multiple stores in each market to gain a larger share of voice and, in turn, drive traffic and margins. We continue to benefit from America’s Best national advertising campaigns, which we believe are cost effective and help raise our brand awareness in both new and existing markets. Additional advertising investments include digital media, search engine, direct mail, email and local store marketing. We are continually tracking consumer media consumption behaviors and adjusting our media plan accordingly.
For our Host brands, we rely on our Host partners’ marketing initiatives to drive traffic into their stores. We then develop and execute highly targeted local marketing campaigns within stores to create awareness of our service and product offerings.
Seasonality
Our business is moderately seasonal in nature. Historically, our business has realized a higher portion of net revenue, operating income and cash flows from operations in the first half of the year, and a lower portion of net revenue, operating income and cash flows from operations in the fourth fiscal quarter. The first half seasonality is attributable primarily to annual health insurance program start/reset periods and predictable consumer propensity to seek eye care and eyewear.
With respect to our fourth quarter results, compared to other retailers, our products and services are less likely to be included in consumers’ holiday spending budgets, therefore reducing spending on personal vision correction during the weeks preceding December 25th of each year. Additionally, although the period between December 25th and the end of our fiscal year is typically a high-volume period, the net revenue associated with substantially all orders of prescription eyeglasses and contact lenses during that period is deferred until January based on generally accepted accounting principles of recognizing revenue only after the product has been accepted by the customer, further contributing to higher revenue results in the first half of the year. Our quarterly results may also be affected by the timing of new store openings and store closings, the amount of sales contributed by new and existing stores, the timing of certain holidays, and the timing of weather-related store closures. Furthermore, changes in consumer behavior in recent years have suggested a departure from the seasonal norms we have experienced in the past and may continue to disrupt the historical quarterly cadence of our results of operations for an unknown period of time.
Our Sourcing and Supplier Relationships
We focus on sourcing well-known frame brands, secondary frame brands, direct import and private label frames and private label contact lenses. We purchase our frame merchandise from a wide variety of vendors, with a limited number of vendors supplying the majority of our eyeglass lenses and contact lenses. We are a large customer for most of our suppliers and we strive to form meaningful, long-lasting and mutually beneficial relationships with our vendors. We have long-term contracts with certain of our key suppliers, including EssilorLuxottica and CooperVision. Under our agreement with EssilorLuxottica, EssilorLuxottica has the sole and exclusive right to supply certain eyeglass lenses to us. The current term of our agreement with EssilorLuxottica runs through May 2028. We are collaborative in our vendor negotiations so as to develop a partnership with our vendors and, in time, a sense of loyalty to National Vision.
Our Optical Laboratories and Distribution Network
We use a highly efficient mix of four domestic, company-operated manufacturing facilities and have an outsourcing relationship with an international, third-party facility. We have state-of-the-art lens processing capabilities in our geographically diverse, company-operated manufacturing facilities in Lawrenceville, Georgia; St. Cloud, Minnesota; Plano, Texas; and Salt Lake City, Utah. Our centralized manufacturing facilities handle all aspects of customizing eyeglass lenses, and have digital capabilities for grinding, coating and edging to customer prescription and eyeglass frame specifications. We have developed a high-volume, low-cost lens processing model to provide approximately seven- to 10-day turnaround service through our domestic owned facilities and our international partner facility. This network was created through significant investment by us and is leveraged across our portfolio of brands to provide efficiency and scale. We route eyeglass orders to both our owned and outsourced facilities through automated logic that optimizes for manufacturing timeline and cost. This architecture is integrated with the point-of-sale system and enables us to minimize our processing costs, while ensuring on-time deliveries. The processing system is designed such that the more eyeglasses we sell, the more efficient the laboratories become, creating significant cost savings over time.
In addition, our Eyeglass World stores are equipped with on-site laboratories, which can process certain customer orders with same-day service. All lens orders that are not processed or completed in store are processed or completed by our centralized manufacturing network.
We have a 118,000 square foot distribution center in Lawrenceville, Georgia. We utilize third-party carriers to transport products from the distribution center to customers and store locations. We utilize a third-party vendor for contact lens fulfillment and distribution.
Human Capital Management
As of January 3, 2026, we had 13,138 full-time and part-time associates, including 635 directly employed optometrists. As of January 3, 2026, our network of optometrists included 2,367 optometrists, of which 635 were directly employed by us, 1,645 were employed by professional corporations or similar entities with which we contract, and 87 who sublease in our store locations.
Our network of optometrists includes a mix of full-time and part-time optometrists, and this mix can change over time.
We are not a party to any collective bargaining agreements. We have never experienced a strike or work stoppage, and we believe that our relations with our associates and optometrists are good.
Board Oversight
Our Board of Directors (the “Board”) through its committees oversees human capital matters with regular updates and discussion on organizational structure, hiring and retention, compensation and benefits, health and safety matters, employee training and development, succession planning, and associate survey results.
Values and Culture
We aim to maintain a strong and resonating culture guided by our Vision, Mission and Values. We believe everyone deserves to see their best to live their best and our mission is to help people achieve this by making quality eye care and eyewear more affordable and accessible. This purpose is supported by our associates and their values – passion for people, committed to community, results done right, and be your best self.
Talent Acquisition
At National Vision, we are committed to attracting talent aligned with our Vision, Mission and Values. We continue to refine our technology to improve both the candidate and hiring manager experience. In addition, we have established critical partnerships with outside vendors that provide us with additional resources to drive candidate flow for key roles. We are continuing our multi-year sponsorship of the Association of Schools and Colleges of Optometry campaign “Optometry Gives Me Life” targeted at high school and college students, and ensuring that graduating optometrists are educated on the variety of career options available to them. Additionally, we support our associates’ interest in attending Optometry school through our internal National Vision Doctor of Optometry Tuition Reimbursement program, which provides for the reimbursement of education expenses to associates attending optometry school. We utilize both in-person events and online platforms for job fairs and on-campus events, and selectively offer key incentives, such as a student loan repayment program.
Talent Development
We are committed to high-quality training support for our associates. We have increased ongoing training in recent years, especially in the areas of safety protocol procedures and customer interactions, and have enhanced virtual, instructor-led training classes, allowing for high-touch training in a remote setting. We provide associates and optometrists with several
opportunities and mechanisms through which they can provide feedback, and this allows us to continue developing programs for training and growth.
In 2025, we continued to strengthen NVI onboarding programs introduced in the prior year. Both the store-based new hire and district manager onboarding programs were reviewed, refined, and enhanced. Additionally, training and talent development efforts focused on equipping our frontline teams with the knowledge, skills, and techniques needed to deliver an exceptional customer experience. Each month, store teams participated in multiple in-person training sessions designed to deepen associates’ understanding of lens and frame product knowledge, managed vision care insurance, and selling techniques to help customers choose the best value for their lifestyle. Our training strategy aimed to build associates’ knowledge and confidence, with the ultimate goal of improving customer satisfaction and overall experience.
Benefits and Wellness
We strive to ensure our people always feel supported so they can bring their best selves to work every day. We demonstrate this commitment through many of our benefits and wellness offerings. Programs like our 401(k) plan, core and supplemental life insurance, health plan, short and long-term disability, wellness and disease management programs, including personalized programs for diabetes and hypertension, paid time off, parental and adoption leave, accident, critical illness, group legal and identity theft programs, and a financial protection resource, provide the needed resources essential for helping our people care for themselves and their families. We also offer free on-demand mental and behavioral health resources, to provide needed guidance when work and personal challenges affect an associate’s overall well-being. Additionally, our associates receive an annual associate eyewear ticket and eyewear gift tickets that provide them, along with their friends and family, discounted eyewear purchases in our stores.
Our college scholarship program was established to assist associates with children age 24 or under, who are high school seniors or graduates and planning to enroll in a full-time undergraduate course of study at an accredited U.S. college or university. Each year, ten recipients are granted an award of $2,500 each, and awards are renewable for up to three years for a total scholarship of $10,000. We also provide current and former associates who are in pursuit of a Doctor of Optometry degree with financial support through a tuition reimbursement program.
Our compensation programs are designed to reinforce our growth agenda and talent acquisition strategy. In addition to competitive base pay, we seek to reward associates with annual incentive awards, recognition programs and equity awards for associates at certain levels.
Health and Safety
Our health and well-being efforts are built on a foundational commitment to the safety of our associates and the doctors in our network. We believe that we are in material compliance with applicable Occupational Safety and Health Administration (“OSHA”) guidelines and state regulations. At each of our labs and distribution centers, there are specific leaders responsible for the management of associate safety. For example, lab directors organize and run safety trainings for local associates, some of which are conducted through our Learning Management System and others through in-person instruction. In our retail locations, we support managers and field leaders in understanding and complying with applicable laws and regulations.
Philanthropic Efforts
At National Vision, we believe everyone deserves to see their best to live their best. Our philanthropic culture instills a sense of purpose and engagement in our associates, from in-store team members to senior management. Our associates feel pride in the positive work they are doing, which helps us to attract and retain both store associates and vision care professionals, thus improving the customer experience in our stores. In addition, our mission has been essential to the recruitment and retention of our management team, whose extensive experience is a key component of our business success.
Our financial success has helped fuel our ever-growing philanthropic engine, conducted primarily through 20/20 Quest, a National Vision-sponsored charitable foundation, chartered for the purpose of providing screenings, eye exams, eyeglasses and refractive error solutions to the optically underserved in both the United States and the developing world. In the U.S., through our partnership with charitable organizations, we provide free vision screenings, eye exams and eyeglasses to underserved communities. In addition, through multiple charitable partnerships with organizations such as VisionSpring, RestoringVision, the International Agency for the Prevention of Blindness and VOSH International, we both directly assist and indirectly help to improve the vision of millions of individuals globally. We also work collaboratively with others in the industry to help a portion of the world’s population who live with uncorrected vision problems.
Information Technology
Information technology systems are critical to our day-to-day operations as well as to our long-term growth strategy. Our systems are designed to deliver a consistent, scalable, high-performing and secure experience for our customers, patients, and partners. We utilize a combination of co-location data centers and cloud-based solutions for our
infrastructure and the majority of our applications consist of standard, integrated software solutions. Our systems provide the data analysis and automation necessary to support our marketing, merchandising, inventory, distribution, store operations and point-of-sale, e-commerce, remote medicine, finance, accounting and human resources initiatives. We believe our current systems allow us to identify and respond to operating trends in our business.
Areas in which we have invested and continue to invest in include, among others, software systems to enhance the growth of enterprise resource planning (“ERP”), CRM, omni-channel, customer engagement efforts, remote medicine and EHR platforms, cybersecurity programs, our overall security posture, point-of-sale systems, and internal user productivity tools.
Intellectual Property
We own a number of registered and common law trademarks and pending applications for trademark registrations in the U.S., primarily through our subsidiaries. Solely for convenience, the trademarks, service marks and trade names referred to in this report are presented without the ®, SM and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. All trademarks, service marks and trade names appearing in this Form 10-K (or in documents we have incorporated by reference) are the property of their respective owners.
Government Regulation
Our operations are subject to extensive federal, state and local laws and regulations. Because of the various facets of our business, the scope and extent of laws and regulations applicable to our business are always subject to the risk of change or material increase. Noncompliance with these laws and regulations can subject us to sanctions (including suspension and loss of operating licenses), fines or various forms of civil or criminal prosecution, any of which could have a material adverse effect on our reputation, business, financial position, results of operations and cash flows. See Item 1A. “Risk Factors” below for a discussion of these and other risks. A summary of certain laws and regulations is described below.
Corporate Practice of Medicine/Optometry and Similar Laws
Many states prohibit the corporate practice of medicine/optometry where an unlicensed entity practices medicine or employs a physician or optometrist to provide professional medical or optometric services. Further, many states interpret these or similar rules broadly to prohibit employment of certain healthcare professionals by corporations like us and to prohibit various financial arrangements, such as fee-splitting, between some healthcare professionals and other entities. Many states also regulate certain business practices as well as landlord-tenant arrangements between optical companies and optometrists. For example, some states prohibit a common entrance to a retail optical location and an optometric office. These laws and regulations can vary significantly by state, requiring us to tailor our operations in each state to the particular laws of such state. Many of these laws and regulations are vague and subject to the interpretation of regulators and enforcement authorities, which may change over time. States periodically revisit these laws and regulations and we are subject to the ongoing risk that the regulatory scheme in any state could change in ways adverse to us. Our America’s Best operations, which feature a bundled offer of eyeglasses and an eye examination, are particularly implicated by these laws. Additionally, state legislators and regulators may be reluctant to accept telehealth and remote medicine as a way to provide access to quality patient care. There is a disparity across jurisdictions in how telehealth is regulated and how we are able to implement our remote medicine solution. Our ability to launch our remote medicine solution in certain jurisdictions at all or in the most cost-efficient manner is highly dependent on the evolution of these state-by-state requirements and restrictions.
Professional Licensure and Regulation
Our operations are subject to state licensing laws. All states license the practice of ophthalmology and optometry and many states license opticians or ophthalmic dispensers. The dispensing of prescription eyewear is also regulated in most states in which we do business and, in some states, we are required to register our stores as optical dispensaries or the equivalent.
Fairness to Contact Lens Consumers Act (“FCLCA”) and E-commerce Laws
In connection with our sales of contact lenses, we must comply with the FCLCA, and its implementing regulations, including the Contact Lens Rule, promulgated by the Federal Trade Commission (“FTC”), which establish a national uniform standard in the U.S. with regard to issuing, releasing and verifying contact lens prescriptions. This law and rule require that we verify prescriptions we receive from our customers prior to selling contact lenses online. A violation of the Contact Lens Rule may constitute an unfair or deceptive act or practice under the Federal Trade Commission Act (the “FTC Act”).
Our e-commerce business must comply with various federal and state laws, most notably the FCLCA. Our online business must also be registered in various states as a non-resident contact lens seller.
Managed Care Regulation
We are engaged in managed vision care, both as a managed care entity and as a provider to managed care payors and insurers. In California, our subsidiary, FirstSight, a specialized health maintenance organization (“HMO”), is subject to the managed care laws of the State of California and is licensed and comprehensively regulated by the California Department of Managed Health Care (the “DMHC”). These regulations contain operating, disclosure, reporting and financial viability requirements, among others. Material changes to the operations of FirstSight, including the opening of America’s Best locations outside of defined service areas, must be approved by the DMHC. This approval process can be complex and can cause delays in the projected opening of our stores. We also offer Eyecare Club programs pursuant to which, in exchange for a fixed payment, individuals can obtain eye examinations and discounts on eyeglasses, contact lenses and accessories during the program period. These programs may be subject to regulation under managed care and related state laws, including those of California, where these programs are offered as managed care products by FirstSight. In addition, our Eyecare Club programs may subject us to state laws regulating discount medical plans. These laws, which have been adopted in a number of states, require the licensing or registration of organizations that provide discounted access to health care providers. It is possible that state regulators could determine that we are operating as a discount medical plan and thus subject to various registration, disclosure and solvency requirements.
Privacy and Security
We directly collect, use, access, disclose, transmit and/or store protected health information (“PHI”) and personally identifiable information (“PII”) in connection with the sales of our products and services, customer service, billing and employment practices. As a health care provider and as a business associate to health care providers, we are subject to federal and state laws governing privacy and security, including the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and its implementing regulations, such as the Privacy Rule, the Security Rule and the Breach Notification Rule. The Health Information Technology for Economic and Clinical Health Act of 2009 (the “HITECH Act”) extends the Privacy Rule and the Security Rule directly to business associates. We are also subject to comparable state health privacy laws to the extent they are more protective of individual privacy than the Privacy Rule. We believe that the Office of Civil Rights, which is the enforcement agency for HIPAA, may implement modest changes to HIPAA in 2026, pursuant to a notice of proposed rulemaking that was issued in December 2020. Moreover, nearly all states have adopted their own data breach laws with comparable (and sometimes conflicting) standards and requirements. These state laws apply to breaches of specified elements of PII. In addition, more than a dozen states, including California, have adopted comprehensive consumer privacy laws, and additional states may amend or adopt new laws or regulations regarding data privacy that may be applicable to us, including additional consumer privacy laws.
Laws Related to Reimbursement by Government Programs
Our participation in federal reimbursement programs, such as Medicare and Medicaid, subjects us to state and federal laws and regulations with respect to anti-kickback, false claims and physician self-referral, among other similar areas. The federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, to induce, or in exchange for, the referral of an individual or purchasing, furnishing, recommending or arranging for a good or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. The definition of “remuneration” has been broadly interpreted to include anything of value, including, for example, gifts, certain discounts, the furnishing of free supplies, equipment, office space or services, credit arrangements, payment of cash and waivers of payments. Healthcare providers that have financial relationships may structure their arrangements to meet certain voluntary safe harbors under the federal Anti-Kickback Statute so that such financial relationships and business practices are not treated as offenses under the statute. Several courts have found a violation of the statute’s intent requirement where the purpose of an arrangement involving remuneration is to induce referrals of patients or consumers purchasing healthcare goods or services paid for, in whole or in part, by federal government programs. There are also a number of healthcare fraud statutes that impose criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. A person or entity does not need to have actual knowledge of the Anti-Kickback Statute or healthcare fraud statutes, or specific intent to violate them in order to have committed a violation. Many states have adopted similar laws that apply to third-party payors including commercial plans.
In addition, the federal Anti-Kickback Statute provides that any claim for government reimbursement in violation of the statute also violates the False Claims Act (“FCA”). The FCA prohibits intentionally submitting, conspiring to submit, or causing to be submitted, false or otherwise improper claims, records or statements to the federal government, or intentionally failing to return overpayments, in connection with reimbursement by federal government programs. Most states have enacted false claims laws analogous to the FCA, and both federal and state false claims laws permit private individuals to file qui tam or “whistleblower” lawsuits on behalf of the federal or state government. The Social Security Act also imposes significant penalties for false or improper Medicare and Medicaid billings.
The U.S. Physician Self-Referral Law, or the Stark Law, generally prohibits physicians (which the Stark Law defines to include optometrists) from referring, for “designated health services” (as defined by the Centers for Medicare & Medicaid Services), Medicare or Medicaid beneficiaries to any entity with which the physician or an immediate family member of the physician has a financial relationship unless an exemption applies. The Stark Law further prohibits the entity receiving a prohibited referral from presenting a claim for reimbursement by Medicare or Medicaid for services furnished pursuant to the prohibited referral. The Stark Law has a number of specific exceptions for financial arrangements that do not pose a risk of abuse to Medicare programs or patient abuse. Many states have adopted similar self-referral laws that may not be limited to Medicare or Medicaid reimbursed services. In some cases, the rental of space constitutes a financial relationship under this law. The Stark Law is a strict liability law, meaning that intent is not required; the mere presence of a prohibited relationship may constitute a violation if an exception is not met.
Federal Food and Drug Administration (“FDA”) Regulation
The FDA generally has authority to, among other things, regulate the manufacture, distribution, sale and labeling of medical devices, including contact and eyeglass lenses. Under the U.S. Federal Food, Drug and Cosmetic Act (the “FDC Act”), medical devices must meet a number of regulatory requirements. We engage in certain manufacturing, repackaging and relabeling activities at our optical laboratories and in certain Eyeglass World stores, which subject us to the FDA’s registration, listing and quality requirements. We are required to register our centralized laboratories with the FDA.
Consumer Protection Laws
Federal and state consumer protection laws and regulations can apply to our operations and retail offers. Some of our promotions, such as our America’s Best offer of a “free” eye exam, are subject to compliance with laws and regulations governing use of this term. Further, FTC’s Contact Lens Rule (referenced above) and the similar Eyeglass Rule require that we provide a copy of eyeglass or contact lens prescriptions upon completion of an eye examination or contact lens fitting, and violations may constitute unfair or deceptive trade practices. The FTC has authority under Section 5 of the FTC Act to investigate and prosecute practices that are “unfair trade practices,” “deceptive trade practices,” or “unfair methods of competition.” State attorneys general typically have comparable authority and many states permit private plaintiffs to bring actions on the basis of these laws. In addition, state regulators or boards of optometry may challenge our promotional practices, including America’s Best’s bundled offers, as, among other things, violating applicable state laws regarding unfair competition, false advertising to consumers or corporate practice of optometry prohibitions.
Foreign Corrupt Practices Act (“FCPA”)
We source a significant portion of our products from outside of the U.S. The FCPA and other similar anti-bribery and anti-kickback laws and regulations generally prohibit companies and their intermediaries from making improper payments or offering anything of value to non-U.S. officials for the purpose of obtaining or retaining business. Our policies and our code of conduct mandate compliance with applicable laws and regulations, including these.
Payment Card Industry Data Security Standard (“PCI Standard”)
Because we accept debit and credit cards for payment, we are subject to the PCI Standard, which contains compliance guidelines with regard to our security surrounding the physical and electronic storage, processing and transmission of cardholder data. Certain states have incorporated these requirements into state law. Our credit card agreements with our banks require that we comply with this standard and pay any fines or assessments imposed by the credit card companies in the event of a compromise of card data.
Service Contract Regulations
We offer product protection plans for our eyeglasses. In certain states, laws governing service contracts regulate these plans. These laws, which vary by state, mandate that sellers of such contracts comply with various registration, disclosure and financial requirements. It is possible that regulators in certain states could determine that our extended warranty plans should be subject to these laws.
Environmental and Safety Regulation
Our optical laboratories in the U.S. and our in-store laboratories within Eyeglass World locations subject us to various federal, state and local laws, regulations, and other requirements pertaining to protection of the environment, public health, and associate safety, including, for example, regulations governing the management of hazardous substances and the maintenance of safe working conditions. These laws also apply generally to all our properties. Our failure to comply with these laws can subject us to criminal and civil liabilities.
Employment Laws and Occupational Safety and Health Administration
We are a labor-intensive business that is subject to complex labor and employment laws established by federal, state and local laws and regulations. These laws and regulations govern areas that include working conditions, paid time off, workplace safety, wage and hour standards and hiring and employment practices.
In particular, we are subject to the requirements of OSHA and other federal and state agencies that address employee health, including from infectious diseases and safety.
We currently have processes in place to support our compliance with these requirements. Based on new or revised regulatory developments, we may be required to take additional actions or increase expenditures in the future to comply with changing employment requirements and higher industry and regulatory safety standards.
Insurance and Risk Management
We use a combination of purchased insurance and self-insurance for workers’ compensation, general liability, property, director and officers’ liability, vehicle liability, and associate health-care benefits, among others. Liabilities associated with the risks that are retained by us are estimated, in part, by considering historical claims experience, demographic factors, severity factors and other actuarial assumptions. Where we have retained risk through self-insurance or similar arrangements, we utilize third-party firms to assist management in assessing the financial impact of risk retention.
Our Website and Availability of SEC Reports and Other Information
Our website is www.nationalvision.com. Investors can obtain copies free of charge of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and amendments to these reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the SEC. You may access these documents on the “Investors” section of our website. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at the following address: http://www.sec.gov.
We also make available free of charge on our website our Corporate Governance Guidelines, our Code of Conduct and the charters of our Audit Committee, our Compensation Committee and our Nominating and Corporate Governance Committee. The information posted to our website is not incorporated into this Form 10-K or any other report we file with the SEC.
Item 1A. Risk Factors
You should carefully consider the risks described below and the other information contained in this report and other filings that we make from time to time with the SEC, including our consolidated financial statements and accompanying notes. Any of the following risks could materially adversely affect our business, financial condition, results of operations or liquidity. These risks are not the only risks we face. Our business, financial condition, results of operations or liquidity could also be adversely affected by additional factors that apply to all companies generally or by risks not currently known to us or that we currently view to be immaterial. We can provide no assurance and make no representation that our risk mitigation efforts, although we believe they are reasonable, will be successful.
Risks Related to Our Business and Operations
Market volatility, an overall decline in the health of the economy, global macroeconomic conditions and other factors may affect consumer spending or behavior, which could materially harm our sales, profitability and financial condition.
Our business depends on consumer demand for our products and, consequently, is sensitive to a number of factors that influence consumer behavior, confidence and spending, including whether consumers make purchases, their choice of price point, their appetite for upgrades or add-on services, or the frequency with which they have an eye exam or replace their eyeglasses. Conditions that have affected, or may in the future affect, consumer behavior include general economic conditions, consumer disposable income, energy and fuel prices, recession and fears of recession, unemployment, minimum wages, availability of consumer credit, consumer debt levels, conditions in the housing market, interest rates, tax rates and policies, inflation, tariffs and trade wars, consumer confidence in future economic conditions, the risk of future government shutdowns, developments related to the U.S. federal debt ceiling and political conditions. In recent years, global markets and economic conditions have been challenging, particularly in light of elevated interest rates and historic inflation, which has created continued economic uncertainty. Additionally, uncertainty and market volatility have been magnified as a result of shifts in U.S. and foreign trade, economic, and other policies, coupled with a consolidation of party control of both chambers of Congress in 2025, which has led to new legislative and regulatory initiatives and the roll-back of certain initiatives of the previous presidential administration, which may impact our business and our clients’ businesses in unpredictable ways, including as a result of the potential implementation of more restrictive trade policies, higher tariffs or the renegotiation of existing trade agreements. These conditions have impacted customer demand and may continue to have similar impacts in the future. Reduced customer confidence and spending cutbacks may result in reduced demand for our merchandise and may force us to mark down inventory, increase selling and promotional expenses or, if part of a prolonged or pervasive economic downturn, may slow the pace of new store openings or cause current stores to close.
Additionally, our business is seasonal in nature, with the first and second quarters typically representing a higher portion of net sales to us than other quarters, due in part to annual health insurance program start/reset periods in the first half of the year. As such, a significant downward trend in the first half of the year could have a substantial negative impact on our annual financial results.
Furthermore, certain of the customers we serve may be disproportionately sensitive to a number of these and other factors outside of our control. A continuation of these or other similar circumstances could have a material negative impact on our financial performance.
Global political, socio-economic, cultural, and geopolitical issues can also impact macroeconomic conditions and consumer sentiment and could have a material adverse impact on our financial results. These issues include, but are not limited to, ongoing conflicts across the globe such as in Russia-Ukraine and the Middle East, as well as disruptions caused by terrorist activities or otherwise. Further escalation of these geopolitical conflicts, including by the imposition of increased trade barriers or restrictions on global trade, could result in, among other things, cyberattacks, supply disruptions, lower consumer demand, and changes to foreign exchange rates and financial markets, any of which may adversely affect our business and financial condition. In addition, the effects of the ongoing conflicts could also heighten many of the other risk factors described herein.
We may not be successful in implementing our strategic initiatives, or in anticipating the impact of important strategic initiatives, and our plans for implementing such initiatives may be altered or delayed due to various factors, which may have a material adverse impact on our business and financial results.
We may not be able to implement our strategic initiatives in accordance with our expectations or in a way that generates expected returns, which may result in an adverse impact on our business and financial results. These strategic initiatives are intended to allow us to better serve our existing customers and expand our target consumer demographics and drive the outcome of a stronger core business and improved operating results.
In addition to other factors listed in this risk factors section, the challenges of company-wide coordination and alignment or our inability to identify or act on opportunities to deliver anticipated cost savings may adversely affect the successful implementation of these initiatives, which could have a material adverse impact on our business and financial results.
The implementation, timing and results of these complex strategic initiatives are subject to various risks and uncertainties, which may require that we make significant estimates and assumptions in our planning. These initiatives place significant demands on our accounting, financial, information technology, and other systems, and on our business overall. We are dependent on our management’s ability to oversee these initiatives effectively and implement them successfully. If our estimates and assumptions about our initiatives are incorrect, or if we miscalculate the resources or time, we need to complete them or fail to execute on them effectively, our pursuit of these initiatives may increase our costs and reduce our margins and profitability, or we may not realize the anticipated improvements.
To be effective, our transformation initiatives have required, and will continue to require, significant investment in cross-functional operations and management focus, along with supporting investments. If we are unable to attract and retain employees or contract with third parties having the specialized skills needed to support our efforts, or implement improvements to systems in a timely manner, our ability to compete and our results of operations could be adversely affected. In addition, if initiatives related to our new store, marketing or merchandising concepts and improved customer experience do not appeal to our customers or if we are unable to consistently meet our brand execution promises in a cost-effective manner, we may experience a loss of customer confidence or lost sales, which could adversely affect our reputation and results of operations.
A failure to properly execute our plans and business strategies, delays in executing our plans and business strategies, increased costs associated with executing on our plans and business strategies, or failure to identify alternative strategies could have a material adverse effect on our business, financial position, results of operations, and cash flows.
The optical retail industry is highly competitive, and if we do not compete successfully, our business may be materially adversely impacted.
We operate in the highly competitive optical retail industry and we may be unable to successfully compete against existing or future competitors. Our inability to respond effectively to competitive pressure or improved performance by our competitors could result in lost market share and have a material adverse effect on our business, financial condition and results of operations. For additional information on our competitive environment and our major competitors, see Part I. Item 1. “Business-Competition.”
Some of our competitors are larger or vertically integrated and engaged in the manufacture and distribution of eyewear as well as managed care. Larger competitors who have greater financial and operational resources, greater brand recognition or broader geographic presence than we do may have large marketing and advertising spends and may be
able to offer more competitive prices. Vertically integrated competitors may advantageously leverage their structure, making it more difficult for others in the industry, including us, to compete. We purchase many of our products from suppliers who are affiliates of our competitors. We also compete for managed vision care contracts with certain of our competitors who are affiliates of managed care payors. The termination of one or more relationships we have with these larger, vertically integrated competitors could have a material adverse effect on our business, financial condition and results of operations. In addition, if any of our competitors were to consolidate operations, such consolidation would exacerbate the aforementioned risks. While we strive to evolve in line with changing consumer shopping habits and new technologies, our business and results of operations may be adversely affected if we are not able to effectively respond to changes in the retail markets at the same rate as our competitors.
Our success depends substantially on the value of our owned brands, and failure to maintain, protect, and enhance their value could have a material negative impact on our business, financial condition, and results of operations.
We believe we have built a strong reputation for delivering exceptional value and convenience to our customers through our owned brands, America’s Best and Eyeglass World. To be successful in the future, we believe we must preserve, grow, and leverage the value of our owned brands across all sales channels. Failure to do so may materially negatively impact our financial condition and results of operations.
In fiscal 2025, we launched a reinvention of our America’s Best brand, including a new logo and a new brand platform, and embarked on a brand positioning review of our Eyeglass World brand. We expect to continue to invest substantial resources to promote and maintain our brands, but there is no guarantee that our brand development strategies will enhance the recognition of our brands or lead to increased sales. The strength of our brands will depend largely on our ability to provide products and services at competitive prices. Brand promotion activities may not yield increased net revenue, and even if they do, the increased net revenue may not offset the expenses we incur in promoting and maintaining our brands and reputation. If our efforts to cost-effectively promote, maintain and grow our brands are not successful, our results of operations and our ability to attract and engage customers, partners, and employees may be materially adversely affected.
Unfavorable publicity regarding our products, customer service, or privacy and security practices could also harm our reputation and diminish confidence in, and the use of, our products and services. In addition, negative publicity related to key brands that we have partnered with may damage our reputation, even if the publicity is not directly related to us. If we fail to maintain, protect, and enhance our brands successfully or to maintain loyalty among customers, or if we incur substantial expenses in unsuccessful attempts to maintain, protect, and enhance our brands, we may fail to attract or increase the engagement of customers, and our business, financial condition, and results of operations may suffer.
Additionally, if we are unsuccessful in maintaining, protecting and enhancing our brands, we may be required to evaluate whether certain assets, including goodwill and other intangibles, have become impaired. In fiscal 2024, we recorded a goodwill impairment charge related to Eyeglass World. In the event we are required to record further impairment charges, it could have a material impact on our financial results.
Our success depends upon our marketing, advertising and promotional efforts. If we are unable to implement them successfully or efficiently, or if our competitors are more effective than we are, we may experience a material adverse effect on our business, financial condition and results of operations.
We use marketing and promotional programs to attract customers to our stores and to encourage purchases by our customers. If we fail to successfully or efficiently develop and implement marketing, advertising and promotional strategies or to incorporate innovative approaches in such endeavors, we may be unable to achieve and maintain brand awareness, and customer traffic to our stores and/or websites may be reduced. We may not be able to advertise cost-effectively in new or smaller markets in which we have lower store density, which could slow growth at such stores. Changes in the amount and degree of promotional intensity or merchandising strategy by our competitors could cause us to have difficulties in retaining existing customers and attracting new customers. We have invested in a new CRM system that we believe will enhance our engagement with customers, in particular underdeveloped customer segments. We have also shifted to a consultative selling model, where we have trained our store associates to provide a more personalized selling experience. If these expectations on enhancing the customer experience are not realized, our business may be adversely affected. If the efficacy of our marketing or promotional activities declines or if such activities of our competitors are more effective than ours, or if for any other reason we lose the loyalty of our customers, we may experience a material adverse effect on our business, financial condition and results of operations.
If we fail to open and operate new stores in a timely and cost-effective manner or fail to successfully enter new markets, our financial performance could be materially adversely affected.
Achieving our growth strategy depends, in part, on growing our store base and expanding our operations, both in new and existing markets, and operating our new stores successfully.
The success of our contemplated expansion depends on many factors, including, among others, our ability to:
•recruit and retain qualified vision care professionals (who may be licensed or unlicensed, depending on state regulations) for any new store;
•address regulatory, competitive, merchandising, marketing, distribution and other challenges encountered in connection with expansion into new markets where we have limited historical experience;
•hire, train and retain an expanded workforce of store managers and other personnel;
•maintain adequate laboratory, distribution facility, information technology and other operational system capabilities;
•successfully integrate new stores into our existing management structure and operations, including information technology integration;
•negotiate acceptable lease terms at suitable retail locations;
•source sufficient levels of inventory at acceptable costs;
•obtain necessary permits and licenses;
•construct and open our stores on a timely basis;
•generate sufficient levels of cash or obtain financing on acceptable terms to support our expansion;
•participate in managed care arrangements for new stores;
•achieve and maintain brand awareness in new and existing markets; and
•identify and satisfy the merchandise, lifestyle and other preferences of our customers.
Accordingly, we cannot assure you that we will achieve our planned growth or that our new stores will perform as expected or achieve net sales or profitability levels comparable to those of our existing stores in the time periods estimated by us or at all. Further, we began temporarily moderating new store openings during fiscal year 2025 and will continue this moderation into fiscal year 2026, after which time we expect to return to our more recent store opening cadence as strategic initiatives begin to take hold. Our failure to implement our growth strategy and to successfully open and operate new stores in the time frames and at the costs estimated by us, or failure to return to our more recent store opening cadence in the expected time period or at all, could have a material adverse effect on our business, financial condition and results of operations.
Additionally, we may, from time to time, have the opportunity to add stores to our portfolio through acquisition, which may involve risks related to integration, including diversion of management attention from existing core businesses and substantial investment of resources to support integration, and difficulties integrating personnel, operations, financial systems, supply chains, and information technology systems could result in higher-than-expected expenses, delays or loss of customers. If we fail to successfully integrate acquired stores, or realize the anticipated benefits of acquisitions, our financial condition and results of operations could be materially adversely affected.
Our growth is dependent on our ability to increase sales in existing stores and to successfully reinvest in existing stores.
Existing store sales growth is critical to strong operating results and is dependent on a variety of factors, including merchandise quality, relevance and availability, doctor availability, store operations and customer satisfaction. In addition, increased competition could adversely affect our sales. We have begun several strategic initiatives to increase our sales and profitability, some of which remain in the early stages. For example, during fiscal 2025 we began to enhance our product offering in areas where we are underdeveloped relative to the optical retail category, including by adding frames at higher price points, enhancing our portfolio offering with premium products to meet consumer demand while remaining the destination for value, and introducing innovative products such as Ray-Ban Meta smart glasses. As we continue to moderate new store openings through fiscal 2026, we intend to reallocate capital to increase investments in enhancing the overall patient and customer experience in our existing stores. If we are unable to successfully reallocate capital to enhance existing stores, it could have a material adverse effect on our business, financial condition and results of operations. For more information, see Part II. Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II. Item 8. Note 1 “Business and Significant Accounting Policies.”
If we are unable to successfully implement our pricing strategies, it could have a material adverse impact on our business.
Our continued success depends in part on our ability to adjust our pricing strategies to respond quickly and effectively to shifting economic and competitive conditions as well as evolving customer preferences. We have historically employed a
simple, low price/high value strategy, seeking to balance our pricing and growth in a way that consistently delivers savings to our customers. We are continuing this commitment to value, while at the same modernizing our pricing strategy to maximize that value across a broader range of consumers. From time to time, and increasingly in connection with our strategic initiatives, we have taken and may continue to take pricing actions and introduce limited-time promotions or new offers designed to increase demand traffic, awareness and drive sales. For example, in fiscal 2025, we implemented price increases to each of our America’s Best and Eyeglass World opening offer and continued to evolve our product mix to include a greater percentage of frames at price points over $99. There can be no assurance that future cost increases will be fully absorbed by our customers without any resulting change to their demand for our products and services. Additionally, many factors, including operating costs, constraints, or changes, and our current and future competitors’ pricing and marketing strategies, could significantly affect our pricing strategies, which may prevent us from competing effectively. If our pricing strategies are not successful, or are not as successful as those of our competitors, our sales and market share could decrease and could have an adverse effect on our sales and financial condition.
Failure to recruit and retain vision care professionals for in-store roles or to provide remote care offerings could adversely affect our business, financial condition and results of operations.
Our ability to hire and/or contract with vision care professionals for in-store roles and remote care offerings is critical to our operations as well as our growth strategy. Our operations, like those of many of our competitors, depend on our ability to offer both eyewear and eye exams, which requires the availability of optometrists in or near our stores. Many states require that opticians be licensed to dispense and fit eyeglasses and contact lenses. Failure to have vision care professionals available in or near our stores could adversely affect our ability to win managed vision care contracts. Additionally, as we enable remote medicine solutions at an increased number of our stores, the ability to hire and retain vision care professionals for such remote care offerings and the continued successful installation, implementation and operation of the applicable equipment and remote medicine technology platform is essential to the expansion of our remote medicine strategy. The inability to attract and retain vision care professionals or enable and maintain remote medicine at applicable locations, could have a material adverse effect on our business, financial condition and results of operations.
Competition for vision care professionals has increased, especially with the increased demand for optometrists in the current constrained labor market. We compete with other optical retail companies, health systems and group practices for vision care professionals. Failure to attract, hire and retain vision care professionals, or to design and successfully implement more flexibility to meet the expectations of prospective and existing vision care professionals, could have a material adverse effect on our business, financial condition and results of operations. There can be no assurance that flexibility initiatives provided to vision care professionals, including with respect to scheduling, will be successful in attracting or retaining vision care professionals or addressing constraints in exam capacity. In recent years, we have experienced an increased degree of vision care professional shortages and related exam capacity constraints, which continued over the course of 2025, and may continue into 2026 and beyond, despite increased recruitment and retention efforts including wage investments and other enhanced compensation efforts. Such efforts have increased, and may continue to increase, our operating costs which could adversely impact our results, and ultimately may be unsuccessful. In addition, due to these same factors, we experienced wage pressure for our vision care professionals and associates in 2025, which we expect to continue in 2026, and which may continue thereafter.
Additionally, our ability to recruit, hire and/or contract with vision care professionals is closely regulated. For example, there is a risk that state authorities in some jurisdictions may find that our contractual relationships with optometrists or professional corporations or similar entities that employ optometrists, violate laws prohibiting the corporate practice of medicine/optometry, in which case we could be required to restructure these arrangements, which may make it more difficult for us to attract and retain vision care professionals. See Item 1. “Business-Government Regulation.”
A material adverse change in our relationship with vision care professionals, whether resulting from constraints in exam capacity, a dispute with an eye care practitioner or a group of eye care practitioners controlling multiple practice locations, a government or regulatory authority challenging our operating structure or our relationship with vision care professionals, or other changes to applicable laws or regulations (or interpretations of the same), or the loss of these relationships, could impair our ability to provide services to our customers, cause our customers to go elsewhere for their optical needs, or result in legal sanctions against us. In addition, a limited number of professional corporations or similar entities provide for the vision care services at a number of our retail locations, exposing us to some concentration risk. Any difficulties or delays in securing the services of these professionals could also adversely affect our relationships with our Host partners. A material change to any of the foregoing relationships could have a material adverse effect on our business, financial condition and results of operations.
We are a value-based provider and our business model relies on value-based inputs. Factors such as wage rate increases, inflation, cost increases, increases in the price of raw materials and energy prices could have a material adverse effect on our business, financial condition and results of operations.
Increases in compensation, wage pressure and other expenses for vision care professionals, as well as our other associates, have adversely affected, and may continue to adversely affect, our profitability. Increases in minimum wages and other wage and hour regulations and labor shortages can exacerbate this risk. In recent years, we have experienced an increasingly competitive labor market for vision care professionals and increased preferences for adjusted work schedules, resulting in the demand for optometrists exceeding supply in certain areas during fiscal year 2025 and causing constraints in exam capacity. Due to these factors, we continued to experience some degree of wage pressure for our vision care professionals and associates in 2025, which may continue in 2026 and possibly thereafter. Targeted wage investments, including increases in compensation and other expenses for our optometrists and associates, along with other initiatives, were implemented in response to these factors that have and will continue to impact our costs applicable to revenue and SG&A. The costs associated with employment or retention of vision care professionals may increase further, potentially materially. See “Failure to recruit and retain vision care professionals could adversely affect our business, financial condition and results of operations” above. Additional tariffs or other future cost increases, such as increases in the cost of merchandise, shipping rates, raw material prices, freight costs and store occupancy costs, may also reduce our profitability. These cost increases may be the result of inflationary pressures which could further reduce our sales or profitability. Increases in other operating costs, including changes in energy prices and lease and utility costs, may increase our cost of products sold or SG&A. Our value-based model and competitive pressures in the optical retail industry may inhibit our ability to reflect these increased costs in the price of our products, in which case such increased costs could have a material adverse effect on our business, financial condition and results of operations.
We require significant capital to fund our expanding business. If we are unable to maintain sufficient levels of cash flow from our operations, we may not be able to execute or sustain our growth strategy or we may require additional financing, which may not be available to us on satisfactory terms or at all.
To support our expanding business and execute our growth strategy and strategic initiatives, we need significant amounts of capital, including funds to pay our lease obligations, build out new store spaces, laboratories and distribution centers, implement and operate remote medicine technology and EHR platforms, purchase inventory, pay personnel and further invest in our infrastructure and facilities, including investments in transitioning and updating our ERP, retail operating platforms and other technological systems and capabilities. In 2026, we intend to continue to progress our CRM, ERP and other initiatives. We cannot guarantee that these projects will be completed on time or within established budgets. Any delay or increased costs could have a material adverse effect on our business, financial condition and results of operations. Further, our plans to grow our store base may create cash flow pressure if new locations do not perform as projected. We have primarily depended, and expect to continue to primarily depend, on cash flow from operations to fund our business and growth plans. If we do not generate sufficient cash flow from operations, we may need to obtain additional equity or debt financing or utilize our revolving credit facility. Tightening in the credit markets, low liquidity, volatility in the capital markets or a downturn in the economy could result in diminished availability of credit, higher cost of borrowing or lack of confidence in the equity markets, any of which may make it more difficult to obtain additional financing on terms that are favorable to us. If such financing is not available to us, or is not available on satisfactory terms, our ability to operate and expand our business could be curtailed and we may need to delay, limit or eliminate planned store openings or operations or other elements of our growth strategy, which may have a material adverse impact on our business, financial condition and results of operations.
Our growth strategies could strain our existing resources and cause the performance of our existing stores to suffer.
Our growth strategies, including our planned expansion, have placed, and continue to place, increased demands on our existing operational, managerial, supply-chain and administrative resources. These increased demands could strain our resources and cause us to operate our business less effectively, which in turn could cause the performance of our new and existing stores to suffer.
We need to continually evaluate the adequacy of, and opportunity to upgrade, our laboratory, distribution and information technology capabilities, including those related to remote medicine. Our laboratories and distribution center have a finite capacity and, to the extent we grow beyond this capacity, we will need to expand our current laboratories and/or distribution center or add new laboratories and/or distribution capabilities, the cost of which could be material. Should we open additional laboratories or distribution centers, any related construction or expansion projects entail risks which could cause delays and cost overruns, such as unavailability of suitable space, shortages of or delays in obtaining materials, shortages of skilled labor or work stoppages, unforeseen construction, scheduling, engineering, environmental or geological problems, weather interference, fires or other casualty losses, and unanticipated cost increases. We cannot guarantee that any project will be completed on time or within established budgets. Any delay or increased costs
associated with any project could adversely affect the financial and overall performance of our existing and planned new stores.
Implementing new operating capabilities or changing existing operating capabilities could present challenges we do not anticipate and could negatively affect our business, financial condition and results of operations. We cannot anticipate all of the demands that our expanding operations will impose on our business, personnel and systems and our failure to address such demands or to profitably manage our growth could have a material adverse effect on our business, financial condition and results of operations.
In addition, opening new stores in our established markets may result in inadvertent oversaturation, temporarily or permanently divert customers and sales from our existing stores to new stores and reduce comparable store sales, thus adversely affecting our overall financial performance. Furthermore, we have opened and expect to continue to open America’s Best and Eyeglass World stores in close proximity to one another. However, we may not be able to effectively manage stores of both brands in the same market, and this close proximity may cause the performance of such America’s Best and/or Eyeglass World stores to suffer. In addition, oversaturation, or the risk of oversaturation, may reduce or adversely affect the number or location of stores we plan to open, and could thereby materially adversely affect our growth plans overall or in particular markets. From time to time, we update the whitespace analysis prepared for us through an established partnership with a third-party real estate data analytics firm. There are many variables that impact this analysis and there can be no guarantee that updates will lead to the same or greater whitespace opportunity, which could impact our ability to execute our growth strategy.
We are subject to risks associated with leasing substantial amounts of space, including future increases in occupancy costs.
We lease our America’s Best and Eyeglass World store locations, our corporate office space, our laboratories in Georgia, Texas and Utah, and our distribution center. Additionally, we are still obligated under the lease for a distribution center in Ohio that was previously used in our AC Lens business; this lease expires in March 2028. We also lease our Vista Optical locations inside Fred Meyer stores. As a result, we are susceptible to changes in the property rental market and increases in our occupancy costs.
The success of our business depends, in part, on our ability to identify suitable premises for our stores and to negotiate acceptable lease terms. We may not be able to renew or extend our existing store leases on acceptable terms, or at all, and may have to abandon desirable locations or renew leases on unfavorable terms. In addition, tenants at shopping centers in which we are located or have executed leases, or to which our locations are near, may fail to open or may cease operations. Decreases in total tenant occupancy in shopping centers in which we are located, or to which our locations are near, may affect traffic at our stores. In addition, the potential default or bankruptcy of landlords in existing or pending leasehold locations may affect our ability to maintain or renew our existing leases. Any of these factors could have a material adverse impact on our operations.
Most of our store leases provide for a minimum rent and typically include escalating rent increases over time. In certain circumstances we pay a percentage rent based upon sales after certain minimum thresholds are achieved. Our failure to achieve these thresholds could cause our occupancy costs for these locations to increase materially on a percentage of sales basis. The leases generally require us to pay insurance, utilities, real estate taxes and common area maintenance expenses, which are highly variable over time. Our substantial lease obligations could have significant negative consequences, including:
•requiring that a substantial portion of our available cash be applied to pay our rental obligations, reducing cash available for other purposes and reducing our operating profitability;
•increasing our vulnerability to general adverse economic and industry conditions;
•limiting our flexibility in planning for, or reacting to changes in, our business or in the industry in which we compete; and
•limiting our ability to obtain additional financing.
If we are not able to make the required payments under our leases, landlords with a contractual or statutory security interest in the assets of the relevant stores may, among other things, repossess those assets, which could adversely affect our ability to conduct our operations.
Further, the substantial majority of our leased sites are both currently and in the future expected to be subject to long-term noncancelable leases. If an existing or future store is not profitable and we decide to close it, we may nonetheless be obligated to perform our obligations under the applicable lease including, among other things, paying the base rent and other charges for the balance of the lease term. Even if a lease has an early cancellation clause, we may not satisfy the contractual requirements for early cancellation under that lease and/or be required to pay substantial termination fees.
As we expand our store base, particularly in certain markets that are more expensive, such as California and the Northeast, our lease expense and our cash outlays for rent under lease agreements may increase. Our inability to enter into new leases or renew existing leases on terms acceptable to us, or be released from our obligations under leases for stores that we close, could materially adversely affect our business, financial condition and results of operations.
Our e-commerce and omni-channel business faces distinct risks, and our failure to successfully manage those risks could have a negative impact on our profitability.
As an e-commerce and omni-channel retailer, we encounter risks and difficulties frequently experienced by Internet-based businesses. The successful operation of our business and our ability to provide a positive shopping experience that will generate orders and drive subsequent visits depends on efficient and uninterrupted operation of our order-taking and fulfillment operations. Risks associated with our e-commerce and omni-channel business include:
•uncertainties associated with our websites, mobile applications and in-store systems, including changes in required technology interfaces, website downtime and other technical failures, costs and technical issues as we upgrade our website software, inadequate system capacity, computer viruses, human error, security breaches, legal claims related to our website operations, and e-commerce fulfillment;
•disruptions in telephone service or power outages;
•reliance on third parties for computer hardware and software, web-hosting, and delivery of merchandise to our customers;
•rapid technology changes, including the successful integration of artificial intelligence;
•time and costs associated with training and implementing new technologies and systems;
•credit or debit card fraud and other payment processing related issues;
•changes in applicable federal, state and international regulations;
•liability for online content;
•cybersecurity and consumer and HIPAA privacy concerns and regulations; and
•natural disasters or adverse weather conditions.
Our online sales also expose us to broader applicability of regulations, as well as additional regulations, such as the prescription verification and other requirements under the FCLCA, rules relating to registration of internet sellers, certain requirements under the Treasury Department’s Office of Foreign Assets Control (“OFAC”), FCPA, anti-money laundering and trade sanction laws, and similar anti-corruption, anti-bribery and international trade laws. Problems in any of these areas could result in a reduction in sales, increased costs, sanctions or penalties, or damage to our reputation and brands.
In addition, we must keep up to date with competitive technology trends, including the use of artificial intelligence to automate business processes and improve the customer experience, the use of new or improved technology, creative user interfaces and other e-commerce marketing tools such as paid search and mobile applications, among others, which may increase our costs and which may not increase sales or attract customers. Our competitors, some of whom have greater resources than we do, may also be able to benefit from changes in e-commerce technologies, which could harm our competitive position. If we are unable to allow real-time and accurate visibility to product availability when customers are ready to purchase, quickly and efficiently fulfill our customers’ orders using the fulfillment and payment methods they demand, provide a convenient and consistent experience for our customers regardless of the ultimate sales channel or effectively manage our online sales, our ability to compete and our results of operations could be adversely affected.
Furthermore, if our e-commerce and omni-channel business successfully grows, it may do so in part by attracting existing customers, rather than new customers, who choose to purchase products from us online rather than from our brick and mortar stores, thereby detracting from the financial performance of our stores.
If we fail to retain our existing senior management team, attract qualified new personnel or successfully implement our succession plans, such failure could have a material adverse effect on our business, financial condition and results of operations.
Our business, including the implementation of our strategic transformation, requires disciplined execution at all levels of our organization. This execution requires an experienced and talented management team. If we were to lose the benefit of the experience, efforts and abilities of key executive personnel, it could have a material adverse effect on our business, financial condition and results of operations. Competition for skilled and experienced management is intense, and we may not be successful in attracting and retaining new qualified personnel required to grow and operate our business profitably. While prepare and regularly review management succession plans, a failure to ensure effective transfers of knowledge and smooth transitions involving senior management could hinder our strategic planning and business operations.
Our operating results and inventory levels fluctuate on a seasonal basis.
Our business is subject to seasonal fluctuation. We typically realize a higher portion of net sales during the first half of the fiscal year, due to, among other things, the impact of healthcare plan resets after the close of the prior year. Adverse events, such as higher unemployment, lapses in or the lack of insurance coverage, deteriorating economic conditions, public transportation disruptions, or unanticipated adverse weather or travel conditions, can deter consumers from shopping. Any significant decrease in net sales during the first half of the fiscal year could have a material adverse effect on us and could negatively impact our annual results. In addition, in order to prepare for our peak shopping quarters, we must increase the staffing at our stores and order and keep in stock more merchandise than we carry during other parts of the year. This staffing increase and inventory build-up may require us to expend cash faster than it is generated by our operations during this period. Any unanticipated decrease in demand for our products during such period could require us to sell excess inventory at a substantial markdown, which could have a material adverse effect on our business, financial condition and results of operations.
Catastrophic events, including changing climate and weather patterns leading to severe weather and natural disasters, may cause significant business interruptions and expenditures.
The risk or actual occurrence of various catastrophic events, including natural disasters or extreme weather events, diseases or pandemics, acts of terrorism, civil unrest, power or water shortages, telecommunications failures, wars, or other conflicts, could have a material adverse effect on our financial performance.
Severe weather conditions and other natural phenomena resulting from changing weather patterns and rising sea levels or other causes, including hurricanes, floods, fires, landslides, extreme temperatures, major or extended winter storms, significant precipitation, and earthquakes, may result in damage to our stores or other facilities and unavailability of our workforce. Additionally, shifts in weather patterns caused by climate change are expected to increase the frequency, severity or duration of certain adverse weather conditions, which could cause more significant business interruptions that result in increased costs, increased liabilities, and decreased revenues. Such losses could materially and adversely affect our business, financial condition and results of operations. Climate change may also have indirect effects on our business, including for example, leading to increased costs (or unavailability) of property or other insurance policies. Additionally, new or additional legal, legislative and regulatory requirements to reduce or mitigate the effects of climate change on the environment could result in increased capital expenditures to improve the energy efficiency of our existing stores and other facilities and could also require us to spend more on new stores or facilities without a corresponding increase in revenue. In addition, changes to the environment, both long- and short-term, may affect consumer sentiment in a way that negatively impacts our revenue and profitability.
From time to time, we have also temporarily closed certain stores due to widespread health concerns like the COVID-19 pandemic; hurricanes, extreme temperatures, and other severe weather; natural disasters such as wildfires, or civil unrest. Such store closures due to factors that are outside of our control could materially adversely affect our sales and profitability.
Certain technological advances, greater availability of, or increased consumer preferences for, vision correction alternatives to prescription eyeglasses or contact lenses, or future drug development for the correction of vision-related problems may reduce the demand for our products and materially adversely impact our business and profitability.
Technological advances in vision care, including the development of artificial intelligence, remote medicine and other new or improved products, as well as future drug development for the correction of vision-related problems, could significantly change how eye exams may be conducted and make our existing products less attractive or even obsolete. Although we have enabled remote medicine technologies in a number of locations to enable the provision of eye examinations by remote doctors to patients in our stores, several companies have developed technologies for, and some companies are incorporating the remote delivery of, eye examinations and eye refractions more broadly. If consumers accept the use of these technologies, they could become less likely to obtain an in-person eye examination and therefore less likely to shop at our retail locations. Additionally, the greater availability and acceptance, or reductions in the cost, of vision correction alternatives to prescription eyeglasses and contact lenses, such as corneal refractive surgery procedures, photo-refractive keratotomy, or PRK and LASIK, may reduce the demand for our products, lower our sales and thereby adversely impact our business and profitability.
Our profitability and cash flows may be materially adversely affected if we are not successful in managing our inventory balances and inventory shrinkage.
Efficient inventory management is a key component of our business success and profitability. To be successful, we must maintain sufficient inventory levels to meet our customers’ demands without allowing those levels to increase to such an extent that the costs to distribution centers, laboratories and stores to hold the goods unduly impacts our financial results. If our buying and distribution decisions do not accurately predict customer trends or spending levels in general or at particular stores, or if we inappropriately price products, we may have to take unanticipated markdowns and discounts to dispose of obsolete or excess inventory or record potential write-downs relating to the value of obsolete or excess inventory. Conversely, if we underestimate future demand for a particular product or do not respond quickly enough to replenish our best-performing products, we may have a shortfall in inventory of such products, likely leading to unfulfilled orders, reduced revenue and customer dissatisfaction.
Maintaining adequate inventory requires significant attention and monitoring of market trends, local markets, developments with suppliers and our distribution network, and it is not certain that we will be effective in our inventory management. We are subject to the risk of inventory loss or theft and we may experience higher rates of inventory shrinkage or incur increased security costs to combat inventory theft. In addition, any casualty or disruption to our laboratories, distribution centers or stores may damage or destroy our inventory located there. As we expand our operations, it may be more difficult to effectively manage our inventory. If we are not successful in managing our inventory balances, it could have a material adverse effect on our business, financial condition and results of operations.
We depend on our distribution centers and optical laboratories. The loss of, or disruption in the operations of, one or more of these facilities may adversely affect our ability to process and fulfill customer orders and deliver our products in a timely manner, or at all, and may result in quality issues, which would materially adversely affect our reputation, our business and our profitability.
Substantially all of our inventory is shipped directly from suppliers to our distribution center in Lawrenceville, Georgia. Inventory is then processed, sorted and shipped using third-party carriers to our stores, to our laboratories for further processing or to our online customers. We operate laboratory facilities in Lawrenceville, Georgia; St. Cloud, Minnesota; Plano, Texas; and Salt Lake City, Utah. We also have outsourcing relationships with third-party laboratories in Mexico. These laboratories process most of the lenses ordered by customers in our stores, as well as on our websites. Once processed at the laboratories, the finished products are returned to our distribution centers for shipment to stores and customers. Additionally, we rely on a third-party vendor for contact lens fulfillment and distribution services.
We depend in large part on the orderly operation of this receiving and distribution process, which depends, in turn, on adherence to shipping schedules and effective management of our distribution centers. Increases in transportation costs (including increases in fuel costs), increased shipping costs, issues with overseas shipments, supplier-side delays, reductions in the transportation capacity of carriers, labor strikes or shortages in the transportation industry, disruptions to the national and international transportation infrastructure, and unexpected delivery interruptions or delays also have the potential to derail our distribution process. We face additional risks related to our international outsourcing laboratory relationships, including port of entry risks such as import restrictions, foreign government regulations, trade restrictions, customs and duties.
If we change the transportation companies we use, we may face logistical difficulties that could adversely affect deliveries and we could incur costs and expend resources in connection with such change. We also may not be able to obtain terms as favorable as those received from the third-party transportation providers we currently use, which could increase our costs. We also may not anticipate changing demands on our distribution system, including the effect of any expansion we may need to implement in our distribution centers.
Events beyond our control, including, but not limited to, disruptions in operations due to natural or man-made disasters, inclement weather conditions, accidents, system failures, or public health emergencies could also result in delays in our receipt of inventory or the delivery of merchandise between our stores, our optical laboratories and our distribution centers, significantly higher costs and longer lead times, or an adverse effect on our ability to fulfill customer orders in a timely manner. Any disruption to our laboratories’ operations may reduce or impair the quality of assembled eyeglasses.
The inability to fulfill, or any delays in processing, customer orders through our laboratory network or any quality issues could result in the loss of customers, issuances of refunds or credits and may also adversely affect our reputation. The insurance we maintain for business interruption may not cover all risk or be sufficient to cover all of our potential losses or may not continue to be available to us on acceptable terms, if at all, and any insurance proceeds may not be paid to us in a timely manner.
If the performance of our Host brands declines or we are unable to maintain or extend our operating relationships with our Host partners, our business, profitability and cash flows may be adversely affected and we may be required to incur impairment charges.
We derive revenues and operating cash flows from our relationships with our Host partners through our operation of, as of January 3, 2026, 18 Vista Optical locations within select Fred Meyer stores and 53 Vista Optical locations on select military bases. Termination or expiration of our Host agreements would result in a reduction of our revenues and operating cash flows, which could be material and which could adversely affect our business, financial condition and results of operations including an impairment of the intangible assets.
Additionally, the loss of our Vista Optical locations could impair our ability to attract and retain management and retail associates, compete for managed vision care contracts, obtain favorable terms, such as discounts and rebates, from optical vendors and generate cash to fund our business and service our debt obligations. We may seek to replace any lost Host locations with new America’s Best or Eyeglass World stores but we may not be able to support the carrying value of the intangible assets at these brands or replace the lost revenues and cash flows.
At January 3, 2026, the carrying value of intangible assets at our Host brands was $7.6 million. We review the carrying value of our goodwill and intangibles for impairment annually, or more frequently when impairment indicators exist. The impairment test requires us to analyze a number of factors, including evaluating the useful life of intangible assets, and make estimates that require judgment. Future changes in the business profitability, expected cash flows, our business strategy and external market conditions, among other factors, could require us to record impairment charges for goodwill or intangible assets, which could lead to decreased assets and reduced net income. If a significant write down were required, the charge could have a material adverse effect on our operating results and stockholders’ equity, and could impact the trading price of our common stock. During fiscal year 2024, we recorded an impairment of our Fred Meyer contracts and relationships intangible asset due to the decision to close certain Fred Meyer stores as part of our store fleet review.
Sustainability issues, including those related to climate change, could have a material adverse effect on our business, financial condition and results of operations.
Investors, customers, employees and other stakeholders have increasingly focused on the sustainability practices of companies in recent years. As we published our fourth Corporate Responsibility Report in 2025 and continue to develop our corporate responsibility strategy, our sustainability practices will be evaluated against stakeholders’ evolving expectations and standards for responsible corporate citizenship. If our practices in the areas of sustainability, climate and environmental stewardship fail to meet the expectations of our investors, customer, employees and other stakeholders, our reputation or employee and customer retention may be negatively impacted. Sustainability, climate and environmental regulations have resulted in, and may continue to result in, increased general and administrative expenses and increased management time and attention spent complying with or meeting such regulations. At the same time, there has been an increase in legal action and political sentiment challenging such regulations. If we fail to meet evolving and divergent stakeholder expectations and legal standards on sustainability issues, investors may reconsider their investment in the company and customers may choose to find alternative providers, which could have a material adverse effect on our business, financial condition and results of operations.
Risks Related to Our Dependence on Third Parties
Our future operational success depends on our ability to develop, maintain and extend relationships with managed vision care companies, vision insurance providers and other third-party payors.
An increasing percentage of our customers receive vision insurance coverage through managed care payors. These payors represent a significant portion of our overall revenues and our revenue growth and represented 42% of our revenues from continuing operations in fiscal 2025. We maintain strong relationships with almost all vision care insurers in the U.S. including the major carriers who dominate market share, subjecting us to concentration risk. Our future operational success could depend on our ability to maintain existing relationships, create partnership opportunities and negotiate contract extensions with managed vision care companies, vision insurance providers and other third-party payors. As our managed care business continues to expand, we have incurred, and expect to incur, additional costs related to this area of our business. In addition, as our managed care business continues to grow closer to overall industry penetration levels, we expect our associated revenue growth rate to slow over time.
We may be unable to establish or maintain satisfactory relationships with managed care and other third-party payors. In addition, many managed care payors have existing provider structures in place that they may be unable or unwilling to change. Some vertically-integrated payors also have their own networks, and these payors may take actions to maintain or protect these networks in ways that negatively affect us, including by increasing costs or not allowing our new or existing stores to participate in their networks. Increasing consolidation in the optical retail industry may give such payors
greater market power which may adversely affect our ability to negotiate reimbursement rates under managed care arrangements. Our inability to enter into arrangements with managed care payors in the future or to maintain existing relationships with managed care payors on commercially reasonable terms could have a material adverse effect on our business, financial condition and results of operations. In addition, delays in receiving or the failure to receive reimbursements under our managed care arrangements, significant changes to the economics of a managed care contract or relationship, or the loss of a significant managed care contract or relationship could have a significant negative impact on our business, financial condition and results of operations.
We rely on third-party coverage and reimbursement, including government programs, for an increasing portion of our revenues, the future reduction of which could materially adversely affect our results of operations.
We rely on third-party coverage and reimbursement, including government and private insurance plans, such as managed vision care plans, for an increasing portion of our net revenue. We are generally reimbursed for the vision care services and products that we provide through payment systems managed by private insurance companies, managed care organizations and governmental agencies. Coverage and payment levels are determined at each third-party payor’s discretion, and we have limited control over third-party payor’s decision-making with respect to coverage and payment levels. Coverage restrictions and reductions in reimbursement levels or payment methodologies may negatively impact our sales and profits. Many third-party payors may continue to explore cost-containment strategies that may potentially impact coverage and/or payment levels for our services and products and impose utilization restrictions and risk-based compensation arrangements. We cannot provide any assurances that we will be able to maintain or increase our participation in managed care arrangements or that we will be adequately reimbursed by managed care payors, vision insurance providers and other third-party payors for the services we provide and the products we sell. From time to time, vision care insurance payors may make changes to their electronic data interchange (“EDI”) claim systems. Such changes may require us to update our processes and could impact our ability to submit claims or to timely receive reimbursements from our managed care partners. If claims for payment are disputed by managed care payors or if we fail to timely or accurately submit claims, we may not receive payment for such claims in a timely manner or at all, which could negatively impact our relationship with managed care organizations and could require us to take write-offs or otherwise have a significant negative impact on our business, financial condition and results of operations. Furthermore, any changes to or repeal of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or any other significant changes to the healthcare regulatory landscape, that may be supported by the current presidential and congressional administrations that recently assumed office, may reduce or eliminate coverage or reimbursement rates of insurance-funded eye exams or eyewear.
We face risks associated with vendors from whom our products and certain services are sourced and are dependent on a limited number of suppliers.
We purchase all of our merchandise from domestic and international vendors and rely on a third-party vendor for contact lens fulfillment and distribution services. For our business to be successful, our suppliers must be willing and able to provide us with products in substantial quantities, in compliance with regulatory requirements, at acceptable costs and on a timely basis. Our ability to obtain a sufficient selection or volume of merchandise on a timely basis at competitive prices could suffer as a result of any deterioration or change in our vendor relationships or events that adversely affect our vendors.
Other than our contracts for the supply of eyeglass lenses and contact lenses, we typically do not enter into long-term contracts with our vendors and, as such, we operate without significant contractual assurances of continued supply, pricing or access to new products. Any of our vendors could discontinue supplying us with desired products in sufficient quantities or offer us less favorable terms on future transactions for a variety of reasons. The benefits we currently experience from our vendor relationships could be adversely affected if our vendors:
•discontinue selling merchandise to us;
•enter into arrangements with competitors that could impair our ability to sell their products, including by giving our competitors exclusivity arrangements or limiting our access to certain products;
•sell similar or identical products to our competitors with similar or better pricing, some of whom may already purchase merchandise in significantly greater volume and at lower prices than we do;
•raise the prices they charge us;
•refuse to allow us to return merchandise purchased from them;
•change pricing terms to require us to pay on delivery or upfront, including as a result of changes in the credit relationships some of our vendors have with their various lending institutions;
•lengthen their lead times; or
•initiate or expand sales of their products to retail customers directly through their own stores, catalogs or on the Internet and compete with us directly.
Events that adversely impact our vendors could impair our ability to obtain adequate and timely supplies. Such events include, among others, difficulties or problems associated with our vendors’ business, the financial instability and labor problems of vendors, merchandise quality and safety issues, natural or man-made disasters, inclement weather conditions, war, acts of terrorism and other political instability, economic conditions, shipment issues, the availability of raw materials, and increased production costs. Our vendors may be forced to reduce their production, shut down their operations or file for bankruptcy. The occurrence of one or more of these events could impact our ability to get products to our customers, result in disruptions to our operations, increase our costs and decrease our profitability.
Material changes in the pricing practices of our suppliers could negatively impact our profitability. For example, we have in the past been subject to the unilateral pricing policies implemented by certain contact lens manufacturers, which mandated the minimum prices at which certain contact lenses could be sold to consumers. Such manufacturers could refuse to supply us with their products if they deem us in breach of such policies. Our vendors may also increase their pricing if their raw materials become more expensive or to offset the impact of tariffs. The raw materials used to manufacture our products are subject to availability constraints and price volatility. Our vendors may pass the increase in sourcing costs to us through price increases, thereby impacting our margins. We have faced such price increases previously and could face material changes in the future, impacting our ability to continue to provide our products to customers at competitive prices.
In addition, some of our vendors may not have the capacity to supply us with sufficient merchandise to keep pace with our growth plans, especially if we need significantly greater amounts of inventory. In such cases, our ability to pursue our growth strategy will depend in part upon our ability to develop new vendor relationships.
Some of our suppliers are owned by vertically-integrated companies with retail divisions that compete with us and, as such, we are exposed to the risk that these suppliers may not be willing, or may become unwilling, to sell their products to us on acceptable terms, or at all.
We rely on a limited number of vendors to supply the majority of our eyeglass lenses and contact lenses and are thus exposed to concentration of supplier risk. In particular, we have agreed to exclusively purchase almost all of our eyeglass lenses from one supplier. During fiscal year 2025, approximately 86% of lens expenditures were from this vendor and approximately 96% of contact lens expenditures were with three vendors. We are less exposed to a supplier risk for our eyeglass frames as only approximately 55% of frame expenditures were with two vendors. If we were to lose any significant supplier, we may be unable to establish additional or replacement sources for our products that meet our quality controls and standards in a timely manner, on commercially reasonable terms or at all. As a few major suppliers dominate the optical retail industry, the risks associated with finding alternative sources may be exacerbated.
Our ability to source merchandise and services outside of the U.S. could be adversely impacted by changes in U.S. or international laws, including the imposition of tariffs by the U.S. and the resulting consequences.
We also source merchandise directly from suppliers outside of the U.S. Additionally, a significant amount of our domestically-purchased merchandise is manufactured abroad. Global sourcing and foreign trade involve numerous factors and uncertainties beyond our control including increased shipping costs, the imposition of additional import or trade restrictions, including legal or economic restrictions on overseas suppliers’ ability to produce and deliver products, increased custom duties and tariffs, unforeseen delays in customs clearance of goods, more restrictive quotas, loss of a most favored nation trading status, currency exchange rates, transportation delays, port of entry issues and foreign government regulations, political instability, public health emergencies, and economic uncertainties in the countries from which we or our vendors source our products. There is significant uncertainty with the U.S. tariff regime following the U.S. Supreme Court decision that struck down certain of the US tariffs implemented by the Trump Administration. While we intend to seek a refund for duties paid under the invalidated regime, it is uncertain if and when we would receive such a refund. Although the U.S. Supreme Court has invalidated certain tariffs, the U.S. government has and may impose additional new or different tariffs under different authority. Any new, increased or modified tariffs or other trade restrictions could materially affect our operations. Moreover, negative press or reports about internationally manufactured products may sway public opinion, and thus customer confidence, away from the products sold in our stores. We also rely on vendors outside of the U.S. to provide certain services, including some call center functions. These services are subject to risks inherent in performing business operations outside of the U.S., including compliance with foreign laws and our ability to adequately oversee such functions. These and other issues affecting our international vendors or internationally manufactured merchandise could have a material adverse effect on our business, financial condition and results of operations.
If the U.S. were to withdraw from or materially modify any other international trade agreement to which it is a party or if the U.S. imposes significant additional tariffs or other restrictions on imports from Mexico, where our outsourced optical laboratories are located, or China, where the majority of our frames are sourced and manufactured, it could have an adverse impact on our business. The United States-Mexico-Canada Agreement (“USMCA”), the free trade agreement among the U.S., Canada and Mexico, is undergoing a joint review in 2026. If the USMCA is terminated, or otherwise substantially amended, it could have a material adverse impact on our financial performance. Any such tariffs, restrictions or other changes could lead to additional costs, delays in shipments, embargoes or other uncertainties that could negatively impact our relationships with our international vendors and labs and materially adversely affect our business, including by requiring us to increase our prices and identify alternative sources for merchandise and labs. For example, we source merchandise from suppliers located in China and a significant amount of domestically-purchased merchandise is manufactured in China. Historically, tariffs have not materially affected our financial results, and we believe that less than 10% of costs applicable to revenue are subject to tariffs on Chinese imports; however, tariff rates are subject to change and have varied over the past few years. There is significant uncertainty regarding trade policies between the U.S. and other countries. While we have implemented mitigation plans and continue to focus on additional mitigation strategies to offset the impact of tariffs, including the termination of our outsourced laboratory relationship with China in early 2024 in connection with the termination of our partnership with Walmart and as part of an ongoing effort to reduce tariff exposure to China, costs with respect to products subject to these tariffs have increased. If we are unable to mitigate the full impact of the enacted tariffs or if there is a further escalation of tariffs, costs on a significant portion of our products may increase further and our financial results may be negatively affected.
We rely heavily on our information technology systems, as well as those of our vendors, for our business to effectively operate and to safeguard confidential and sensitive information; any significant failure, inadequacy, interruption or security incident could materially adversely affect our business, financial condition and operations.
We rely heavily on our information technology systems, as well as those of our vendors, for many functions across our operations, including ERP, managing our supply chain and inventory, processing customer transactions in our stores, allocating lens processing jobs to the appropriate laboratories, providing and maintaining our remote medicine and EHR platforms, our financial accounting and reporting systems, maintenance of certain of our cybersecurity programs, CRM and customer engagement efforts, operating our websites, growing our omni-channel and e-commerce business, and human resources administration. Our ability to effectively manage our business and coordinate the sourcing, distribution and sale of our products depends significantly on the reliability and capacity of these systems. We also collect, process and store sensitive and confidential information, including our proprietary business information and that of our customers, associates, suppliers and business partners. The secure processing, maintenance and transmission of this information is critical to our operations.
Our systems, and those of our vendors, may be subject to damage or interruption from power outages or damages, telecommunications problems, data corruption, software errors, network failures, acts of war or terrorist attacks, fire, flood, ransomware or other cybersecurity attacks, and natural disasters. Our existing information security systems, data backup, access protection, user management and information technology emergency planning may not be sufficient to prevent data loss or long-term network outages. In addition, we may need to upgrade our existing information technology systems or choose to incorporate new technology systems from time to time in order for such systems to support the increasing needs of our expanding business and ever-changing cybersecurity threats. Costs and potential problems or interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or adequate support of existing systems could disrupt or reduce the efficiency of our operations. In particular, we recently implemented an ERP system to replace many of our former operating and financial systems. This type of implementation is a major undertaking, both financially and from a management and personnel perspective. Any material disruptions, delays or deficiencies in the implementation of our new ERP system could adversely affect our ability to process orders, ship products, provide services and customer support, send invoices and track payments, fulfill contractual obligations or otherwise operate our business.
Our systems and those of our third-party vendors and business partners may be vulnerable to security attacks by threat actors (including employees, criminal actors, and other third parties), acts of vandalism, use of computer malware, misplaced or lost data, human errors, or other similar events and are from time to time subject to such incidents. Security incidents, use of computer malware, and computer intrusions or compromises have become more prevalent across industries and are increasing in their frequency, level of persistence, sophistication and intensity, and are being conducted by sophisticated, criminal organized groups and individuals. We may face increased cybersecurity risks due to our reliance on Internet technology and the increased number of employees working remotely. If unauthorized parties gain access to our networks or databases, or those of our third-party vendors or business partners they may be able to exfiltrate, publish, delete, or use inappropriately or modify our or our customers’ confidential and sensitive information, including protected health information, payment card information and PII. In addition, employees may intentionally or inadvertently cause data or security incidents that result in unauthorized access to or release of sensitive or confidential
information. Because the techniques used to circumvent security systems can be highly sophisticated, change frequently, are often not recognized until launched against a target and may originate from less regulated areas around the world, we may be unable to proactively address all possible vulnerabilities or implement adequate preventive measures to prevent all attacks. Although the incidents that we have experienced to date have not had a material effect on our business, there can be no assurance that such incidents will not have a material adverse effect on us in the future. Any such incident, attack, or other event could result in costly investigations, regulatory scrutiny, and litigation exceeding applicable insurance coverage or contractual rights available to us, lost profits, increased expenses, civil or criminal penalties, operational changes or other response measures, loss of consumer confidence in our security measures, or negative publicity that could adversely affect our financial condition, results of operations and reputation.
Any material disruption or slowdown of our systems or those of our third-party service providers and business partners, could have a material adverse effect on our business, financial condition and results of operations.
Risks Related to Our Legal and Regulatory Environment
We are subject to extensive state, local and federal vision care and healthcare laws and regulations and failure to adhere to such laws and regulations would materially adversely affect our business.
We are subject to extensive state, local and federal vision care and healthcare laws and regulations. See Part I. Item 1. “Business-Government Regulation.” The laws applicable to us are also subject to evolving interpretations. As such, we must monitor our compliance with laws in every jurisdiction in which we operate on an ongoing basis and we cannot guarantee that subsequent interpretation of, or changes to, the applicable laws will not negatively affect our business operations.
For example, the arrangements we have implemented with optometrists and professional corporations or similar entities owned by eye care practitioners could subject us to scrutiny by federal and state regulatory bodies regarding federal and state anti-kickback, fraud and abuse, or other laws. In addition, our failure, or the failure of vision care professionals who are our associates or with whom we have contractual arrangements, to obtain and maintain appropriate licenses could result in the unavailability of vision care professionals in or near our stores, loss of sales and/or the closure of our stores without licensed professionals, as well as fines and penalties for dispensing prescription eyewear without such licensed professionals.
Additionally, our ability to recruit, hire and/or contract with vision care professionals is closely regulated. For example, there is a risk that state authorities in some jurisdictions may find that our contractual relationships with optometrists or professional corporations or similar entities that employ optometrists violate laws prohibiting the corporate practice of medicine/optometry, in which case we may be required to restructure these arrangements, which may make it more difficult for us to attract and retain their services.
State legislators and regulators may also be reluctant to accept telehealth and remote medicine as an additional way to provide access to quality patient care. There is a disparity across jurisdictions with respect to how telehealth is regulated and how we are able to implement our remote medicine solution. Our ability to launch our remote medicine solution in certain jurisdictions or in the most cost-efficient manner is highly dependent on the evolution of these state-by-state requirements and restrictions. Some states have taken positions on telehealth that significantly limit our ability to deploy our current remote medicine solution, or that prohibit the use of telehealth by optometrists to conduct eye examinations. The ever-changing regulatory landscape may cause disruption as we launch our remote medicine solution in various states, causing us to significantly reconfigure the solution or potentially decide to not deploy the solution in that particular state. This may have an abrupt and material effect on our business operations or financial status. If a legal challenge to our chosen remote medicine solution were successful, and we are unable to modify the model to comply with the requirements and still meet the needs of patients and optometrists, this may have a material effect on our business operations or financial status in that jurisdiction. We cannot provide any assurances that we will not be subject to reprimands, sanctions, probation, fines, suspension or revocation of operating or business permits, or that our ability to offer remote medicine services in that jurisdiction will not be challenged. We also may be the subject of administrative complaints or actions in the future. Our ability to recruit optometrists who are willing and able to provide telehealth services where permitted may be affected by their respective licensing authorities or state optometry boards or association’s view on telehealth practice. We must continuously monitor legislative and rulemaking activities for changes in telehealth requirements and work with various stakeholders to educate lawmakers on how remote optometry services may be provided safely and effectively. We cannot guarantee that our interpretation of existing or future requirements is aligned with how regulators may interpret such requirements, and we cannot assure that, if challenged, our current remote medicine solution will be found to be in compliance with the law.
We must comply with the FCLCA and its implementing regulations with respect to verifying contact lens prescriptions in connection with our online sales of contact lenses. Our extended warranty plans may subject us to state laws, which vary by state, that regulate the sale of product service contracts or insurance-like arrangements. It is possible that regulators in
certain states could determine that our warranty plans should be subject to these laws and mandate that we comply with various registration, disclosure and financial requirements. In such event, we could be required to incur enhanced compliance costs, or be at risk of cease and desist orders and monetary penalties.
Our participation in federal healthcare programs, such as Medicare and Medicaid, requires us to comply with laws regarding the way in which we conduct business and submit claims. These laws include the federal Anti-Kickback Statute, which attaches criminal liability to unlawful inducements for the referral of business reimbursable under federally-funded healthcare programs; the federal physician self-referral laws, which attach repayment and monetary damages where a healthcare service provider seeks reimbursement for providing certain services to a patient who was referred by a physician that has certain types of direct or indirect financial relationships with such service provider; and the FCA, which attaches per-claim liability and potentially treble damages to the filing of false claims for payment under federally funded programs. Many states have also adopted similar laws that apply to any third-party payor including commercial plans. Our operating results could be negatively impacted by developments in these areas due to the costs of compliance in addition to possible civil and criminal penalties, litigation and exclusion from government healthcare programs in the event of deemed noncompliance.
In addition, a person who offers or transfers to a federal healthcare program beneficiary any remuneration, including the transfer of items or services for free or other than fair market value, that the person knows or should know is likely to influence the beneficiary’s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services, may be liable for significant civil monetary penalties. Although this prohibition applies only to federal healthcare program beneficiaries; the provision of free items and services to patients covered by commercial payors may implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts, and statutory or common law fraud. In addition, state regulators or boards of optometry may also challenge our promotional practices, including America’s Best’s bundled offers, as, among other things, violating applicable state laws regarding unfair competition, false advertising to consumers or corporate practice of optometry prohibitions. To the extent our promotional programs are found to be inconsistent with applicable laws, we may be required to restructure or discontinue such programs, or be subject to other significant penalties.
Eyeglasses and contact lenses are regulated as medical devices in the U.S. by the FDA, and under the FDC Act, such medical devices must meet a number of regulatory requirements. We do not hold any marketing authorizations for the eyeglasses and contact lenses that we sell as we serve as the retailer for third-party manufacturers’ devices. We cannot provide assurance that such third-party manufacturers’ eyeglasses or contact lenses we sell comply with these regulatory requirements. We also engage in certain manufacturing, repackaging and relabeling activities that subject us to direct oversight by the FDA under the FDC Act and its implementing regulations. If we, or any of the third-party manufacturers whose products we sell, fail to comply with applicable requirements, we or they may be subject to legal action by the U.S. Department of Justice, on behalf of the FDA and/or various forms of FDA enforcement and compliance actions, which include recalls, fines, penalties, injunctions, seizures, prosecutions, adverse publicity (such as FDA press releases) or other adverse actions.
Our failure to comply with applicable regulations could have severe consequences, including the closure of our stores, possible breaches of the agreements relating to certain of our brands, changes to our way of doing business and the imposition of fines and penalties and have a materially negative impact on our business, financial condition or results of operations.
We are subject to managed vision care laws and regulations and the failure to comply with such laws and regulations could have a materially negative impact on our business, financial condition or results of operations.
We are engaged in managed vision care, both as a managed care entity through our subsidiary, FirstSight, and as a provider to managed care payors and insurers, and are subject to additional regulations as a result. FirstSight is licensed as a single-service HMO and is subject to the managed care laws of the State of California and is comprehensively regulated by the DMHC. FirstSight’s failure to comply with the regulations and requirements under such managed care laws may result in the imposition of various sanctions, including the suspension or revocation of FirstSight’s license, civil penalties and appointment of a receiver, among others. Material changes to the operations of FirstSight, including the opening of America’s Best locations outside of defined service areas, must be approved by the DMHC. This approval process can be complex and can cause delays in the projected opening of our stores. The sale of managed care products by FirstSight is essential to our America’s Best operations in California, and the suspension or loss of our license or our failure to otherwise comply with applicable regulatory requirements could have a material adverse impact on such business in California.
In addition, our Eyecare Club programs may be subject to regulation under managed care and related state laws, including those of California, where these programs are offered by FirstSight. Our Eyecare Club programs may also subject us to state statutes regulating discount medical plans, requiring the licensing or registration of organizations that provide discounted access to health care providers. It is possible that state regulators could determine that we are operating as a discount medical plan and as such are subject to various registration, disclosure and solvency requirements. We could incur increased compliance costs as a result. We would also be subject to the risk of cease and desist orders and monetary penalties.
We are subject to rapidly changing and increasingly stringent laws, regulations, contractual obligations, and industry standards relating to privacy, data security and data protection. The restrictions and costs imposed by these laws and other obligations, or our actual or perceived failure to comply with them, could subject us to liabilities that materially adversely affect our business, and financial condition or results of operations.
We are subject to HIPAA, the HITECH Act and the health data privacy, security and breach notification regulations issued pursuant to these statutes, which govern our collection, use, access, disclosure, transmission and/or storage of PHI, in connection with the sales of our products and services, customer service, billing and employment practices, as well as our operations as a business associate to multiple healthcare providers. HIPAA has several rules with which we must comply, including the HIPAA Privacy, Security, and Breach Notification rules. Each of these rules sets forth specific standards and controls that covered entities and business associates must implement, and the ongoing implementation of these requirements may take significant time, effort and resources, including engaging external resources to assess compliance with these rules. While we take precautions to detect and prevent non-compliance among our associates, subcontractors and vendors, it is not always possible to identify and deter misconduct related to unauthorized access, use, disclosure or destruction of PHI.
In addition, there are existing state privacy, security and breach notification laws and regulations that apply to both PHI and PII collected and/or processed by us and/or our third-party vendors. These existing laws and regulations may be amended and states may adopt new laws or regulations regarding consumer data security and privacy, including individual data privacy rights (such as rights to request a business for access to, deletion or modification of, or a portable copy of such individual’s personal information). In the states that have enacted comprehensive consumer privacy and data protection laws, companies generally must publicly disclose in a privacy notice how PII is used and shared with vendors, contractors, and third parties. Moreover, individuals in these states can usually opt out of the selling or sharing of their PII and restrict the use of cookies and similar tracking technologies by companies for non-essential purposes. Our failure to effectively implement the required or addressable data privacy and security safeguards and breach notification procedures, and to implement consumer data rights processes, or our failure to accurately anticipate the application or interpretation of these laws and regulations and standards, could lead to invalidation or modification of our agreements with optometrists or professional corporations or similar entities owned by eye care practitioners, create material civil and/or criminal liability for us or require us to change our business practices, which could result in adverse publicity and loss of consumer trust, and have a material adverse effect on our business, financial condition and results of operations.
The regulatory environment surrounding information security and privacy is increasingly demanding, with the frequent imposition of new and changing requirements across our business. For instance, as an entity that collects and maintains PII and PHI, we could be required, in the event of a data incident, to report the incident not only to affected customers, but also to various government agencies, regulators, and media outlets, potentially harming our reputation and our business. Our business partners may have contractual rights of indemnification against us or seek to terminate our contracts with them in the event that their customer or proprietary business information is disclosed as a result of a compromise of our information technology systems. Additionally, business partners may also face a data security incident, resulting in our customer or proprietary business information to be disclosed, which could result in a loss of consumer confidence in our security measures, harm our business, financial condition and results of operations, and lead to costly investigations, regulatory scrutiny, and litigation. Such an incident also may not be adequately covered under contractual rights of indemnification or by cyber insurance policies. Further, if we are unable to comply with the security standards established by banks and the payment card industry, we may be subject to fines, restrictions or expulsion from card acceptance programs, which could adversely affect our business, financial condition and results of retail operations. As privacy and information security laws and regulations change and vary from state to state, we may incur additional compliance costs.
We could be materially adversely affected by product liability, product recall or personal injury issues.
We could be materially adversely impacted by the supply of defective products, including the infiltration of counterfeit products into the supply chain and contamination or product mishandling issues. Product liability or personal injury claims may be asserted against us with respect to any of the products we sell or services we provide. The provision of professional eye care services by the vision care professionals employed by us or with whom we have contractual arrangements also increases our exposure to professional liability claims. There is a risk that these claims may exceed, or fall outside the scope of, our insurance coverage. In addition, a government or other regulatory agency could require us or one of our vendors or suppliers to remove a particular product from the market for, among other reasons, failure to adhere to product safety requirements or quality control standards. Product recalls can result in the disposal or write-off of merchandise, harm our reputation and cause us to lose customers, particularly if those recalls cause consumers to question the performance, quality, safety or reliability of our products. Any significant returns or warranty claims, as well as the timing of such returns or claims, could result in significant additional costs to us and could adversely affect our results of operations.
We rely on our suppliers to control the quality of both eyeglass components and contact lenses. We are not involved in the manufacture of the merchandise we purchase from our vendors for sale to our customers, and we do not independently investigate whether these vendors legally hold sufficient intellectual property rights to the merchandise that they are manufacturing or distributing. Our ability to seek recourse for liabilities and recover costs from our vendors depends on our contractual rights as well as on the financial condition and integrity of the vendors. Moreover, we engage in certain manufacturing, repackaging and relabeling activities at our optical laboratories and at certain Eyeglass World stores. If the products that we manufacture, repackage or relabel are defective or otherwise result in product liability or personal injury claims against us, our business could be adversely affected and we could be subject to adverse regulatory action.
If our merchandise or services do not meet applicable governmental safety standards or our customers’ expectations regarding quality or safety, we could experience lost sales and increased costs, be exposed to legal and reputational risk, or face fines or penalties which could materially adversely affect our financial results.
Failure to comply with laws, regulations and enforcement activities or changes in statutory, regulatory, accounting and other legal requirements could materially negatively impact our business, financial condition or results of operations.
In addition to the vision care and healthcare laws and regulations discussed above, we are subject to numerous federal, state, local and foreign laws and governmental regulations including those relating to environmental protection, building, land use and zoning requirements, workplace regulations, public accommodation, wage and hour, privacy and information security, consumer protection, immigration, and employment matters. If we fail to comply with existing or future laws or regulations, or if these laws or regulations are violated by importers, manufacturers or distributors, we may be subject to governmental or judicial fines or sanctions, while incurring substantial legal fees and costs. In addition, our capital expenditures could increase due to remediation measures that may be required if we are found to be noncompliant with any existing or future laws or regulations.
Further, the FTC has authority to investigate and prosecute practices that constitute “unfair trade practices,” “deceptive trade practices” or “unfair methods of competition.” State attorneys general typically have comparable authority and many states also permit private plaintiffs to bring actions on the basis of these laws. Federal and state consumer protection laws and regulations may apply to our operations and retail offers. For example, our America’s Best offer of a “free” eye exam is subject to compliance with laws and regulations governing the use of this term.
Our transactions with vendors engaged in international trade including the non-U.S. laboratories we contract with may subject us to the FCPA and trade sanction laws, and similar anti-corruption, anti-bribery and international trade laws, any violation of which could create substantial liability for us and also harm our reputation.
Our four laboratories in the U.S. and our in-store laboratories at Eyeglass World locations subject us to various federal, state and local laws, regulations and other requirements pertaining to protection of the environment, public health and associate safety, including regulations governing the management of hazardous substances and the maintenance of safe working conditions, such as the Occupational Safety and Health Act of 1970, as amended. These laws also apply generally to all of our properties. Our failure to comply with these laws can subject us to criminal and civil liabilities. In connection with our Vista Optical military locations, we must comply with regulations governing the occupancy of military bases. In connection with our philanthropic endeavors, we must also comply with additional federal, state and local tax and other laws and regulations.
Additionally, because we accept debit and credit cards for payment, we are subject to the PCI Standard issued by the Payment Card Industry Security Standards Council, with respect to payment card information. The PCI Standard contains compliance guidelines with regard to our security surrounding the physical and electronic storage, processing and transmission of cardholder data. Compliance with the PCI Standard and implementing related procedures, technology and information security measures requires significant resources and ongoing attention. Costs and potential problems and interruptions associated with the implementation of new or upgraded systems and technology such as those necessary to achieve compliance with the PCI Standard or with maintenance or adequate support of existing systems could also disrupt or reduce the efficiency of our operations. We rely on third-party vendors to handle PCI matters and ensure compliance. Any material interruptions or failures in our payment-related systems could have a material adverse effect on our business, financial condition and results of operations. If there are amendments to the PCI Standard, the cost of compliance with new requirements could also be substantial and we may suffer loss of critical data and interruptions or delays in our operations as a result.
Adverse judgments or settlements resulting from legal proceedings relating to our business operations could materially adversely affect our business, financial condition and results of operations.
From time to time, we are subject to allegations, and may be party to legal claims and regulatory proceedings, relating to our business operations. See Part I. Item 3. “Legal Proceedings.” Such allegations, claims and proceedings may be brought by third parties, including our shareholders, customers, associates, governmental or regulatory bodies, or competitors and may include class actions. Defending against such claims and proceedings is costly and time consuming and may divert management’s attention and resources from our normal business operations, and the outcome of many of these claims and proceedings cannot be predicted. If any of these claims or proceedings were to be determined adversely to us, if a judgment, a fine or a settlement involving a payment of a material sum of money were to occur, or if injunctive relief were issued against us, our business, financial condition and results of operations could be materially adversely affected.
We are and may in the future be the target of securities-related litigation. Litigation can divert our management’s attention and resources, result in substantial costs, and have an adverse effect on our business, results of operations, financial condition and stock price.
We maintain director and officer insurance to mitigate the risks associated with potential claims; however, we are responsible for meeting certain deductibles under such policies, and there can be no assurance that our insurance coverage will adequately protect us from all claims made against us. Further, as a result of the litigation, the costs of insurance may increase, and the availability of coverage may decrease. As a result, we may not be able to maintain our current levels of insurance at a reasonable cost, or at all, which might make it more difficult to attract qualified candidates to serve as executive officers or directors. There also may be adverse publicity associated with litigation that could negatively affect customer perception of our business and materially damage our reputation.
We may not be able to adequately protect our intellectual property, which could harm the value of our brand and materially adversely affect our business.
Our ability to implement our business plan successfully depends in part on our ability to further build brand recognition using our trademarks, service marks and other proprietary intellectual property, including our name and logos. While it is our policy to protect and defend vigorously our rights to our intellectual property, we cannot predict whether steps taken by us to protect our intellectual property rights will be adequate to prevent infringement or misappropriation of these rights. It may be difficult for us to prevent others from copying elements of our products and any litigation to enforce our rights could be costly, divert attention of management and may not ultimately be successful. Although we believe that we have sufficient rights to all of our trademarks, service marks and other intellectual property rights, we may face claims of infringement that could interfere with our ability to market and promote our brands. Any such litigation may be costly and divert resources from our business. Moreover, if we are unable to successfully defend against such claims, we may be prevented from using our trademarks, service marks or other intellectual property rights in the future and may be liable for damages, which in turn could materially adversely affect our business, financial condition or results of operations.
Risks Related to Our Indebtedness
We have a significant amount of indebtedness which could adversely affect our business and financial position, including by limiting our business flexibility and preventing us from meeting our debt obligations.
We have a significant amount of indebtedness. As of January 3, 2026, we had approximately $237.6 million of aggregate principal amount of indebtedness associated with our first lien term loan (the “Term Loan A”) due in 2028. Our leverage could have a number of consequences for us, including:
•requiring us to utilize a substantial portion of our cash flows from operations to make payments on our indebtedness, reducing the availability of our cash flows to fund working capital, capital expenditures, general corporate and other purposes;
•increasing our vulnerability to adverse economic, industry or competitive developments;
•making it more difficult for us to satisfy our obligations with respect to our indebtedness, and any failure to comply with the obligations of any of our debt instruments, including any financial maintenance and restrictive covenants, could result in an event of default under the agreements governing our indebtedness;
•restricting us from capitalizing on business opportunities;
•limiting our ability to obtain additional financing for working capital, capital expenditures, execution of our business strategy, debt service requirements, acquisitions or other general corporate purposes; and
•limiting our flexibility in planning for, or reacting to, changes in our business or market conditions and placing us at a competitive disadvantage compared to our competitors who are less highly leveraged and who, therefore, may be able to take advantage of opportunities that our leverage prevents us from exploiting.
Our ability to make principal and interest payments on and to refinance our indebtedness will depend on our ability to generate cash in the future and is subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control. If we cannot generate sufficient cash flow from operations to make scheduled principal and interest payments in the future, we may need to refinance all or a portion of our indebtedness on or before maturity, sell assets, delay capital expenditures or seek additional equity. The terms of our existing or future debt agreements may also restrict us from effecting any of these alternatives. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. In addition to refinancing, we may elect to deploy capital to reduce outstanding debt and such capital deployment would reduce our ability to use funds for other purposes. Further, changes in the credit and capital markets, including market disruptions and interest rate fluctuations, may increase the cost of financing, make it more difficult to obtain favorable terms, or restrict our access to these sources of future liquidity. In addition, any failure to make scheduled payments of interest and principal on our outstanding indebtedness would likely result in a reduction of our credit rating, which could harm our ability to incur additional indebtedness on commercially reasonable terms or at all. Our inability to generate sufficient cash flow to satisfy our debt service obligations, or to refinance or restructure our obligations on commercially reasonable terms or at all, could have a material adverse effect on our business, financial condition and results of operations, as well as on our ability to satisfy our obligations in respect of our indebtedness.
A change in interest rates may adversely affect our business.
As of January 3, 2026, our term loan borrowings of $237.6 million were subject to variable interest rates, with a weighted average borrowing rate of 5.6%. Our interest rate collar matured in 2024. We entered into an interest rate swap during the fourth quarter of 2025 to help offset the variability of cash flows in term loan interest payments attributable to changes in Term SOFR. The notional amount of the hedge is $100.0 million. See Note 13. “Interest Rate Derivatives” for further details. An increase in interest rates, whether because of an increase in market interest rates or a decrease in our creditworthiness, could increase the cost of servicing our debt and could materially reduce our profitability and cash flows.
Moreover, at this time, it is not possible to predict the full effect that the recent discontinuance of London Interbank Offered Rate (“LIBOR”), or the establishment of alternative reference rates such as SOFR, will have on us or our borrowing costs and such changes may result in an increase in the cost of our variable rate indebtedness. SOFR is a relatively new reference rate and its composition and characteristics are not the same as LIBOR. Given the limited history of this rate and potential volatility as compared to other benchmark or market rates, the future performance of this rate cannot be predicted based on historical performance.
Our credit agreement contains restrictions that limit our flexibility in operating our business.
Our credit agreement imposes significant operating and financial restrictions. These covenants may limit our ability and the ability of our subsidiaries, under certain circumstances, to, among other things:
•incur additional indebtedness;
•create or incur liens;
•engage in certain fundamental changes, including mergers or consolidations;
•sell or transfer assets;
•pay dividends and distributions on our subsidiaries’ capital stock;
•make acquisitions, investments, loans or advances;
•pay or modify the terms of certain indebtedness;
•engage in certain transactions with affiliates; and
•enter into negative pledge clauses and clauses restricting subsidiary distributions.
Our credit agreement also contains certain customary affirmative covenants and events of default, including a change of control and financial maintenance covenants prohibiting us from exceeding a certain total leverage ratio or falling below a certain interest coverage ratio. As a result of these covenants and restrictions, we are limited in how we conduct our business, and we may be unable to raise additional debt or equity financing to compete effectively or to take advantage of new business opportunities. The terms of any future indebtedness we may incur could include more restrictive covenants. We cannot guarantee that we will be able to maintain compliance with these covenants in the future and, if we fail to do so, that we will be able to obtain waivers from the lenders and/or amend the covenants.
Our failure to comply with the restrictive covenants described above as well as others contained in our future debt instruments from time to time could result in an event of default, which, if not cured or waived, could result in our being required to repay these borrowings before their maturity dates. In addition, any event of default or declaration of acceleration under one debt instrument could also result in an event of default under one or more of our other debt instruments. If we are unable to repay, refinance or restructure our indebtedness under our secured debt, the holders of such debt could proceed against the collateral securing that indebtedness. If we are forced to refinance these borrowings on less favorable terms or if we are unable to repay, refinance or restructure such indebtedness, our financial condition and results of operations could be adversely affected.
Risks Related to Ownership of Common Stock
Our stock price may be volatile or may decline regardless of our operating performance.
The trading price of our common stock may be volatile and subject to fluctuations due to a number of factors, most of which we cannot control, including those listed under these “Risk Factors,” and the following:
•actual or anticipated variations in our results of operations;
•changes in expectations as to our future financial performance, including financial estimates and investment recommendations by securities analysts and investors;
•additions or departures of key management personnel;
•strategic actions by us or our competitors, including announcements by us, our competitors, our suppliers or our Host organizations of significant contracts, price reductions, new products or technologies, acquisitions, joint marketing relationships, joint ventures, other strategic relationships, or capital commitments;
•changes in general economic or market conditions or trends in our industry or the economy as a whole and, in particular, in the consumer spending environment;
•changes in business or regulatory conditions;
•investor perceptions of or the investment opportunity associated with our common stock relative to other investment alternatives;
•the public’s response to press releases or other public announcements by us or third parties, including our filings with the SEC;
•announcements relating to litigation or governmental investigations;
•guidance, if any, that we provide to the public, any changes in this guidance or our failure to meet this guidance;
Furthermore, the stock market may experience extreme volatility that, in some cases, may be unrelated or disproportionate to the operating performance of particular companies. These broad market and industry fluctuations may adversely affect the market price of our common stock, regardless of our actual operating performance. In addition, price volatility may be greater if the public float and trading volume of our common stock is low.
Because we have no current plans to pay cash dividends on our common stock, investors may not receive any return on investment unless they sell their common stock for a price greater than that which they paid for it.
We have no current plans to pay cash dividends on our common stock. The declaration, amount and payment of any future dividends on our common stock will be at the sole discretion of our Board of Directors. Our Board of Directors may take into account general and economic conditions, our financial condition and results of operations, our available cash and current and anticipated cash needs, capital requirements, contractual, legal, tax and regulatory restrictions and implications on the payment of dividends by us to our stockholders or by our subsidiaries to us, including restrictions under our credit agreement and other indebtedness we may incur, and such other factors as our Board of Directors may deem relevant. As a result, investors may not receive any return on an investment in our common stock unless they sell our common stock for a price greater than their purchase price.
We are a holding company with no operations of our own and, as such, we depend on our subsidiaries for cash to fund all of our operations and expenses, including future dividend payments, if any.
Our operations are conducted entirely through our subsidiaries and our ability to generate cash to meet our debt service obligations or to make future dividend payments, if any, is highly dependent on the earnings and the receipt of funds from our subsidiaries via dividends or intercompany loans. We do not currently expect to declare or pay dividends on our common stock for the foreseeable future; however, to the extent that we determine in the future to pay dividends on our common stock, the agreements governing our indebtedness may restrict the ability of our subsidiaries to pay dividends or otherwise transfer assets to us.
Anti-takeover provisions in our organizational documents could delay or prevent a change of control.
Certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws may have an anti-takeover effect and may delay, defer or prevent a merger, acquisition, tender offer, takeover attempt, or other change of control transaction that a stockholder might consider in its best interest, including those attempts that might result in a premium over the market price for the shares held by our stockholders.
These provisions provide for, among other things:
•the ability of our Board of Directors to issue one or more series of preferred stock;
•advance notice requirements for nominations of directors by stockholders and for stockholders to include matters to be considered at our annual meetings; and
•certain limitations on convening special stockholder meetings.
These anti-takeover provisions could make it more difficult for a third party to acquire us, even if the third party’s offer may be considered beneficial by many of our stockholders. As a result, our stockholders may be limited in their ability to obtain a premium for their shares.
Our Board of Directors is authorized to issue and designate shares of our preferred stock in additional series without stockholder approval.
Our amended and restated certificate of incorporation authorizes our Board of Directors, without the approval of our stockholders, to issue 50,000,000 shares of our preferred stock, subject to limitations prescribed by applicable law, rules and regulations and the provisions of our amended and restated certificate of incorporation, as shares of preferred stock in series, to establish from time to time the number of shares to be included in each such series and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations or restrictions thereof. The powers, preferences and rights of these additional series of preferred stock may be senior to or in parity with our common stock, which may reduce its value.
Our certificate of incorporation provides, subject to limited exceptions, that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain stockholder litigation matters, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, associates or stockholders.
Our amended and restated certificate of incorporation provides, subject to limited exceptions, that unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for any (i) derivative action or proceeding brought on behalf of our company, (ii) action asserting a claim of breach of a fiduciary duty owed by any director, officer, or other associate or stockholder of our company to the Company or our stockholders, creditors or other constituents, (iii) action asserting a claim against the Company or any director or officer of the Company arising pursuant to any provision of the Delaware General Corporation Law, or the DGCL, or our amended and restated certificate of incorporation or our amended and restated bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv) action asserting a claim against the Company or any director or officer of the Company governed by the internal affairs doctrine.
Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our amended and restated certificate of incorporation. This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other associates or stockholders which may discourage lawsuits with respect to such claims.
Application of the choice of forum provision may be limited in some instances by law. Section 27 of the Securities Exchange Act of 1934 (“Exchange Act”) provides for exclusive federal court jurisdiction over Exchange Act claims. Accordingly, to the extent the exclusive forum provision is held to cover a shareholder derivative action asserting claims under the Exchange Act, such claims could not be brought in the Delaware Court of Chancery and would instead be within the jurisdiction of the federal district court for the District of Delaware. Section 22 of the Securities Act of 1933 (“Securities Act”) creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Moreover, our stockholders will not be deemed by operation of our choice of forum provision to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.
Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition.
If securities or industry analysts do not publish research or reports about our business or if they downgrade our stock or our sector, our stock price and trading volume could decline.
The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. We do not control these analysts. Furthermore, if one or more of the analysts who do cover us downgrade our stock or our industry, or change their views regarding the stock of any of our competitors, or publish inaccurate or unfavorable research about our business, the price of our stock could decline. If one or more of these analysts stop covering us or fail to publish reports on us regularly, we could lose visibility in the market, which in turn could cause our stock price or trading volume to decline.
Item 1B. Unresolved Staff Comments
None.
Item 1C. Cybersecurity
Risk Management and Strategy
We have developed processes for assessing, identifying and managing material risks from cybersecurity threats. Our enterprise risk assessment and management system incorporates risks from cybersecurity threats alongside other risks to the Company. We also have a management-level risk management council that supports our processes to assess and manage cybersecurity and other risks. Our information security team oversees and implements security controls designed to minimize the risk or impact of any compromise or unauthorized disclosure of our or our customers’ confidential and sensitive data, including protected health information and PII. These controls include endpoint protection and response software (anti-virus), network intrusion detection devices, a vulnerability management program, IT and third-party risk management programs, and multifactor authentication. We provide annual security awareness training for corporate and
store associates, and we administer periodic phishing testing and training to associates who have access to a company email address.
The security of the National Vision network is monitored by a Security Operations Center (“SOC”), which works with our information security team with the aim of preventing, detecting, and responding to cybersecurity attacks. We also maintain an incident response plan which, among other things, is designed to outline the response actions to an incident, mitigate the impact of an incident, assist in restoring normal business operations, and comply with applicable regulatory obligations arising from an incident. Our risk management processes also address cybersecurity threat risks associated with our use of third-party vendors. Our Chief Technology Officer (“CTO”) collaborates with our information security and legal teams to conduct periodic tabletop exercises to test our data security and incident response procedures. Periodically, we engage specialized third parties to assist in conducting these exercises. We also conduct third-party HIPAA security risk assessments to identify and catalog potential security risks to health data.
In the last three fiscal years, we have not experienced a material information security incident, and we are not aware of any cybersecurity risks that are reasonably likely to materially affect our business, including our business strategy, results of operations, or financial condition. Further discussion of the potential impacts on our business from cybersecurity incidents is provided in “Item 1A. Risk Factors – We rely heavily on our information technology systems, as well as those of our vendors, for our business to effectively operate and to safeguard sensitive and confidential information; any significant failure, inadequacy, interruption or security incident could adversely affect our business, financial condition and operations,” the sophistication of cyber threats continues to increase, and the actions we take to reduce the risk of cyber incidents and protect our systems and information may be insufficient. As such, no matter how well our controls are designed or implemented, we cannot assure that we will be able to anticipate all security incidents, and we may not be able to implement effective preventive measures against such security incidents in a timely manner.
Governance
Our CTO oversees our cybersecurity program and is responsible for assessing and managing our material risks from cybersecurity threats. Our CTO has served in this role at the Company since September 2025 and brings more than 30 years of industry experience in various senior roles involving managing global information technology and providing technology services in the areas of application development, infrastructure, data, and technology strategy, and specializing in Agentic AI, cloud solutions, enterprise software, and technology strategy. The Vice President of Information Technology Infrastructure collaborates with the CTO and a supporting team to maintain and update the Company’s technology infrastructure and corresponding safety measures. Our VP of Information Technology Infrastructure has served in this role at the Company for over eight years, has over 25 years of experience in information technology systems and holds a bachelor of science degree in computer information systems.
Our CTO is informed about, and monitors the prevention, detection, mitigation and remediation of, cybersecurity incidents through the management of and participation in the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. When a cybersecurity incident occurs or we identify a vulnerability, we have cross-functional teams that are responsible for leading the initial assessment of priority and severity, and external experts may also be engaged as appropriate.
The Audit Committee of our Board, pursuant to its charter, oversees our enterprise risk management process, which includes risks from cybersecurity threats. The Audit Committee regularly receives reports from management with respect to risks from cybersecurity threats and quarterly reviews cybersecurity and data security risks and mitigation strategies, along with program assessments, planned improvements and the status of information technology initiatives with the CTO. These risks and mitigation strategies are also periodically reviewed by the entire Board.
Item 2. Properties
We lease all of our America’s Best and Eyeglass World retail stores. Our leases generally have noncancelable lease terms of between five and 10 years, with an option to renew for additional terms of one to 10 years or more. In recent years, we have entered into more leases with 10-year initial terms with renewal options. Most leases for these retail stores provide for a minimum rent, typically with escalating rent increases. In certain circumstances we pay a percentage rent based upon sales after certain minimum thresholds are achieved. These leases generally require us to pay insurance, utilities, real estate taxes and common area maintenance expenses.
We occupy our Host locations through master agreements with our Host partners, which contain standard terms and conditions, such as fixed and percentage-based payments.
A summary of our stores by location as of January 3, 2026 is shown below.
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| State | America’s Best | Eyeglass World | Other | | State | America’s Best | Eyeglass World | Other |
| AK | — | — | 6 | | MO | 27 | 1 | 1 |
| AL | 25 | 1 | 3 | | MS | — | — | 2 |
| AR | — | — | 1 | | NC | 28 | — | 2 |
| AZ | 32 | 11 | 2 | | NE | 6 | 1 | 1 |
| CA | 93 | — | 3 | | NJ | 45 | — | 1 |
| CO | 27 | 7 | 3 | | NM | — | 2 | 3 |
| CT | 8 | — | — | | NV | — | 4 | 1 |
| FL | 110 | 44 | 2 | | NY | 33 | — | 1 |
| GA | 56 | 4 | 5 | | OH | 46 | 1 | 1 |
| IA | 6 | 1 | — | | OR | 12 | — | 5 |
| ID | 7 | — | — | | PA | 50 | 5 | — |
| IL | 62 | 2 | — | | SC | 23 | 2 | 1 |
| IN | 18 | 11 | — | | TN | 29 | 6 | — |
| KS | — | 2 | 2 | | TX | 138 | 6 | 5 |
| KY | 5 | 1 | 2 | | UT | 14 | 5 | 1 |
| LA | 15 | — | 1 | | VA | 38 | — | 1 |
| MD | 24 | — | 1 | | WA | 20 | 1 | 13 |
| MI | 37 | 4 | — | | WI | 9 | — | — |
| MN | 13 | — | — | | WY | 1 | — | — |
___________
Note: ‘Other’ includes Vista Optical in Fred Meyer stores and on military bases. There is one Vista Optical location in Puerto Rico.
We lease laboratories in Georgia, Texas and Utah, a distribution center in Georgia, and we own our laboratory in Minnesota. We operated our distribution center in Ohio through June 2024 and have subsequently subleased the property to a third party.
Our corporate office is located in leased space in Duluth, Georgia. In addition, we lease office space for our FirstSight corporate office in Upland, California.
Item 3. Legal Proceedings
See Note 11. “Commitments and Contingencies” in our consolidated financial statements included in Part II. Item 8. of this Form 10-K for information regarding certain legal proceedings in which we are involved, which discussion is incorporated herein by reference.
Item 4. Mine Safety Disclosures
Not applicable.
Information About Our Executive Officers
Information about our executive officers is incorporated by reference from Part III—Item 10 of this Form 10-K.
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
Our common stock is listed on the Nasdaq Global Select Market under the symbol “EYE.”
Holders
As of February 20, 2026, there were approximately 12 holders of record of our common stock. The number of holders of record is based upon the actual number of holders registered at such date and does not represent the actual number of beneficial owners of our common stock because shares are frequently held in “street name” by securities dealers and others for the benefit of individual owners.
Issuer Purchases of Equity Securities
During the quarter ended January 3, 2026, we did not purchase any of our equity securities that are registered under Section 12(b) of the Exchange Act.
The Company’s original share repurchase authorization expired on January 3, 2026, and had remaining capacity of $50 million. Effective March 2, 2026, the Company’s Board of Directors (the “Board”) authorized the Company to repurchase up to $50 million aggregate amount of shares of the Company’s common stock until December 28, 2030. The authorization permits the Company to make purchases of its common stock from time to time in the open market or privately negotiated transactions, and pursuant to pre-set trading plans meeting the requirements of all applicable securities laws and regulations. The timing and amounts of any such repurchases will depend on a variety of factors, including the market price of the Company’s shares, general market and economic conditions, legal requirements and tax implications. The Company expects to fund the share repurchases using cash on hand.
Dividends
We have not paid dividends in the past and have no current plans to pay dividends on our common stock.
Performance Graph
This performance graph shall not be deemed “soliciting material” or “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act or the Exchange Act.
The graph below presents the Company’s cumulative total stockholder returns relative to the performance of the Nasdaq Global Composite Index and the Nasdaq US Benchmark Retail Index commencing December 31, 2020 and through January 2, 2026. All values assume a $100 initial investment in the Company’s common stock on Nasdaq and data for the Nasdaq Global Composite Index and the Nasdaq US Benchmark Retail Index assumes all dividends were reinvested on the date paid. The points on the graph represent fiscal year-end values based on the last trading day of each fiscal year. The comparisons are based on historical data and are not indicative of, nor intended to forecast, the future performance of our common stock.
Unregistered Sales of Equity Securities
None.
Item 6. Reserved
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion contains management’s discussion and analysis of our financial condition and results of operations and should be read together with the consolidated financial statements and the related notes thereto included elsewhere in this Form 10-K (this “Form 10-K”). This discussion contains forward-looking statements that reflect our plans, estimates and beliefs and involve numerous risks and uncertainties, including, but not limited to, those described in the “Risk Factors” section included in Part I. Item 1A. in this Form 10-K, as such risk factors may be updated from time to time in our periodic filings with the SEC. Actual results may differ materially from those contained in any forward-looking statements. You should carefully read “Special Note Regarding Forward-Looking Statements” in this Form 10-K.
We conduct substantially all of our activities through our indirect wholly-owned subsidiary, NVI, and its subsidiaries. We operate on a retail fiscal calendar that results in a given fiscal year consisting of a 52- or 53-week period ending on the Saturday closest to December 31. In a 52-week fiscal year, each quarter contains 13 weeks of operations; in a 53-week fiscal year, each of the first, second and third quarters includes 13 weeks of operations and the fourth quarter includes 14 weeks of operations. References herein to “fiscal year 2025” relate to the 53 weeks ended January 3, 2026, references
herein to “fiscal year 2024” relate to the 52 weeks ended December 28, 2024 and references herein to “fiscal year 2023” relate to the 52 weeks ended December 30, 2023.
The disclosures contained in this Form 10-K are made only as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by law. For further information, please see “Risk Factors” and “Forward-Looking Statements.”
Overview
We are one of the largest optical retailers in the United States (“U.S.”) and a leader in the value segment of the U.S. optical retail industry. We believe that vision is central to quality of life and that people deserve to see their best to live their best. Our mission is to help people by making quality eye care and eyewear more affordable and accessible. We achieve this by providing eye exams, eyeglasses and contact lenses to consumers across the nation. Our range of quality product offerings at multiple price points makes us an attractive destination for consumers of all income levels. As of January 3, 2026, our 2025 fiscal year end, we reach our customers through a diverse portfolio of 1,250 retail stores across four brands, our associated omni-channel consumer websites, and our dedicated e-commerce consumer website.
Brand and Segment Information
As of January 3, 2026, our operations consisted of one reportable segment. During fiscal year 2024, our Walmart store operations, including our former Legacy reportable segment (“Legacy”) and components of our AC Lens operating segment met the requirements to be classified as discontinued operations.
•Owned & Host – As of fiscal year end 2025, our owned brands consisted of 1,057 America’s Best Contacts and Eyeglasses (“America’s Best”) retail stores and 122 Eyeglass World retail stores. In America’s Best stores, vision care services are provided by optometrists employed by us or by independent professional corporations or similar entities. America’s Best stores are primarily located in high-traffic strip centers next to value-focused retailers. Eyeglass World locations offer eye exams, provided by optometrists employed either by us or independent professional corporations or similar entities, and have on-site optical laboratories that enable stores to quickly fulfill many customer orders and make repairs on site. Eyeglass World stores are primarily located in freestanding or in-line locations near high-foot-traffic shopping centers. Our Host brands consisted of 53 Vista Optical locations on select military bases and 18 Vista Optical locations within select Fred Meyer stores as of fiscal year end 2025. We have strong, long-standing relationships with our Host partners and have maintained each partnership for over 20 years. These brands provide eye exams primarily by independent optometrists. All brands utilize our centralized laboratories. This segment also includes sales from our America’s Best, Eyeglass World, and Military omni-channel websites.
Our consolidated results for all periods presented in this Form 10-K also include the following:
•Corporate and other — Our corporate and other category includes the results of our dedicated e-commerce website, which sells contact lenses and optical accessory products to retail customers, and recognizes revenue when products have been delivered to the customer and our managed care business conducted by FirstSight, our wholly-owned subsidiary that is licensed as a single-service health plan under California law, which issues individual vision plans in connection with our America’s Best operations in California. Our “corporate and other” category also includes unallocated corporate overhead expenses, which are a component of Selling, general and administrative expenses (“SG&A”) and are comprised of various home office expenses such as payroll, occupancy costs and consulting and professional fees. Corporate overhead expenses also include field services for our four retail brands. Other expenses included in this category include certain non-cash charges, including asset impairment, stock-based compensation expense, and the impact of certain events, gains, or losses excluded from the assessment of segment performance.
•Effects of unearned and deferred revenue — Reportable segment information is presented on the same basis as our consolidated financial statements, except reportable segment revenues and associated costs applicable to revenue which exclude the effects of unearned and deferred revenue, consistent with what our chief operating decision maker (“CODM”) regularly reviews. We present the effects of unearned and deferred revenues separately from our reportable segment information. See Note 15. “Segment Reporting” in our consolidated financial statements. Deferred revenue represents the timing difference between the point of sale and when services related to product protection plans and eye care club memberships are performed. Increases or decreases in deferred revenue during the reporting period represent cash collections in excess of, or below the recognition of, previous deferrals. Unearned revenue represents the timing difference between the point of sale transaction and delivery/customer acceptance, and includes sales of prescription eyewear during approximately the last two weeks of the reporting period.
Trends and Other Factors Affecting Our Business
Historically, our business model primarily targeted lower-income consumers with a go-to-market strategy focused on merchandise and messaging of the lowest price. We evolved our operating model in light of the impact of Covid to address changing consumer and doctor preferences, including by introducing cutting edge remote telehealth capabilities, which are now installed in over 800 of our locations. We believe this differentiator greatly improves our ability to provide consistent access to patient care across our network of stores. In fiscal 2024, we began implementing transformation initiatives designed to accelerate long-term growth and strengthen profitability, including new additions to our executive leadership team, continued expansion of exam capacity, new traffic-driving initiatives.
In 2025, we embarked on the next phase of our transformation, focused on the rapid modernization of our business in the context of contemporary consumer needs and wants. Our strategy is focused around creating a more joyful consumer experience with refreshed merchandising, updated marketing and brand assets, new in-store technologies to support the customer journey, and an updated pricing architecture, all of which allow us to better serve our existing customers and expand our target consumer demographics. During 2025, as an embodiment of our transformation, we refreshed the National Vision and America’s Best brand identities. We also introduced a new America’s Best brand promise, “Every Eye Deserves Better,” which better reflects our customer mix. These consumer-facing strategies are paired with an increased focus on cost optimization and operating margin expansion, all of which are intended to drive the outcome of a stronger core business and improved operating results.
The overall economic environment continues to be challenging and macroeconomic factors that may affect customer spending patterns, and thereby our results of operations, include inflation, employment rates, business conditions, changes in the housing market, the availability of credit, interest rates, tax rates and policies, fuel and energy costs and overall consumer confidence in future economic conditions, as well as global political, socio-economic, cultural, and geopolitical uncertainty. The effects of the current macroeconomic environment and geopolitical uncertainty, resulted in reduced customer demand in 2025 and have caused shifts in consumer behaviors and preferences, which impact the demand for our products. As a result, the predictability of recurring purchase behavior for the future remains uncertain, primarily for the cash pay consumer.
We operate in the highly competitive and fragmented U.S. optical retail industry. We face competition from mass merchants, specialty retail chains, online retailers and independent eye practitioners and opticians, along with large national retailers. Increased consolidation activity in the industry may enable our competitors to benefit from purchasing advantages and the ability to leverage management capabilities across a larger business base. Along with our competitors, we are affected by a number of various trends and factors, including, but not limited to, economic conditions, availability of vision care professionals, inflation, consumer preferences and demand.
Our ability to continue to attract and retain qualified vision care professionals impacts exam capacity and our operations, like those of many of our competitors, depend on our ability to offer both eyewear and eye exams. We believe factors such as an increasingly challenging recruiting market (in particular for new graduates), preferences for adjusted work schedules, and the demand for optometrists exceeding supply in certain areas caused constraints in vision care professional availability and therefore exam capacity in recent years, which may continue. As a result, recruiting and retaining optometrists has become more challenging and the costs to employee or retain optometrists have increased and may increase further, potentially materially. Targeted wage investments, including increases in compensation for our optometrists and associates, and flexibility initiatives have impacted our costs applicable to revenue and SG&A expenses. We anticipate that wage pressures in certain markets may continue to some degree in 2026. Wage investment pressure and increases to costs applicable to revenue from increases in raw materials prices may not be able to be fully offset by leverage from revenue growth, productivity efficiency and, as appropriate, various pricing actions. We are continuing to strategically invest in recruitment and retention initiatives, including flexible adjusted work schedules, along with continuing our implementation of remote medicine technologies, which has expanded our offerings while also increasing costs.
We believe remote medicine not only helps provide more access to eye care for patients, it also helps address constraints in exam capacity. We anticipate continuing the investment in remote medicine primarily in America’s Best stores in the near term, adding select locations where feasible and advantageous and depending on the state-by-state regulatory
environment. While the remote medicine and EHR platforms have increased exam capacity, revenue and profitability, we have experienced higher costs applicable to revenue as a percentage of revenue, when compared with in-store exams.
In addition to the central factors impacting our business outlined above, we have identified the following key drivers, challenges and risks on which we are focused and which are detailed below.
Inflation
Elevated inflation can result in increased costs and greater profitability pressure for us. While pressures from increases to the price of our raw materials have had an impact on our costs applicable to revenue in fiscal year 2025, we have been able to offset these pressures with efficiencies in our laboratory network, pricing actions and lower freight costs. We anticipate that pressures from increases to our raw materials prices could have an impact on our costs applicable to revenue in fiscal year 2026. Such an inflationary environment and labor market challenges can also result in wage pressures in certain markets. Wage investments as a result of inflation and an increasingly competitive recruiting market for vision care professionals that became more acute during the COVID -19 pandemic and related effects have had, and may continue to have, an impact on our profitability.
New Store Openings
We expect that new stores will continue to be a key driver of growth in our net revenue and operating profit in the future. Our results of operations have been and will continue to be materially affected by the timing and number of new store openings. As stores mature, profitability typically increases significantly. The performance of new stores is dependent upon factors such as the availability of optometrists, implementation and operation of remote medicine technology, the time of year of a particular opening, the amount of store pre-opening costs, labor and occupancy costs in the specified market, level of participation in managed care plans, and location, including whether they are in new or existing markets. During fiscal 2025, we opened 33 new stores, and we plan to open approximately 30 to 35 new stores in 2026, primarily comprised of America’s Best stores, after which time we expect to return to our more recent store opening cadence as strategic initiatives begin to take hold.
Comparable Store Sales Growth
Comparable store sales growth is a key driver of our business. Many factors affect comparable store sales, including:
•consumer confidence, preferences and buying trends and overall economic trends including inflation;
•the availability of optometrists and other vision care professionals;
•advertising strategies;
•participation in managed care programs;
•the recurring nature of eye care purchases;
•our ability to identify and respond effectively to customer preferences and trends;
•our ability to provide an assortment of high quality/low-cost product offerings that generate new and repeat visits to our stores;
•foot traffic in retail shopping centers where our stores are predominantly located;
•the customer experience we provide in our stores;
•our ability to source and receive products accurately and timely;
•changes in product pricing, including promotional activities;
•the number of items purchased per store visit;
•the number of stores that have been in operation for more than 12 months;
•impact of competition and consolidation in the U.S. optical retail industry;
•impact and timing of weather-related store closures; and
•public health emergencies which may exacerbate the effects and relevant risk exposures listed above.
A new store is included in the comparable store sales calculation during the 13th full fiscal month following the store’s opening. Closed stores are removed from the calculation for time periods that are not comparable. In the past, we have closed stores as a result of poor store performance, lease expiration or non-renewal and/or the terms of our arrangements with our Host partners.
Managed Care and Insurance
Managed care has become increasingly important to the optical retail industry. An increasing percentage of our customers receive vision care insurance coverage through managed care payors. Our participation in these programs represent an increasingly significant portion of our overall revenues and represented 42% of our overall revenues from continuing operations in fiscal 2025. While we have relationships with almost all vision care insurers in the U.S. and with all of the major carriers, currently, a relatively small number of payors comprise the majority of our managed care revenues, subjecting us to concentration risk. As our participation in managed care programs continues to expand, we have incurred and expect to incur additional costs related to this area of our business. Our comparable store sales growth as noted
above as well as overall future operational success could depend on our ability to negotiate, maintain and extend contracts with managed vision care companies, vision insurance providers and other third-party payors, several of whom have significant market share. Coverage and payment levels are determined at each third-party payor’s discretion, and we have limited control over a third-party payor’s decision-making with respect to coverage and payment levels. Coverage restrictions and reductions in reimbursement levels or payment methodologies may negatively impact our sales and profits. In addition, as our participation in managed care programs continues to approach overall industry penetration levels, we expect our associated managed care revenue growth rate to slow over time.
Through our point-of-sale system and our back-office electronic data interchange (“EDI”) capabilities, we attempt to create a seamless transactional experience for our managed care customers and we have increased training for our store associates with this goal in mind. From time to time, vision care insurance payors may make changes to their benefit designs or claim systems, or experience system outages. Such changes or outages may require us to update our processes and could impact our ability to submit claims or timely receive reimbursements from our managed care partners. As such, we have worked proactively with our larger vision care insurance payors to implement technology to improve eligibility and benefit verification processes via application programming interfaces (“APIs”). We have implemented such APIs with some of our largest payors and have seen improvements in the customer experience and reductions in claim errors that would otherwise result in rejections and potential write-offs.
Infrastructure Investment
Our historical results of operations reflect the impact of our ongoing investments in infrastructure to support our growth. We have made and continue to make significant investments in information technology systems, including those to support our point-of-sale system, ERP, CRM, e-commerce platforms, supply chain systems, marketing, and personnel, as well as experienced industry executives, and management and merchandising teams to support our long-term growth objectives. We intend to continue to make targeted investments in our infrastructure to support our growth and continue the digitization of our stores and corporate office.
Pricing Strategy
We are committed to providing our products to our customers at exceptional value. We have historically employed a simple, low price/high value strategy, seeking to balance our pricing and growth in a way that consistently delivers savings to our customers. We are continuing this commitment to value, while at the same modernizing our pricing strategy to maximize that value across a broader range of consumers. We have taken and may continue to take pricing actions and introduce limited-time promotions or new offers designed to increase demand traffic, awareness and drive sales. In fiscal 2025, we implemented price increases to each of our America’s Best and Eyeglass World opening offers and continued to evolve our product mix to include a greater percentage of frames at price points over $99. We believe that these changes will enable us to continue to offer the best possible value and service to our customers at prices that allow us to maintain our brands’ strong value propositions in the marketplace. Inflationary pressures, including elevated wages, consumer confidence and preferences and increased raw material costs, could impact our profitability and lead us to attempt to offset such increases through various pricing actions.
Interim Results and Seasonality
Historically, our business has realized a higher portion of net revenue, operating income, and cash flows from operations in the first half of the fiscal year, and a lower portion of net revenue, operating income, and cash flows from operations in the fourth fiscal quarter. The first half seasonality is attributable primarily to annual health insurance program start/reset periods and predictable consumer propensity to seek eye care and eyewear.
With respect to our fourth quarter results, compared to other retailers, our products and services are less likely to be included in consumers’ holiday spending budgets, therefore reducing spending on personal vision correction during the weeks preceding December 25th of each year. Additionally, although the period between December 25th and the end of our fiscal year is typically a high-volume period, the net revenue associated with a significant portion of orders of prescription eyeglasses and contact lenses during that period is deferred until the following fiscal period due to our policy of recognizing revenue only after the product has been accepted by the customer, further contributing to higher revenue results in the first half of the year. Our quarterly results may also be affected by the timing of new store openings and store closings, the amount of sales contributed by new and existing stores, the timing of certain holidays, and the timing of weather-related store closures.
For fiscal years 2025 and 2024, approximately 25% and 24% of our revenue was recorded in the respective fourth quarters, but approximately 26% and 25% of annual SG&A costs were recorded in the respective fourth quarters of these fiscal years.
How We Assess the Performance of Our Business
We consider a variety of financial and operating measures in assessing the performance of our business. The key measures we use to determine how our consolidated business and operating segments are performing are net revenue, costs applicable to revenue, and selling, general, and administrative expenses, which are described further in Note 15. “Segment Reporting” and Note 1. “Business and Significant Accounting Policies,” to our consolidated financial statements included in Part II. Item 8. of this Form 10-K. In addition, we also review store growth, Adjusted Comparable Store Sales Growth, Adjusted Operating Income, Adjusted Operating Margin, Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted Diluted EPS.
Net Revenue
We report as net revenue amounts generated in transactions with retail customers who are the end users of our products, services, and plans. Comparable store sales growth and new store openings are key drivers of net revenue and are discussed below. Also, the timing of unearned revenue can affect revenue recognized in a particular period.
Costs Applicable to Revenue
Customer tastes and preferences, product mix, changes in technology, significant increases or slowdowns in production, and other factors impact costs applicable to revenue. The components of our costs applicable to revenue may not be comparable to other retailers.
Selling, General and Administrative
SG&A generally fluctuates consistently with revenue due to the variable store, field office and corporate support costs; however, some fixed costs slightly improve as a percentage of net revenue as our net revenues grow over time.
New Store Openings
The total number of new stores per year and the timing of store openings has, and will continue to have, an impact on our results. We opened 33 stores during fiscal year 2025, and we plan to open approximately 30 to 35 new stores in fiscal 2026, primarily comprised of America’s Best stores, after which time we expect to return to our more recent store opening cadence as strategic initiatives begin to take hold. We will continue to monitor and determine our plans for future new store openings based on health, safety and economic conditions.
Adjusted Comparable Store Sales Growth
We measure Adjusted Comparable Store Sales Growth as the increase or decrease in sales recorded by the comparable store base in any fiscal reporting period, compared to sales recorded by the comparable store base in the prior fiscal reporting period, which we calculate as follows: (i) sales are recorded at the point of sale (ii) sales are adjusted for managed care insurance collection estimates; (iii) stores are added to the calculation during the 13th full fiscal month following the store’s opening; (iv) closed stores are removed from the calculation for time periods that are not comparable; (v) sales from partial months of operation are excluded when stores do not open or close on the first day of the month; and (vi) when applicable, we adjust for the effect of the 53rd week. Quarterly, year-to-date and annual adjusted comparable store sales are aggregated using only sales from all whole months of operation included in both the current reporting period and the prior reporting period. When a partial month is excluded from the calculation, the corresponding month in the subsequent period is also excluded from the calculation. There may be variations in the way in which some of our competitors and other retailers calculate comparable store sales. As a result, our adjusted comparable store sales may not be comparable to similar data made available by other retailers.
Adjusted Comparable Store Sales Growth is a non-GAAP financial measure, which we believe is useful because it provides timely and accurate information relating to the two core metrics of retail sales: number of transactions and value of transactions. We use Adjusted Comparable Store Sales Growth as the basis for key operating decisions, such as allocation of advertising to particular markets and implementation of special marketing programs. Accordingly, we believe that Adjusted Comparable Store Sales Growth provides timely and accurate information relating to the operational health and overall performance of each brand. We also believe that, for the same reasons, investors find our calculation of Adjusted Comparable Stores Sales Growth to be meaningful.
Adjusted Operating Income, Adjusted Operating Margin, Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted Diluted EPS (collectively, the “Company Non-GAAP Measures”)
The Company Non-GAAP Measures are key measures used by management to assess our financial performance. The Company Non-GAAP Measures are also frequently used by analysts, investors and other interested parties. We use the Company Non-GAAP Measures to supplement U.S. GAAP measures of performance to evaluate the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. See “Non-GAAP Financial Measures” for definitions of the Company Non-GAAP Measures and for additional information.
Results of Operations
The following table summarizes key components of our results of operations for the periods indicated, both in dollars and as a percentage of our net revenue.
| | | | | | | | | | | | | | | | | |
| In thousands, except earnings per share, percentage and store data | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Revenue: | | | | | |
| Net product sales | $ | 1,604,592 | | | $ | 1,463,139 | | | $ | 1,423,229 | |
| Net sales of services and plans | 382,896 | | | 360,181 | | | 333,142 | |
| Total net revenue | 1,987,488 | | | 1,823,320 | | | 1,756,371 | |
| Costs applicable to revenue (exclusive of depreciation and amortization): | | | | | |
| Products | 461,213 | | | 433,194 | | | 424,011 | |
| Services and plans | 358,256 | | | 330,862 | | | 310,644 | |
| Total costs applicable to revenue | 819,469 | | | 764,056 | | | 734,655 | |
| Operating expenses: | | | | | |
| Selling, general and administrative expenses | 1,016,251 | | | 938,524 | | | 904,757 | |
| Depreciation and amortization | 91,152 | | | 91,349 | | | 89,874 | |
| Asset impairment | 1,991 | | | 39,851 | | | 2,699 | |
| Other expense (income), net | (204) | | | (101) | | | (104) | |
| Total operating expenses | 1,109,190 | | | 1,069,623 | | | 997,226 | |
| Income (loss) from operations | 58,829 | | | (10,359) | | | 24,490 | |
| Interest expense, net | 17,148 | | | 16,184 | | | 14,339 | |
| (Gain) loss on extinguishment of debt | — | | | (859) | | | 599 | |
| Earnings (loss) from continuing operations before income taxes | 41,681 | | | (25,684) | | | 9,552 | |
Income tax provision | 12,081 | | | 1,481 | | | 6,006 | |
Income (loss) from continuing operations | 29,600 | | | (27,165) | | | 3,546 | |
| Income (loss) from discontinued operations, net of tax (See Note 2) | — | | | (1,334) | | | (69,447) | |
| Net income (loss) | $ | 29,600 | | | $ | (28,499) | | | $ | (65,901) | |
| | | | | |
| Supplemental operating data: | | | | | |
| Number of stores open at end of period | 1,250 | | | 1,240 | | | 1,188 | |
| New stores opened during the period | 33 | | | 69 | | | 70 | |
Adjusted Operating Income from continuing operations(1) | $ | 102,468 | | | $ | 65,489 | | | $ | 53,894 | |
| Diluted earnings (loss) per share from continuing operations | $ | 0.37 | | | $ | (0.35) | | | $ | 0.05 | |
Adjusted Diluted EPS from continuing operations(1) | $ | 0.80 | | | $ | 0.52 | | | $ | 0.47 | |
Adjusted EBITDA from continuing operations(1) | $ | 192,943 | | | $ | 155,525 | | | $ | 142,237 | |
(1) Refer to Non-GAAP Financial Measures section below for our presentation of Adjusted Operating Income, Adjusted Diluted EPS and Adjusted EBITDA. |
| | | | | | | | | | | | | | | | | |
| Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| Percentage of net revenue: | | | | | |
| Total costs applicable to revenue | 41.2 | % | | 41.9 | % | | 41.8 | % |
| Selling, general and administrative expenses | 51.1 | % | | 51.5 | % | | 51.5 | % |
| Total operating expenses | 55.8 | % | | 58.7 | % | | 56.8 | % |
| Income (loss) from continuing operations, net of tax | 1.5 | % | | (1.5) | % | | 0.2 | % |
| | | | | |
| Adjusted Operating Income from continuing operations | 5.2 | % | | 3.6 | % | | 3.1 | % |
| Adjusted EBITDA from continuing operations | 9.7 | % | | 8.5 | % | | 8.1 | % |
Fiscal Year 2025 compared to Fiscal Year 2024
In 2024, certain components of our operations met the requirements to be classified as discontinued operations. Refer to Note 2 “Discontinued Operations” for information related to our discontinued operations. Unless otherwise noted, the discussion of U.S. GAAP results below is based on results from continuing operations, substantially all of which are attributable to our single reportable segment, Owned & Host. Fiscal 2025 consisted of 53 weeks compared to 52 weeks in fiscal 2024.
Net revenue
The following presents, by segment and by brand, comparable store sales growth, stores open at the end of the period and net revenue for fiscal year 2025 compared to fiscal year 2024.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Comparable store sales growth(1) | | Stores open at end of period | | Net revenue(2) |
| In thousands, except percentage and store data | | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2025 | | Fiscal Year 2024 |
| Owned & Host segment | | | | | | | | | | | | | | |
| America’s Best | | 6.3 | % | | 1.8 | % | | 1,057 | | | 1,036 | | | $ | 1,743,304 | | 87.7 | % | | $ | 1,561,062 | | 85.6 | % |
| Eyeglass World | | 4.2 | % | | (2.2) | % | | 122 | | | 122 | | | 202,404 | | 10.2 | % | | 200,107 | | 11.0 | % |
| Military | | 2.6 | % | | (0.5) | % | | 53 | | | 53 | | | 23,555 | | 1.2 | % | | 22,596 | | 1.2 | % |
| Fred Meyer | | 4.9 | % | | (4.5) | % | | 18 | | | 29 | | | 9,625 | | 0.5 | % | | 10,482 | | 0.6 | % |
| Owned & Host segment total | | | | | | 1,250 | | | 1,240 | | | $ | 1,978,888 | | 99.6 | % | | $ | 1,794,247 | | 98.4 | % |
| | | | | | | | | | | | | | |
Corporate and other | | — | | | — | | | — | | | — | | | 20,972 | | 1.0 | % | | 27,621 | | 1.5 | % |
| Effects of unearned and deferred revenue | | — | | | — | | | — | | | — | | | (12,372) | | (0.6) | % | | 1,452 | | 0.1 | % |
| Total | | 5.9 | % | | 1.9 | % | | 1,250 | | | 1,240 | | | $ | 1,987,488 | | 100.0 | % | | $ | 1,823,320 | | 100.0 | % |
Effect of deferred and unearned revenue on comparable store sales | | 0.1 | % | | (0.6) | % | | | | | | | | | | |
Adjusted Comparable Store Sales Growth from continuing operations | | 6.0 | % | | 1.3 | % | | | | | | | | | | |
(1)We calculate total comparable store sales from continuing operations based on consolidated net revenue from continuing operations excluding the impact of (i) Corporate and other revenue, (ii) sales from stores opened less than 13 months, (iii) stores closed in the periods presented, (iv) sales from partial months of operation when stores do not open or close on the first day of the month and (v) if applicable, the impact of a 53rd week in a fiscal year. Brand-level comparable store sales growth is calculated based on point-of-sale revenues consistent with what the CODM reviews, and consistent with reportable segment revenues presented in Note 15. “Segment Reporting” in our consolidated financial statements.
(2)Percentages reflect line item as a percentage of net revenue, adjusted for rounding.
Total net revenue of $1,987.5 million for fiscal year 2025 increased $164.2 million, or 9.0%, from $1,823.3 million for fiscal year 2024. The increase was primarily driven by Adjusted Comparable Store Sales Growth and new store sales, partially offset by closed stores and the timing of unearned revenue. Unearned and deferred revenue negatively impacted net revenue by $13.8 million during fiscal year 2025 compared to fiscal year 2024, primarily driven by the timing of unearned revenue recognition. The 53rd week in fiscal 2025 added $35.6 million to net revenue and approximately $0.03 to diluted EPS for the year.
Comparable store sales growth and Adjusted Comparable Store Sales Growth from continuing operations for fiscal year 2025 were 5.9% and 6.0%, respectively, both primarily driven by higher average ticket and continued strength in the Company’s managed care cohort, partially offset by a slight decrease in customer traffic.
During fiscal year 2025, we opened 33 new America’s Best stores and closed 12 America’s Best stores and 11 Fred Meyer stores. Two of the Fred Meyer stores closed as a result of the host partner’s decision to cease its overall operations at these locations. Overall, store count grew 0.8% from the end of fiscal year 2024 to the end of fiscal year 2025.
| | | | | | | | | | | | | | |
| Fiscal Year Ended | | |
(in thousands) | January 3, 2026 | December 28, 2024 | $ Change | % Change |
Total net revenue | $ | 1,987,488 | | $ | 1,823,320 | | $ | 164,168 | | 9.0 | % |
Net product sales | $ | 1,604,592 | | $ | 1,463,139 | | $ | 141,453 | | 9.7 | % |
As a percentage of total net revenue | 80.7 | % | 80.2 | % | | |
Net sales of services and plans | $ | 382,896 | | $ | 360,181 | | $ | 22,715 | | 6.3 | % |
As a percentage of total net revenue | 19.3 | % | 19.8 | % | | |
Net product sales increased $141.5 million, or 9.7% during fiscal year 2025 compared to fiscal year 2024, primarily due to pricing and product mix initiatives in eyeglass sales of $123.4 million, or 10.8%, contact lens sales of $16.9 million, or 5.5%, and other add-on sales.
Net sales of services and plans increased $22.7 million, or 6.3%, driven primarily by higher exam revenues of $21.1 million, or 9.0%.
Costs applicable to revenue
| | | | | | | | | | | | | | |
| Fiscal Year Ended | | |
(in thousands) | January 3, 2026 | December 28, 2024 | $ Change | % Change |
Total costs applicable to revenue | $ | 819,469 | | $ | 764,056 | | $ | 55,413 | | 7.3 | % |
As a percentage of total net revenue | 41.2 | % | 41.9 | % | | |
Total costs of products | $ | 461,213 | | $ | 433,194 | | $ | 28,019 | | 6.5 | % |
As a percentage of net product sales | 28.7 | % | 29.6 | % | | |
Total costs of services and plans | $ | 358,256 | | $ | 330,862 | | $ | 27,394 | | 8.3 | % |
As a percentage of net sales of services and plans | 93.6 | % | 91.9 | % | | |
Costs applicable to revenue of $819.5 million for fiscal year 2025 increased $55.4 million, or 7.3%, from $764.1 million for fiscal year 2024. As a percentage of net revenue, costs applicable to revenue decreased 70 basis points primarily driven by eyeglass mix and margin improvement of 140 basis points related to a successful execution of pricing and product mix initiatives and leveraging of optometrist-related costs of 10 basis points, partially offset by lower contact lens margin of 20 basis points and other mix and margin effects of 60 basis points.
Costs of products as a percentage of net product sales decreased 90 basis points primarily driven by eyeglass mix and margin improvement related to a successful execution of pricing and product mix initiatives, partially offset by lower contact lens margin.
Costs of services and plans as a percentage of net sales of services and plans increased 170 basis points primarily driven by lower growth in add-ons and eye exam revenues relative to the growth in optometrist-related costs.
Selling, general and administrative
| | | | | | | | | | | | | | |
| Fiscal Year Ended | | |
(in thousands) | January 3, 2026 | December 28, 2024 | $ Change | % Change |
SG&A | $ | 1,016,251 | | $ | 938,524 | | $ | 77,727 | | 8.3 | % |
| As a percentage of total revenue | 51.1 | % | 51.5 | % | | |
SG&A of $1,016.3 million for fiscal year 2025 increased $77.7 million, or 8.3%, from fiscal year 2024. SG&A as a percentage of net revenue decreased 40 basis points and was primarily impacted by improved leverage of advertising investments and other expenses of 170 basis points, which included an offset from higher healthcare expenses. These were partially offset by increases in variable incentive compensation expenses of 100 basis points and an increase in stock-based compensation of 30 basis points primarily related to revenue and profitability growth.
Depreciation and amortization
Depreciation and amortization expense of $91.2 million for fiscal year 2025 decreased $0.2 million, or 0.2%, from $91.3 million for fiscal year 2024 primarily driven by fewer new store openings, partially offset by higher depreciation related to investments in existing stores.
Asset impairment
We recognized $2.0 million of impairment charges during fiscal year 2025 primarily for tangible long-lived assets and right of use (“ROU”) assets associated with our retail stores. We recognized $39.9 million of impairment charges in fiscal year 2024, primarily for the Eyeglass World goodwill and Fred Meyer contracts and relationships intangible asset, and tangible long-lived assets and ROU assets associated with our retail stores. Asset impairment expenses were recognized in Corporate and other. Refer to Note 12 “Fair Value Measurement” and Note 4 “Goodwill and Intangible Assets” for further details.
Interest expense, net
Interest expense, net, of $17.1 million for fiscal year 2025 increased $1.0 million, or 6.0%, from $16.2 million for fiscal year 2024. The change was primarily a result of lower income on cash balances of $3.8 million, partially offset by lower interest expense on our debt of $2.7 million.
Income tax provision
Our effective tax rates for fiscal year 2025 and fiscal year 2024 were 29.0% and (5.8)%, respectively. The change in effective tax rates reflects our statutory federal and state rate of 25.1% and 25.2%, respectively, the tax impacts of the partial disallowance of Eyeglass World goodwill impairment loss for income tax purposes and other effects of permanent items. Refer to Note 7 "Income Taxes" for further details.
Discontinued Operations
Loss from discontinued operations, net of tax, of $1.3 million for fiscal year 2024 represents loss prior to the termination of our partnership with Walmart and the wind-down of the AC Lens operations. There were no discontinued operations results for fiscal year 2025.
Fiscal Year 2024 compared to Fiscal Year 2023
For a comparison of our results of operations for the years ended December 28, 2024 to December 30, 2023, see "Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" of our annual report on Form 10-K for the fiscal year ended December 28, 2024, filed with the SEC on February 26, 2025.
Non-GAAP Financial Measures
Adjusted Operating Income, Adjusted Operating Margin, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted Diluted EPS
We define Adjusted Operating Income as net income (loss), plus interest expense (income), net and income tax provision (benefit), further adjusted to exclude stock-based compensation expense, (gain) loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, amortization of acquisition intangibles, ERP and CRM implementation expenses, shareholder activism costs, severance and associate-related costs associated with organizational restructuring and certain other expenses. We define Adjusted Operating Margin as Adjusted Operating Income as a percentage of net revenue.
We define EBITDA as net income (loss), plus interest expense (income), net, income tax provision (benefit) and depreciation and amortization.
We define Adjusted EBITDA as net income (loss), plus interest expense (income), net, income tax provision (benefit) and depreciation and amortization, further adjusted to exclude stock-based compensation expense, (gain) loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, ERP and CRM implementation expenses, shareholder activism costs, severance and associate-related costs associated with organizational restructuring and certain other expenses.
We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of net revenue.
We define Adjusted Diluted EPS as diluted earnings (loss) per share, adjusted for the per share impact of stock-based compensation expense, (gain) loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, amortization of debt discounts and deferred financing costs of our term loan borrowings, amortization of the conversion feature and deferred financing costs related to our 2025 Notes when not required under U.S. GAAP to be added back for diluted earnings (loss) per share, derivative fair value adjustments, ERP and CRM implementation expenses, shareholder activism costs, severance and associate-related costs associated with organizational restructuring, and certain other expenses, less the tax effect of these adjustments including tax expense (benefit) from stock-based compensation.
When presenting Adjusted Operating Income from continuing operations, EBITDA from continuing operations and Adjusted EBITDA from continuing operations we use the same definitions for Adjusted Operating Income, EBITDA and Adjusted EBITDA, respectively, and also exclude income (loss) from discontinued operations, net of tax. When presenting Adjusted Diluted EPS from continuing operations, we use the same definition for Adjusted Diluted EPS, and also exclude diluted earnings (loss) per share from discontinued operations. When presenting Adjusted Operating Margin from continuing operations, we use Adjusted Operating Income from continuing operations as a percentage of total net revenue. When presenting Adjusted EBITDA Margin from continuing operations, we use Adjusted EBITDA from continuing operations as a percentage of total net revenue.
EBITDA and the Company Non-GAAP Measures can vary substantially in size from one period to the next, and certain types of expenses are non-recurring in nature and consequently may not have been incurred in any of the periods presented below.
EBITDA and the Company Non-GAAP Measures have been presented as supplemental measures of financial performance that are not required by, or presented in accordance with U.S. GAAP, because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes EBITDA, and the Company Non-GAAP Measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. We also use EBITDA and the Company Non-GAAP Measures to supplement U.S. GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements U.S. GAAP results with Non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than U.S. GAAP results alone. We continue to evaluate our use of the Company Non-GAAP measures in the context of the development of our business, and may introduce or discontinue certain measures in the future as we deem appropriate.
EBITDA and the Company Non-GAAP Measures are not recognized terms under U.S. GAAP and should not be considered as an alternative to net income or income from operations as a measure of financial performance or cash flows provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with U.S. GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use as they do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. In evaluating EBITDA and the Company Non-GAAP Measures, we may incur expenses in the future that are the same as or similar to some of the adjustments in this presentation. Our presentation of EBITDA and the Company Non-GAAP Measures should not be construed to imply that our future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on our U.S. GAAP results in addition to using EBITDA and the Company Non-GAAP Measures.
The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are:
•they do not reflect costs or cash outlays for capital expenditures or contractual commitments;
•they do not reflect changes in, or cash requirements for, our working capital needs;
•EBITDA, Adjusted EBITDA and Adjusted Operating Income do not reflect the interest expense (income), net or the cash requirements necessary to service interest or principal payments, on our debt;
•EBITDA, Adjusted EBITDA and Adjusted Operating Income do not reflect period to period changes in taxes, income tax provision or the cash necessary to pay income taxes;
•they do not reflect the impact of earnings or charges resulting from matters we consider not to be indicative of our ongoing operations;
•although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect cash requirements for such replacements; and
•other companies in our industry may calculate these measures differently than we do, limiting their usefulness as comparative measures.
Because of these limitations, EBITDA and the Company Non-GAAP Measures should not be considered as measures of discretionary cash available to invest in business growth or to reduce indebtedness.
The following table reconciles our Adjusted Operating Income from continuing operations, Adjusted Operating Margin from continuing operations, EBITDA from continuing operations, Adjusted EBITDA from continuing operations, Adjusted EBITDA Margin from continuing operations to Net income margin from continuing operations; and Adjusted Diluted EPS from continuing operations to Diluted EPS from continuing operations for the periods presented:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Net income (loss) | $ | 29,600 | | | 1.5 | % | | $ | (28,499) | | | (1.6) | % | | $ | (65,901) | | | (3.8) | % |
| Income (loss) from discontinued operations, net of tax | — | | | — | % | | (1,334) | | | (1.0) | % | | (69,447) | | | (18.8) | % |
| Income (loss) from continuing operations, net of tax | 29,600 | | | 1.5 | % | | (27,165) | | | (1.5) | % | | 3,546 | | | 0.2 | % |
| Interest expense, net | 17,148 | | | 0.9 | % | | 16,184 | | | 0.9 | % | | 14,339 | | | 0.8 | % |
| Income tax provision | 12,081 | | | 0.6 | % | | 1,481 | | | 0.1 | % | | 6,006 | | | 0.3 | % |
Stock-based compensation expense (a) | 23,686 | | | 1.2 | % | | 16,708 | | | 0.9 | % | | 19,203 | | | 1.1 | % |
(Gain) loss on extinguishment of debt (b) | — | | | — | % | | (859) | | | — | % | | 599 | | | — | % |
Asset impairment (c) | 1,991 | | | 0.1 | % | | 39,851 | | | 2.2 | % | | 2,699 | | | 0.2 | % |
Litigation settlement (d) | 1,903 | | | 0.1 | % | | 4,450 | | | 0.2 | % | | — | | | — | % |
Amortization of acquisition intangibles (e) | 677 | | | — | % | | 1,313 | | | 0.1 | % | | 1,525 | | | 0.1 | % |
ERP and CRM implementation expenses (h) | 6,420 | | | 0.3 | % | | 5,990 | | | 0.3 | % | | 484 | | | — | % |
Other (i) | 8,962 | | | 0.5 | % | | 7,536 | | | 0.4 | % | | 5,493 | | | 0.3 | % |
| Adjusted Operating Income from continuing operations / Adjusted Operating Margin from continuing operations | $ | 102,468 | | | 5.2 | % | | $ | 65,489 | | | 3.6 | % | | $ | 53,894 | | | 3.1 | % |
|
Note: Percentages reflect line item as a percentage of net revenue, adjusted for rounding. |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Net income (loss) | $ | 29,600 | | | 1.5 | % | | $ | (28,499) | | | (1.6) | % | | $ | (65,901) | | | (3.8) | % |
| Income (loss) from discontinued operations, net of tax | — | | | — | % | | (1,334) | | | (1.0) | % | | (69,447) | | | (18.8) | % |
| Income (loss) from continuing operations, net of tax | 29,600 | | | 1.5 | % | | (27,165) | | | (1.5) | % | | 3,546 | | | 0.2 | % |
| Interest expense, net | 17,148 | | | 0.9 | % | | 16,184 | | | 0.9 | % | | 14,339 | | | 0.8 | % |
| Income tax provision | 12,081 | | | 0.6 | % | | 1,481 | | | 0.1 | % | | 6,006 | | | 0.3 | % |
| Depreciation and amortization | 91,152 | | | 4.6 | % | | 91,349 | | | 5.0 | % | | 89,874 | | | 5.1 | % |
| EBITDA from continuing operations | 149,981 | | | 7.5 | % | | 81,849 | | | 4.5 | % | | 113,765 | | | 6.5 | % |
| | | | | | | | | | | |
Stock-based compensation expense (a) | 23,686 | | | 1.2 | % | | 16,708 | | | 0.9 | % | | 19,203 | | | 1.1 | % |
(Gain) loss of extinguishment of debt (b) | — | | | — | % | | (859) | | | — | % | | 599 | | | — | % |
Asset impairment (c) | 1,991 | | | 0.1 | % | | 39,851 | | | 2.2 | % | | 2,699 | | | 0.2 | % |
Litigation settlement (d) | 1,903 | | | 0.1 | % | | 4,450 | | | 0.2 | % | | — | | | — | % |
ERP and CRM implementation expenses (h) | 6,420 | | | 0.3 | % | | 5,990 | | | 0.3 | % | | 484 | | | — | % |
Other (i) | 8,962 | | | 0.5 | % | | 7,536 | | | 0.4 | % | | 5,487 | | | 0.3 | % |
| Adjusted EBITDA from continuing operations / Adjusted EBITDA Margin from continuing operations | $ | 192,943 | | | 9.7 | % | | $ | 155,525 | | | 8.5 | % | | $ | 142,237 | | | 8.1 | % |
|
Note: Percentages reflect line item as a percentage of net revenue, adjusted for rounding. |
| | | | | | | | | | | | | | | | | |
| In thousands, except per share amounts | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Diluted EPS | $ | 0.37 | | | $ | (0.36) | | | $ | (0.84) | |
| Diluted EPS from discontinued operations | — | | | (0.02) | | | (0.88) | |
| Diluted EPS from continuing operations | 0.37 | | | (0.35) | | | 0.05 | |
Stock-based compensation expense (a) | 0.29 | | | 0.21 | | | 0.24 | |
(Gain) loss on extinguishment of debt (b) | — | | | (0.01) | | | 0.01 | |
Asset impairment (c) | 0.02 | | | 0.51 | | | 0.03 | |
Litigation settlement (d) | 0.02 | | | 0.06 | | | — | |
Amortization of acquisition intangibles (e) | 0.01 | | | 0.02 | | | 0.02 | |
Amortization of debt discounts and deferred financing costs (f) | 0.02 | | | 0.03 | | | 0.04 | |
Derivative fair value adjustments (g) | — | | | 0.08 | | | 0.12 | |
ERP and CRM implementation expenses (h) | 0.08 | | | 0.08 | | | 0.01 | |
Other (i) | 0.12 | | | 0.10 | | | 0.07 | |
Tax effects (j) | (0.13) | | | (0.19) | | | (0.12) | |
| Adjusted Diluted EPS from continuing operations | $ | 0.80 | | | $ | 0.52 | | | $ | 0.47 | |
| | | | | |
| Weighted average diluted shares outstanding | 80,576 | | | 78,592 | | | 78,596 | |
Note: Some of the totals in the table above do not foot due to rounding differences. |
|
____________
(a)Non-cash charges related to stock-based compensation programs, which vary from period to period depending on the timing of awards and performance vesting conditions.
(b)Reflects the extinguishment (gain) loss related to the repurchase of the 2025 Notes of $100.0 million and $217.7 million during fiscal years 2023 and 2024, respectively.
(c)Reflects write-off related to non-cash impairment charges, primarily impairment of Eyeglass World goodwill, impairment of Fred Meyer contracts and relationship asset, and impairment of property, equipment and lease-related assets on closed or underperforming stores and certain store closure decisions made as part of the Company’s store optimization review.
(d)Expenses associated with settlement of certain litigation.
(e)Amortization of the increase in carrying values of finite-lived intangible assets resulting from the purchase accounting following the acquisition of the Company by affiliates of KKR & Co. Inc.
(f)Amortization of deferred financing costs and other non-cash charges related to our debt. We adjust for amortization of deferred financing costs related to the 2025 Notes only when adjustment for these costs is not required in the calculation of diluted earnings per share under U.S. GAAP.
(g)The adjustments for the derivative fair value (gains) and losses have the effect of adjusting the (gain) or loss for changes in the fair value of derivative instruments and amortization of AOCL for derivatives not designated as accounting hedges. This results in reflecting derivative (gains) and losses within Adjusted Diluted EPS during the period the derivative is settled.
(h)Costs related to the Company’s ERP and CRM implementation.
(i)Other adjustments include amounts that management believes are not representative of our operating performance (amounts in brackets represent reductions in Adjusted Operating Income, Adjusted Diluted EPS and Adjusted EBITDA), which are primarily related to costs associated with the digitization of paper-based records of $2.2 million, $5.8 million and $2.2 million for fiscal years 2025, 2024 and 2023, respectively, severance and associate-related costs related to organizational restructuring of $3.6 million and shareholder activism of $2.1 million for fiscal year 2025, and other expenses and adjustments.
(j)Represents the income tax effect of the total adjustments at our combined statutory federal and state income tax rates, excluding a portion of Eyeglass World goodwill impairment charge, which was disallowed for income tax purposes in fiscal year 2024, and including tax expense (benefit) from stock-based compensation.
Liquidity and Capital Resources
Our primary cash needs are for inventory, payroll, store rent, advertising, capital expenditures associated with new stores and updating existing stores, as well as information and remote medicine technology and infrastructure, including our corporate office, distribution centers and laboratories. When appropriate, the Company may utilize excess liquidity towards debt service requirements, including voluntary debt prepayments, or required interest and principal payments, if any, as well as repurchases of common stock or other securities, based on excess cash flows. The most significant components of our operating assets and liabilities are inventories, accounts receivable, prepaid expenses and other assets, accounts payable, deferred and unearned revenue and other payables and accrued expenses. We exercise prudence in our use of cash and closely monitor various items related to cash flow including, but not limited to, cash receipts, cash disbursements, payment terms and alternative sources of funding. We continue to be focused on these items in addition to other key measures we use to determine how our consolidated business and operating segments are performing. We believe that cash on hand, cash expected to be generated from operations and the availability of borrowings under our revolving credit facility will be sufficient to fund our working capital requirements, liquidity obligations, anticipated capital expenditures and payments due under our existing debt for the next 12 months and
thereafter for the foreseeable future. Depending on our liquidity levels, conditions in the capital markets and other factors, we may from time to time consider the prepayment, refinancing or issuance of debt, issuance of equity or other securities, the proceeds of which could provide additional liquidity for our operations, as well as modifications to our Term Loan A where possible.
In August 2024, we incurred an incremental term loan in the amount of $115.0 million and used the proceeds in addition to cash on hand to repurchase $217.7 million aggregate principal amount of the 2025 Notes. In May 2025, we fully repaid the remaining $84.8 million principal balance of the 2025 Notes using a combination of cash on hand and borrowings from our Revolving Loans. Later, in 2025, we fully repaid our balance outstanding under our Revolving Loans. Refer to Note 5. "Debt" for more information. Our ability to maintain sufficient liquidity may be affected by numerous factors, many of which are outside of our control. We primarily fund our working capital needs using cash provided by operations. Our working capital requirements for inventory will increase as we continue to open additional stores.
During the fourth quarter of 2025, we entered into an interest rate swap with a notional amount of $100.0 million to mitigate the variability of cash flows associated with these interest payments. See Note 13. “Interest Rate Derivatives” for additional information.
As of fiscal year end 2025, we had $38.7 million in cash and cash equivalents and $293.3 million of availability under our revolving credit facility, net of $6.7 million in outstanding letters of credit.
The following table summarizes cash flows provided by (used for) operating activities, investing activities and financing activities for the periods indicated:
| | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Cash flows provided by (used for): | | | | | |
| Operating activities | $ | 146,293 | | | $ | 133,649 | | | $ | 173,033 | |
| Investing activities | (76,606) | | | (96,094) | | | (115,822) | |
| Financing activities | (104,622) | | | (113,345) | | | (136,808) | |
Net change in cash, cash equivalents and restricted cash | $ | (34,935) | | | $ | (75,790) | | | $ | (79,597) | |
|
Net Cash Provided by Operating Activities
Cash flows provided by operating activities increased by $12.6 million to $146.3 million, during fiscal year 2025 from $133.6 million during fiscal year 2024 as a result of an increase in net income of $58.1 million. This was partially offset by changes in net working capital and other assets and liabilities of $30.8 million and a decrease in non-cash adjustments items of $14.7 million primarily driven by a decrease in asset impairment, partially offset by increases in deferred income taxes and stock-based compensation.
Working capital was primarily impacted by changes in trade receivables, other assets, inventory, accounts payable, other liabilities, and timing of unearned and deferred revenue. Changes in trade receivables used $44.5 million more in cash and were primarily driven by changes in sales. Changes in other assets used $38.4 million more in cash, primarily due to increased cloud-based software assets. Changes in inventories used $22.3 million more in cash due to product mix initiatives. These were partially offset by changes in accounts payable, which contributed $39.3 million more in cash. Changes in other liabilities contributed $16.0 million more in cash primarily due to increases in compensation-related and other accruals. The timing of unearned and deferred revenue contributed $18.6 million more in cash. Year-over-year changes in working capital were also impacted by the AC Lens wind down and the termination of the Walmart partnership in 2024 that did not recur in 2025.
Net Cash Used for Investing Activities
Net cash used for investing activities decreased by $19.5 million, to $76.6 million, during fiscal year 2025 from $96.1 million during fiscal year 2024. The decrease was primarily due to lower store openings, partially offset by higher investments in doctor and other in-store equipment in existing stores.
Net Cash Provided by (Used for) Financing Activities
Net cash used for financing activities decreased $8.7 million, from $113.3 million use of cash during fiscal year 2024 to $104.6 million use of cash during fiscal year 2025. The $8.7 million decrease was primarily due to borrowings on the Revolving Loans of $25.0 million offset by a repayment of $84.8 million of the 2025 Notes and $25.0 million of Revolving Loans in fiscal year 2025 as compared to a prepayment of $217.7 million aggregate principal amount of the 2025 Notes for an aggregate cash repurchase price of $215.0 million, which was partially offset by additional term loan borrowings of $115.0 million in fiscal year 2024.
Debt
The following table sets forth the amounts owed under our term loan and the interest rate on such outstanding amount, and the amount available for additional borrowing thereunder, as of the end of fiscal year 2025:
| | | | | | | | | | | | | | | | | | | | |
| In thousands | | Interest Rate (2) | | Amount Outstanding | | Amount Available for Additional Borrowing |
| | | | | | |
| Term Loan A, due June 13, 2028 | | Variable | | $ | 237,625 | | | $ | — | |
Revolving Loans, due June 13, 2028(1) | | Variable | | — | | | 293,300 | |
| Total | | | | $ | 237,625 | | | $ | 293,300 | |
____________
(1)At January 3, 2026, the amount available under our revolving credit facility reflected a reduction of $6.7 million of letters of credit outstanding.
(2)Refer to Note 5. Debt for the interest rates used on the term loan and revolving credit facility.
Share Repurchase Authority
On February 23, 2022, our Board of Directors authorized a $100 million increase to the share repurchase authorization, resulting in total authorization of $200 million. During fiscal year 2023, the Company repurchased 1.1 million shares of its common stock for $25 million under the share repurchase program. The Company’s original share repurchase authorization expired on December 30, 2023, and had remaining capacity of $25 million. Effective February 23, 2024, the Board authorized the Company to repurchase up to $50 million aggregate amount of shares of the Company’s common stock until January 3, 2026. No additional shares were repurchased in fiscal years 2024 and 2025. The share repurchase authorization expired on January 3, 2026, and had remaining capacity of $50 million. Effective March 2, 2026, the Board authorized the Company to repurchase up to $50 million aggregate amount of shares of the Company’s common stock until December 28, 2030. The authorization permits the Company to make purchases of its common stock from time to time in the open market or privately negotiated transactions, and pursuant to pre-set trading plans meeting the requirements of all applicable securities laws and regulations. The timing and amounts of any such repurchases will depend on a variety of factors, including the market price of the Company’s shares, general market and economic conditions, legal requirements and tax implications. The Company expects to fund the share repurchases using cash on hand.
Capital Expenditures
| | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| New stores (owned brands) | $ | 16,798 | | | $ | 44,347 | | | $ | 51,938 | |
| Laboratories, distribution centers and optometric equipment | 21,935 | | | 7,981 | | | 26,030 | |
| Information technology and other | 34,107 | | | 43,177 | | | 36,806 | |
| Total | $ | 72,840 | | | $ | 95,505 | | | $ | 114,774 | |
|
We expect capital expenditures in fiscal year 2026 to be approximately between $73 million and $78 million and to be used primarily in supporting the Company’s growth through investments in new and existing stores, and IT infrastructure. We expect to fund capital expenditures with cash flows from operations, but may also use existing cash balances or funds available through our revolving credit facility.
Material Cash Requirements
As of fiscal year end 2025, our current and long-term material cash requirements include the following commitments and contractual obligations:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| In thousands | | 2026 | | 2027 | | 2028 | | 2029 | | 2030 | | Thereafter | | Total |
| | | | | | | | | | | | | | |
Term loan(a) | | $ | 13,250 | | | $ | 13,250 | | | $ | 211,125 | | | $ | — | | | $ | — | | | $ | — | | | $ | 237,625 | |
| | | | | | | | | | | | | | |
Revolving credit facility(b) | | — | | | — | | | — | | | — | | | — | | | — | | | — | |
Estimated interest(c) | | 12,266 | | | 10,976 | | | 4,816 | | | — | | | — | | | — | | | 28,058 | |
Noncancelable operating leases(d) | | 110,992 | | | 102,659 | | | 80,021 | | | 70,742 | | | 53,573 | | | 111,690 | | | 529,677 | |
Finance leases(e) | | 4,249 | | | 3,370 | | | 1,959 | | | 612 | | | 273 | | | 136 | | | 10,599 | |
Other commitments(f) | | 79,975 | | | 43,561 | | | 27,631 | | | 18,092 | | | 4,244 | | | 749 | | | 174,252 | |
| Total | | $ | 220,732 | | | $ | 173,816 | | | $ | 325,552 | | | $ | 89,446 | | | $ | 58,090 | | | $ | 112,575 | | | $ | 980,211 | |
____________
(a)Refer to Note 5. “Debt” to our consolidated financial statements for more information on our term loan.
(b)Refer to Note 5. “Debt” for more information on our revolving credit facility.
(c)We have estimated our interest payments on our term loan based on Term Secured Overnight Financing Rate as of the end of fiscal year 2025. Amounts and timing may be different from our estimated interest payments due to potential voluntary prepayments, borrowings and interest rate fluctuations. Cash flows related to our hedging instruments are excluded from estimated interest presented in the table above.
(d)We lease our retail stores, optometric examination offices, distribution centers, office space and all of our optical laboratories with the exception of our St. Cloud, Minnesota lab, which we own. The vast majority of our leases are classified as operating leases under current accounting guidance. Although rent expense on operating leases is recorded in SG&A on a straight-line basis over the term of the lease, contractual obligations above represent required cash payments. Our lease arrangements require us to pay executory costs such as insurance, real estate taxes and common area maintenance and some of our leases are based on a percentage of sales. These expenses are generally variable, not included above, and were approximately $40.1 million during fiscal year ended 2025. Refer to Note 10. “Leases” for our current and long-term lease payment obligations.
(e)For leases classified as finance leases, the finance lease asset is recorded as property and equipment and a corresponding amount is recorded as a long-term debt obligation in the Consolidated Balance Sheets at the net present value of the minimum lease payments to be made over the lease term for new finance leases. We allocate each lease payment between a reduction of the lease obligation and interest expense using the effective interest method. Finance lease amounts above represent required contractual cash payments in the periods presented. Refer to Note 10. “Leases” for our current and long-term lease payment obligations.
(f)Other commitments include minimum purchase commitments with certain trade vendors and contractual agreements to purchase goods or services in the ordinary course of business.
In addition to lease commitments and contractual obligations, our material cash requirements also include operating expenses such as payroll, store rent, and advertising expenses, which we expect to fund primarily with existing cash balances and cash flows from operations.
We follow U.S. GAAP in making the determination as to whether to record an asset or liability related to our arrangements with third parties. Consistent with current accounting guidance, we do not record an asset or liability associated with long-term purchase, marketing and promotional commitments, or commitments to philanthropic endeavors. We have disclosed the amount of future commitments associated with these items in our consolidated financial statements. We are not a party to any other off-balance sheet arrangements.
Critical Accounting Policies and Estimates
The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions about future events that affect amounts reported in our consolidated financial statements and related notes, as well as the related disclosure of contingent assets and liabilities at the date of the financial statements. Management evaluates the accounting policies, estimates and judgments on an ongoing basis. We base our estimates and judgments on historical experience and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions and conditions.
We have evaluated the accounting policies used in the preparation of the Company’s consolidated financial statements and related notes and believe those policies to be reasonable and appropriate. Certain of these accounting policies require the application of significant judgment in selecting appropriate assumptions for calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. These judgments are based on historical experience, trends in the industry, information provided by customers and information available from other outside sources, as appropriate. More information on all of our significant accounting policies can be found in Note 1. “Business and Significant Accounting Policies,” to our consolidated financial statements, as well as in certain other notes to the consolidated financial statements as indicated below.
Revenue Recognition
At our America’s Best brand, our signature offer is an eye exam plus two pairs of eyeglasses for one great price. Since an eye exam is a key component in the ability for acceptable prescription eyewear to be delivered to a customer, we concluded that the eye exam service, while capable of being distinct from the eyeglass product delivery, was not distinct in the context of the two-pair offer. As a result, we do not allocate revenue to the eye exam associated with the two-pair offer, and we record all revenue associated with the offer in net product sales when the customer has received and accepted the merchandise.
We recognize revenue across our product protection plan and club membership contract portfolio based on the value delivered to the customers relative to the remaining services promised under the programs. We determine the value delivered based on the expected timing and amount of customer usage of benefits over the terms of the contracts. A 100 basis point change in our estimate of value delivered to customers compared to expected customer usage of benefits would have affected revenues in fiscal year 2025 by approximately $1.5 million; this amount would have been recognized at different times over the contract period.
Unearned revenue at the end of a reporting period is estimated based on processing and delivery times throughout the current month and is generally within two weeks. All unearned revenue at the end of a reporting period is recognized in the next fiscal period. A one-day increase in our estimate of the average days needed to process delivery would have affected revenues in fiscal year 2025 by approximately $5 million, which would ultimately have been recorded in the next fiscal year.
The Company considers its revenue from managed care customers to include variable consideration and estimates such amounts associated with managed care customer revenues using the history of concessions provided and cash receipts from managed care providers; a 100 basis point change in our rate of concessions granted would have reduced our revenues in fiscal year 2025 by approximately $2 million.
See Note 8. “Revenue from Contracts with Customers” in our audited consolidated financial statements for additional information.
Impairment of P&E and ROU assets
In evaluating store-level property and equipment and ROU assets for recoverability and impairment, we may consider multiple factors including financial performance of the stores, regional and local business climates, future plans for the store operations and other qualitative factors. We estimate the fair value of the asset group using an income approach based on discounted cash flows, which requires estimates and assumptions of forecasted store revenue growth rates and store profitability. We consider market-based indications of prevailing rental rates, lease incentives and discount rates for retail space when estimating the fair value of ROU assets. Developing the estimates and assumptions used in our recovery and impairment evaluations require judgment.
We had $344.6 million of property and equipment, net, and ROU assets of $394.9 million as of January 3, 2026. Changes in estimates and assumptions used in our impairment testing of property and equipment could result in future impairment losses, which could be material. We recognized impairments of property and equipment and ROU assets of $2.0 million, $10.1 million and $2.7 million in fiscal years 2025, 2024 and 2023, respectively. Refer to Note 12. “Fair Value Measurement” for further information on impairments recognized in fiscal year 2025.
Impairment of Goodwill and Intangible Assets
We calculate the fair value of our reporting units using a combination of income and market approaches. The income approach uses estimated after-tax cash flows discounted using a weighted average cost of capital. The cash flows used in the analysis are based on financial forecasts developed internally by management and require judgment. Significant unobservable inputs used in the fair value measurement of the reporting units include, but are not limited to, revenue growth rates, costs applicable to revenue, SG&A and discount rates. These assumptions are sensitive to future changes in the business profitability, changes in our business strategy, customer concentration risk and external market conditions, among other factors. The market approach estimates fair value using market‑based multiples for comparable companies and requires significant management judgment. Changes to the comparable company set or selected market‑based inputs can materially affect the estimated fair value of our reporting units.
See Note 4. “Goodwill and Intangible Assets” for further detail on goodwill impairment. As of January 3, 2026, we had $700.6 million of goodwill, $240.5 million of non-amortizing intangible assets, and $7.6 million of other intangible assets, net of accumulated amortization. Changes in estimates and assumptions used in our impairment testing could result in future impairment losses, which could be material.
Our America’s Best reporting unit was not at risk of failing the annual goodwill impairment test in fiscal year 2025. A hypothetical 100 basis point increase in the discount rate used to estimate the fair value of the America’s Best reporting unit would not result in goodwill impairment in fiscal year 2025. Our Eyeglass World reporting unit was not at risk of failing the annual goodwill impairment test in fiscal year 2025. A hypothetical 100 basis point increase in the discount rate used to estimate the fair value of the Company’s Eyeglass World reporting unit would not result in goodwill impairment in fiscal year 2025. Future changes in a reporting unit’s business profitability, expected cash flows, changes in business strategy and external market conditions, among other factors, could require us to record an impairment charge for goodwill.
When evaluating indefinite-lived, non-amortizing trademarks and trade names for impairment, we use the relief-from-royalty method to estimate fair value, whereby an estimated royalty rate is determined based on comparable licensing arrangements, which is then applied to the revenue projections for the subject asset. The estimated fair value is calculated using a discounted cash flow analysis. We record an impairment charge as the excess of carrying value over estimated fair value. A hypothetical 100 basis point increase in discount rates used to estimate the fair value of the Company’s trademarks and trade names would not result in an impairment of the America’s Best or Eyeglass World assets. A 10 basis point decrease in the royalty rates used in the analyses would not result in an impairment of America’s Best or Eyeglass World’s assets.
If impairment indicators related to finite-lived, amortizing intangible assets are present, we estimate cash flows expected to be generated over the remaining useful lives of the related assets based on current projections. If the projected net undiscounted cash flows are less than the carrying value of the related assets, we then measure impairment based on a discounted cash flow model and record an impairment charge as the excess of carrying value over the estimated fair value.
Refer to Note 1. “Business and Significant Accounting Policies”, Note 4. “Goodwill and Intangible Assets”, and Note 12. “Fair Value Measurement” for further detail on impairment of goodwill and intangible assets.
Income Taxes
Income tax accounting involves the use of estimates and complex judgments in a number of areas including the recognition of deferred tax assets and liabilities and the evaluation of uncertain tax positions. Our net deferred liability balance as of January 3, 2026 was $82.6 million. As future events, including tax law changes, are unpredictable, we continue to monitor developments in the tax landscape and adjust our assumptions and estimates accordingly. Changes in our assumptions and estimates could result in material changes to these balances. See Note 7. “Income Taxes” to our consolidated financial statements.
Inventories
Inventory shrinkage is estimated and recorded throughout the period in cost of sales based on historical results and current inventory levels. Inventory values are adjusted for estimated obsolescence and written down to net realizable value (“NRV”) based on estimates of current and anticipated demand, customer preference, and merchandise age. Actual shrinkage is recorded throughout the year based upon periodic physical counts. As of January 3, 2026, our total inventory balance was $89.3 million. A 10% increase in the obsolescence and shrinkage reserves will not have a material impact on our financial position. See Note 1. “Business and Significant Accounting Policies” to our consolidated financial statements.
Recently Issued Accounting Pronouncements
For information on recently issued accounting pronouncements, see Note 1. “Business and Significant Accounting Policies” to our consolidated financial statements.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
We have market risk exposure from changes in interest rates. When appropriate, we may use derivative financial instruments to mitigate the risk from such exposure. A discussion of our accounting policies for derivative financial instruments is included in Note 1. “Business and Significant Accounting Policies” and Note 12. “Fair Value Measurement” to our consolidated financial statements.
A portion of our debt bears interest at variable rates. If market interest rates increase, the interest rate on our variable rate debt will increase and will create higher debt service requirements, which would adversely affect our cash flow and could adversely impact our results of operations. In December 2025, we entered into an interest rate swap agreement to help manage interest rate exposure by economically converting a portion of our variable-rate debt to fixed-rate debt. Our interest rate swap is intended to mitigate some of the effects of increases in interest rates. See Note 13. “Interest Rate Derivatives” to our consolidated financial statements for more information on our interest rate swap.
As of January 3, 2026, our total borrowing consisted of $237.6 million of term loan borrowings subject to variable interest rates with a weighted average borrowing rate of 5.6%. An increase to market rates of 1.0% would result in a $1.3 million impact to interest expense as of January 3, 2026. A decrease to market rates of 1.0% would result in a $1.3 million impact to interest expense as of January 3, 2026.
Item 8. Consolidated Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| | | | | |
| Page |
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | 62 |
| |
Consolidated Balance Sheets as of January 3, 2026 and December 28, 2024 | 63 |
| |
Consolidated Statements of Operations and Comprehensive (Loss) Income for the Fiscal Years Ended January 3, 2026, December 28, 2024, and December 30, 2023 | 64 |
| |
Consolidated Statements of Stockholders’ Equity for the Fiscal Years Ended January 3, 2026, December 28, 2024, and December 30, 2023 | 65 |
| |
Consolidated Statements of Cash Flows for the Fiscal Years Ended January 3, 2026, December 28, 2024, and December 30, 2023 | 66 |
| |
Notes to Consolidated Financial Statements | 67 |
| |
Schedule I – Condensed Financial Information of Registrant | 98 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of National Vision Holdings, Inc. and Subsidiaries
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of National Vision Holdings, Inc. and subsidiaries (the “Company”) as of January 3, 2026 and December 28, 2024, the related consolidated statements of operations and comprehensive (loss) income, stockholders' equity, and cash flows, for each of the three years in the period ended January 3, 2026, and the related notes and the schedule listed in the Index at Item 15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of January 3, 2026 and December 28, 2024, and the results of its operations and its cash flows for each of the three years in the period ended January 3, 2026, in conformity with accounting principles generally accepted in the United States of America.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of January 3, 2026, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 4, 2026, expressed an unqualified opinion on the Company's internal control over financial reporting.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.
/s/ Deloitte & Touche LLP
Atlanta, GA
March 4, 2026
We have served as the Company's auditor since 2002.
National Vision Holdings, Inc. and Subsidiaries
Consolidated Balance Sheets
In Thousands, Except Share Data
| | | | | | | | | | | |
| As of January 3, 2026 | | As of December 28, 2024 |
| ASSETS | | | |
| Current assets: | | | |
| Cash and cash equivalents | $ | 38,708 | | | $ | 73,948 | |
| Accounts receivable, net | 57,322 | | | 49,938 | |
| Inventories | 89,318 | | | 93,918 | |
| Prepaid expenses and other current assets | 40,374 | | | 32,024 | |
| Total current assets | 225,722 | | | 249,828 | |
| | | |
Noncurrent assets: | | | |
| Property and equipment, net | 344,619 | | | 362,175 | |
| Goodwill | 700,642 | | | 698,305 | |
| Trademarks and trade names | 240,547 | | | 240,547 | |
| Other intangible assets, net | 7,554 | | | 8,269 | |
| Right of use assets | 394,896 | | | 408,589 | |
| Other assets | 69,698 | | | 40,058 | |
| | | |
| Total noncurrent assets | 1,757,956 | | | 1,757,943 | |
| Total assets | $ | 1,983,678 | | | $ | 2,007,771 | |
| | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | |
| Current liabilities: | | | |
| Accounts payable | $ | 78,999 | | | $ | 53,643 | |
| Other payables and accrued expenses | 109,674 | | | 109,036 | |
| Unearned revenue | 52,279 | | | 42,002 | |
| Deferred revenue | 64,560 | | | 62,507 | |
| Current maturities of long-term debt and finance lease obligations | 16,583 | | | 101,392 | |
| Current operating lease obligations | 90,313 | | | 99,694 | |
| | | |
| Total current liabilities | 412,408 | | | 468,274 | |
| | | |
| Noncurrent liabilities: | | | |
| Long-term debt and finance lease obligations, less current portion and debt discount | 229,327 | | | 248,610 | |
| Noncurrent operating lease obligations | 358,377 | | | 366,335 | |
| Deferred revenue | 22,517 | | | 22,082 | |
| Other liabilities | 8,944 | | | 8,228 | |
| Deferred income taxes, net | 82,572 | | | 77,909 | |
| Total noncurrent liabilities | 701,737 | | | 723,164 | |
Commitments and contingencies (See Note 11) | | | |
| Stockholders’ equity: | | | |
Common stock, $0.01 par value; 200,000,000 shares authorized; 86,278,538 and 85,444,263 shares issued as of January 3, 2026 and December 28, 2024, respectively; 79,416,050 and 78,775,117 shares outstanding as of January 3, 2026 and December 28, 2024, respectively | 862 | | | 854 | |
| | | |
| Additional paid-in capital | 834,000 | | | 807,048 | |
| Accumulated other comprehensive loss | (121) | | | — | |
| Retained earnings | 255,717 | | | 226,117 | |
Treasury stock, at cost; 6,862,488 and 6,669,146 shares as of January 3, 2026 and December 28, 2024, respectively | (220,925) | | | (217,686) | |
| Total stockholders’ equity | 869,533 | | | 816,333 | |
| Total liabilities and stockholders’ equity | $ | 1,983,678 | | | $ | 2,007,771 | |
Note: Fiscal year 2025 includes 53 weeks. Fiscal year 2024 includes 52 weeks.
The accompanying notes are an integral part of these consolidated financial statements.
National Vision Holdings, Inc. and Subsidiaries
Consolidated Statements of Operations and Comprehensive (Loss) Income
In Thousands, Except Per Share Amounts
| | | | | | | | | | | | | | | | | |
| Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Revenue: | | | | | |
| Net product sales | $ | 1,604,592 | | | $ | 1,463,139 | | | $ | 1,423,229 | |
| Net sales of services and plans | 382,896 | | | 360,181 | | | 333,142 | |
| Total net revenue | 1,987,488 | | | 1,823,320 | | | 1,756,371 | |
| Costs applicable to revenue (exclusive of depreciation and amortization): | | | | | |
| Products | 461,213 | | | 433,194 | | | 424,011 | |
| Services and plans | 358,256 | | | 330,862 | | | 310,644 | |
| Total costs applicable to revenue | 819,469 | | | 764,056 | | | 734,655 | |
| Operating expenses: | | | | | |
| Selling, general and administrative expenses | 1,016,251 | | | 938,524 | | | 904,757 | |
| Depreciation and amortization | 91,152 | | | 91,349 | | | 89,874 | |
| Asset impairment | 1,991 | | | 39,851 | | | 2,699 | |
| Other expense (income), net | (204) | | | (101) | | | (104) | |
| Total operating expenses | 1,109,190 | | | 1,069,623 | | | 997,226 | |
| Income (loss) from operations | 58,829 | | | (10,359) | | | 24,490 | |
| Interest expense, net | 17,148 | | | 16,184 | | | 14,339 | |
| (Gain) loss on extinguishment of debt | — | | | (859) | | | 599 | |
| Earnings (loss) from continuing operations before income taxes | 41,681 | | | (25,684) | | | 9,552 | |
Income tax provision | 12,081 | | | 1,481 | | | 6,006 | |
Income (loss) from continuing operations | 29,600 | | | (27,165) | | | 3,546 | |
| Income (loss) from discontinued operations, net of tax (See Note 2) | — | | | (1,334) | | | (69,447) | |
| Net income (loss) | $ | 29,600 | | | $ | (28,499) | | | $ | (65,901) | |
| | | | | |
| | | | | |
| Basic Earnings (loss) per share: | | | | | |
| Continuing operations | $ | 0.37 | | | $ | (0.35) | | | $ | 0.05 | |
| Discontinued operations | $ | — | | | $ | (0.02) | | | $ | (0.89) | |
| Total | $ | 0.37 | | | $ | (0.36) | | | $ | (0.84) | |
| Diluted Earnings (loss) per share: | | | | | |
| Continuing operations | $ | 0.37 | | | $ | (0.35) | | | $ | 0.05 | |
| Discontinued operations | $ | — | | | $ | (0.02) | | | $ | (0.88) | |
| Total | $ | 0.37 | | | $ | (0.36) | | | $ | (0.84) | |
| | | | | |
| Weighted average shares outstanding: | | | | | |
| Basic | 79,131 | | | 78,592 | | | 78,313 | |
| Diluted | 80,576 | | | 78,592 | | | 78,596 | |
| | | | | |
| Comprehensive income (loss): | | | | | |
| Net income (loss) | $ | 29,600 | | | $ | (28,499) | | | $ | (65,901) | |
Unrealized gain (loss) on hedge instruments | (161) | | | 548 | | | 1,019 | |
Tax provision of unrealized gain (loss) on hedge instruments | (40) | | | 129 | | | 259 | |
| Comprehensive income (loss) | $ | 29,479 | | | $ | (28,080) | | | $ | (65,141) | |
Note: Fiscal year 2025 includes 53 weeks. Fiscal years 2024 and 2023 include 52 weeks.
The accompanying notes are an integral part of these consolidated financial statements.
National Vision Holdings, Inc. and Subsidiaries
Consolidated Statements of Stockholders’ Equity
In Thousands
| | | | | | | | | | | | | | | | | | | | | | | |
| Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Loss | Retained Earnings | Treasury Stock | Total Stockholders’ Equity |
| Shares | Amount |
| | | | | | | |
| | | | | | | |
| Balances at December 31, 2022 | 78,992 | | $ | 842 | | $ | 767,112 | | $ | (1,179) | | $ | 320,517 | | $ | (186,179) | | $ | 901,113 | |
Issuance of common stock (1) | 558 | | 6 | | 1,832 | | — | | — | | — | | 1,838 | |
| Stock-based compensation | — | | — | | 20,023 | | — | | — | | — | | 20,023 | |
| Purchase of treasury stock | (1,239) | | — | | — | | — | | — | | (28,415) | | (28,415) | |
| | | | | | | |
| Unrealized gain on hedge instruments, net of tax | — | | — | | — | | 760 | | — | | — | | 760 | |
| Net income (loss) | — | | — | | — | | — | | (65,901) | | — | | (65,901) | |
| Balances at December 30, 2023 | 78,311 | | 848 | | 788,967 | | (419) | | 254,616 | | (214,594) | | 829,418 | |
Issuance of common stock (1) | 613 | | 6 | | 1,501 | | — | | — | | — | | 1,507 | |
| Stock-based compensation | — | | — | | 16,580 | | — | | — | | — | | 16,580 | |
| Purchase of treasury stock | (149) | | — | | — | | — | | — | | (3,092) | | (3,092) | |
| | | | | | | |
| Unrealized gain on hedge instruments, net of tax | — | | — | | — | | 419 | | — | | — | | 419 | |
| Net income (loss) | — | | — | | — | | — | | (28,499) | | — | | (28,499) | |
| Balances at December 28, 2024 | 78,775 | | 854 | | 807,048 | | — | | 226,117 | | (217,686) | | 816,333 | |
Issuance of common stock (1) | 834 | | 8 | | 3,387 | | — | | — | | — | | 3,395 | |
| Stock-based compensation | — | | — | | 23,565 | | — | | — | | — | | 23,565 | |
| Purchase of treasury stock | (193) | | — | | — | | — | | — | | (3,239) | | (3,239) | |
Unrealized gain (loss) on hedge instruments, net of tax | — | | — | | — | | (121) | | — | | — | | (121) | |
| Net income | — | | — | | — | | — | | 29,600 | | — | | 29,600 | |
| Balances at January 3, 2026 | 79,416 | | $ | 862 | | $ | 834,000 | | $ | (121) | | $ | 255,717 | | $ | (220,925) | | $ | 869,533 | |
(1) Consists primarily of the vesting of shares issued under the Company’s stock incentive plans and Associate Share Purchase Plan. |
Note: Fiscal year 2025 includes 53 weeks. Fiscal years 2024 and 2023 include 52 weeks.
The accompanying notes are an integral part of these consolidated financial statements.
National Vision Holdings, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
In Thousands
| | | | | | | | | | | | | | | | | |
| Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Cash flows from operating activities: | | | | | |
| Net income (loss) | $ | 29,600 | | | $ | (28,499) | | | $ | (65,901) | |
| Adjustments to reconcile net income (loss) to cash provided by operating activities: | | | | | |
| Depreciation and amortization | 91,152 | | | 92,680 | | | 98,252 | |
| Amortization of debt discount and deferred financing costs | 1,217 | | | 2,121 | | | 3,351 | |
| Amortization of cloud computing implementation costs | 8,741 | | | 6,402 | | | 3,170 | |
| Asset impairment | 1,991 | | | 40,099 | | | 82,413 | |
| Deferred income tax expense (benefit) | 4,663 | | | (9,975) | | | (5,989) | |
| Stock-based compensation expense | 23,686 | | | 16,708 | | | 20,174 | |
(Gains) on change in fair value of derivatives | — | | | (34) | | | (1,274) | |
| Inventory adjustments | 5,327 | | | 4,391 | | | 3,707 | |
| | | | | |
| | | | | |
| Other | (56) | | | (1,013) | | | 3,891 | |
| Changes in operating assets and liabilities: | | | | | |
| Accounts receivable | (8,069) | | | 36,399 | | | (7,817) | |
| Inventories | (728) | | | 21,598 | | | (457) | |
| Operating lease right of use assets and liabilities | (1,822) | | | (2,321) | | | 524 | |
| Other assets | (45,656) | | | (7,286) | | | (3,171) | |
| Accounts payable | 25,356 | | | (13,913) | | | 2,280 | |
| Deferred and unearned revenue | 12,766 | | | (5,852) | | | 7,401 | |
| Other liabilities | (1,875) | | | (17,856) | | | 32,479 | |
| Net cash provided by operating activities | 146,293 | | | 133,649 | | | 173,033 | |
| Cash flows from investing activities: | | | | | |
| Purchase of property and equipment | (72,840) | | | (95,505) | | | (114,774) | |
| Other | (3,766) | | | (589) | | | (1,048) | |
| Net cash used for investing activities | (76,606) | | | (96,094) | | | (115,822) | |
| Cash flows from financing activities: | | | | | |
| Repayments on long-term debt | (126,337) | | | (222,064) | | | (103,000) | |
Borrowings on long-term debt | 25,000 | | | 115,000 | | | — | |
| Payments of debt issuance costs | — | | | (1,703) | | | (3,312) | |
| Payments on finance lease obligations | (3,475) | | | (2,993) | | | (3,918) | |
| Proceeds from issuance of common stock | 3,395 | | | 1,507 | | | 1,837 | |
| Purchase of treasury stock | (3,205) | | | (3,092) | | | (28,415) | |
| Net cash used for financing activities | (104,622) | | | (113,345) | | | (136,808) | |
| Net change in cash, cash equivalents and restricted cash | (34,935) | | | (75,790) | | | (79,597) | |
| Cash, cash equivalents and restricted cash, beginning of year | 75,237 | | | 151,027 | | | 230,624 | |
Cash, cash equivalents and restricted cash, end of year (See Note 3) | $ | 40,302 | | | $ | 75,237 | | | $ | 151,027 | |
| | | | | |
| Supplemental cash flow disclosure information: | | | | | |
| Cash paid for interest | $ | 19,091 | | | $ | 13,398 | | | $ | 11,735 | |
| | | | | |
| Capital expenditures accrued at the end of the period | $ | 12,186 | | | $ | 9,248 | | | $ | 5,412 | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
Note: Fiscal year 2025 includes 53 weeks. Fiscal years 2024 and 2023 include 52 weeks.
The accompanying notes are an integral part of these consolidated financial statements.
National Vision Holdings, Inc. and Subsidiaries
Index to Notes to Consolidated Financial Statements
| | | | | |
1. Business and Significant Accounting Policies | 68 |
2. Discontinued Operations | 76 |
3. Details of Certain Balance Sheet Accounts | 77 |
4. Goodwill and Intangible Assets | 79 |
5. Debt | 80 |
6. Stock Incentive Plan | 81 |
7. Income Taxes | 84 |
8. Revenue from Contracts with Customers | 86 |
9. Deferred Revenue | 87 |
10. Leases | 88 |
11. Commitments and Contingencies | 89 |
12 Fair Value Measurement of Financial Assets and Liabilities | 91 |
13. Interest Rate Derivatives | 93 |
14. Earnings Per Share | 94 |
15. Segment Reporting | 94 |
16. Accumulated Other Comprehensive Loss | 97 |
| |
| |
National Vision Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
1. Business and Significant Accounting Policies
Nature of Operations
National Vision Holdings, Inc. (“NVHI,” the “Company,” “we,” “our,” or “us”) is a holding company whose operating subsidiaries include its indirect wholly owned subsidiary, National Vision, Inc. (“NVI”) and NVI’s direct wholly owned subsidiaries. We are a leading value retailer of eyeglasses and contact lenses in the United States (“U.S”). We operated 1,250 and 1,240 retail optical locations in the U.S. and its territories as of the fiscal years ended January 3, 2026 and December 28, 2024, respectively, through our four store brands, including America’s Best Contacts and Eyeglasses (“America’s Best”), Eyeglass World, Vista Optical locations on select U.S. Army/Air Force military bases (“Military”) and within select Fred Meyer stores. We also operate omni-channel websites for our America’s Best, Eyeglass World and Military brands, as well as a dedicated e-commerce website.
We also operate a specialized health maintenance organization (“HMO”) that is licensed as a single-service health plan under California law. The HMO issues individual vision plans in connection with our America’s Best operations in California.
Fiscal Year
We operate on a retail fiscal calendar that results in a given fiscal year consisting of a 52-week or 53-week period ending on the Saturday closest to December 31. In a 52-week fiscal year, each quarter contains 13 weeks of operations; in a 53-week fiscal year, each of the first, second and third quarters include 13 weeks of operations and the fourth quarter includes 14 weeks of operations.
References herein to “fiscal year 2025” relate to the 53 weeks ended January 3, 2026. References herein to “fiscal year 2024” and “fiscal year 2023,” relate to the 52 weeks ended December 28, 2024, and December 30, 2023, respectively. Unless otherwise stated, references to years in this report relate to fiscal years rather than calendar years.
Basis of Presentation and Principles of Consolidation
We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include our accounts and those of our subsidiaries, all of which are wholly-owned. All intercompany balances and transactions have been eliminated in consolidation. Certain amounts within the consolidated financial statements and footnotes to the financial statements for fiscal year 2024 and fiscal year 2023 have been reclassified to conform to the fiscal year 2025 presentation.
The Company has consolidated certain entities meeting the definition of a variable interest entity (“VIE”) as the Company concluded that it is the primary beneficiary of the entities under the provisions of Accounting Standards Codification 810, Consolidation. As of January 3, 2026, the variable interest entities include 29 professional corporations. The total assets of the consolidated VIEs included in the accompanying Consolidated Balance Sheets as of January 3, 2026 and December 28, 2024, were $4.6 million and $7.0 million, respectively, and the total liabilities of the consolidated VIEs were $6.9 million and $8.4 million, respectively.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Share Repurchases
On February 23, 2022, our Board of Directors authorized a $100 million increase to the share repurchase authorization, resulting in total authorization of $200 million. During fiscal year 2023, the Company repurchased 1.1 million shares of its common stock for $25 million under the share repurchase program. The Company’s original share repurchase authorization expired on December 30, 2023, and had remaining capacity of $25 million. Effective February 23, 2024, the Board authorized the Company to repurchase up to $50 million aggregate amount of shares of the Company’s common stock until January 3, 2026. No additional shares were repurchased in fiscal years 2024 and 2025. The share repurchase authorization expired on January 3, 2026, and had remaining capacity of $50 million. Effective March 2, 2026, the Board authorized the Company to repurchase up to $50 million aggregate amount of shares of the Company’s common stock until December 28, 2030. The authorization permits the Company to make purchases of its common stock from time to time in the open market or privately negotiated transactions, and pursuant to pre-set trading plans meeting the
requirements of all applicable securities laws and regulations. The timing and amounts of any such repurchases will depend on a variety of factors, including the market price of the Company’s shares, general market and economic conditions, legal requirements and tax implications. The Company expects to fund the share repurchases using cash on hand.
CARES Act
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, accelerates a company’s ability to recover Alternative Minimum Tax (“AMT”) refundable credits that otherwise could have been claimed in 2020 and 2021, to 2018 and 2019, with an option to elect recovery of the full credit amount for 2018. The Company recognizes government grants for which there is a reasonable assurance of compliance with grant conditions and receipt of credits. Amounts receivable under the CARES Act were $9.0 million as of January 3, 2026 and December 28, 2024. Credits recognized under the CARES Act offset deferred payroll taxes that would otherwise have been payable as of January 1, 2022. In January 2026, subsequent to the balance sheet date, the Company received the full payment of these CARES Act credits.
Cash and Cash Equivalents
Cash and cash equivalents include cash on hand, demand deposits, and highly liquid investments with original maturities of three months or less at the date of purchase. Substantially all our cash and cash equivalents are held at a limited number of financial institutions and may exceed federally insured limits.
Accounts Receivable, Net
Accounts receivable associated with revenues consist primarily of trade receivables, which include credit card receivables from credit card companies. Trade receivables consist primarily of receivables from managed care payors. While we have relationships with almost all vision care insurers in the U.S. and with all of the major carriers, currently, a relatively small number of payors comprise the majority of our managed care revenues, subjecting us to concentration risk. Accounts receivable are reduced by allowances for credit losses. Estimates of our allowance for credit losses are based on our historical and current operating, billing, and collection trends, as well as current conditions and reasonable and supportable forecasts about the future. Accounts receivable are written off after all collection attempts have been exhausted. Credit loss expense recognized on our receivables, which is presented in Selling, general and administrative expenses (“SG&A”) in the Company’s Consolidated Statements of Operations, was approximately $1.0 million, $0.4 million and $0.6 million for the fiscal years 2025, 2024 and 2023, respectively.
Inventories
The cost of inventory is determined using the weighted average cost method. Inventories at retail stores consist of finished goods and are valued at the lower of cost or estimated net realizable value (“NRV”). Manufactured inventories are valued using absorption accounting which includes material, labor, other variable costs and other applicable manufacturing overhead. Inventory values are adjusted for estimated obsolescence and written down to NRV based on estimates of current and anticipated demand, customer preference, and merchandise age. Shrinkage is estimated and recorded throughout the period in costs applicable to revenue based on historical results and current inventory levels. Actual shrinkage is recorded throughout the year based upon periodic physical counts. See Note 3. “Details of Certain Balance Sheet Accounts” for further details.
The Company’s inventory consists primarily of eyeglass frames, contact lenses, and unprocessed eyeglass lenses. A significant portion of our inventory is supplied by a small number of key vendors. During fiscal year 2025, approximately 96% of contact lens expenditures were with three vendors and approximately 86% of lens expenditures were with one vendor. This exposes us to vendor concentration risk. We are less exposed to a supplier risk for our eyeglass frames as only approximately 55% of frame expenditures were with two vendors.
Property and Equipment
Property and equipment (“P&E”) is stated at cost less accumulated depreciation. Depreciation associated with P&E is included in Depreciation and amortization in the accompanying Consolidated Statements of Operations. When we retire or otherwise dispose of P&E, we remove the cost and related accumulated depreciation from our accounts and recognize any gain or loss on the sale of such assets in SG&A in the Consolidated Statements of Operations and Comprehensive (Loss) Income. We capitalize major replacements and remodeling, and recognize expenditures for maintenance and repairs in SG&A.
We depreciate P&E for financial accounting purposes using the straight-line method over the following estimated useful lives:
| | | | | |
| Buildings | 34 years |
| |
| Equipment | 3 - 10 years |
Information technology hardware and software (a) | 2 - 5 years |
| Furniture and fixtures | 6 years |
Leasehold improvements(b) | 5 - 10 years |
P&E under finance leases (b) | 10 years |
____________ |
(a)Costs of developing or obtaining software for internal use, such as direct costs of materials or services and internal payroll costs related to the software development projects, are capitalized to information technology hardware and software. (b)Depreciation of leasehold improvements is recognized over the shorter of the estimated useful life of the asset or the term of the lease. The term of the lease includes renewal options for additional periods if the exercise of the renewal is considered to be reasonably assured. |
Cloud Computing Arrangements
The Company capitalizes certain costs related to the acquisition and development of internal use software, including implementation costs incurred in a cloud computing arrangement during the application development stages of projects. Capitalized implementation costs are amortized on a straight-line basis over the expected term of the hosting arrangement, which includes consideration of the non-cancellable contractual term and reasonably certain renewals. Costs incurred during the preliminary project or the post-implementation stages of the project are expensed as incurred. Capitalized implementation costs are included in Other assets in our Consolidated Balance Sheets. Amortization of capitalized implementation costs is included in SG&A in the Consolidated Statements of Operations and Comprehensive (Loss) Income.
Goodwill and Intangible Assets
Indefinite-lived intangible assets include goodwill and our trademarks and tradenames; we evaluate these assets annually for impairment, or more frequently if events and circumstances indicate that it is more likely than not that goodwill or intangible assets are impaired. Our annual testing date for impairment of goodwill and indefinite-lived intangible assets is the first day of the fourth fiscal quarter, which for fiscal year 2025 was September 28, 2025. Costs to renew intangible assets are expensed as incurred.
Goodwill is impaired if a reporting unit’s carrying value exceeds its fair value, and impairment is calculated as the excess between carrying value over fair value. We consider each of our operating segments to be reporting units. We estimate the fair value of our reporting units using a combination of income and market approaches. The income approach is based on a discounted cash flow analysis and involves estimating after-tax cash flows that are discounted using a weighted average cost of capital that considers both market risk and company-specific risk. The cash flows used in the analysis are based on financial forecasts developed internally by management and require significant judgment. Significant unobservable inputs used in the fair value measurement of the reporting units include, but are not limited to, revenue growth rates, costs applicable to revenue, SG&A and discount rates. These assumptions are sensitive to future changes in the business profitability, changes in our business strategy and external market conditions, among other factors. A decrease to the long-term revenue growth rate assumption or an increase to the expense growth rate assumptions could require us to record goodwill impairment charges. The market approach estimates fair value using market‑based multiples for comparable companies and requires significant management judgment. Changes to the comparable company set or selected market‑based inputs can materially affect the estimated fair value of our reporting units. Both the income and market approaches incorporate entity‑specific inputs (Level 3) and observable market information (Level 2) within the fair value hierarchy.
We use the relief-from-royalty method to estimate fair value of our trademarks and trade names, which involves estimating a royalty rate based on comparable licensing arrangements, applying that rate to the revenue projections for the subject asset, and then estimating fair value using a discounted cash flow analysis; the discounted cash flow analysis uses a weighted average cost of capital that considers both market risk and company-specific risk. We record an impairment charge as the excess of carrying value over estimated fair value.
Finite-lived, amortizing intangible assets consist of our Fred Meyer contracts and relationship. We amortize finite-lived intangible assets on a straight-line basis over their estimated useful lives. Amortization expense associated with finite-lived intangible assets is included in Depreciation and amortization in the accompanying Consolidated Statements of Operations.
If impairment indicators related to amortizing intangible assets are present, we estimate cash flows expected to be generated over the remaining useful lives of the related assets based on current projections. If the projected net undiscounted cash flows are less than the carrying value of the related assets, we then measure impairment based on a discounted cash flow model and record an impairment charge as the excess of carrying value over estimated fair value.
See Note 4. “Goodwill and Intangible Assets”, and Note 12. “Fair Value Measurement” for further detail on impairment of goodwill and intangible assets.
Investments
In the second quarter of fiscal year 2023, we completed an investment in an entity specializing in applying artificial intelligence-powered screening and diagnostic tools to retinal imaging. During fiscal years 2024 and 2023, we invested $1.5 million and $1.8 million, respectively. The investment is valued at cost. In fiscal year 2024, we completed an investment in a convertible promissory note issued by this entity. The investments are recognized in Other assets in the Consolidated Balance Sheets and in Other in the investing section of the Consolidated Statements of Cash Flows for fiscal years fiscal years 2025, 2024 and 2023. In the fourth quarter of fiscal year 2025, the investee entered into an agreement and plan of merger pursuant to which it will be acquired by the Company’s co-preferred investor in the entity. In connection with the sale, the Company anticipates receiving full repayment in cash of its capital and promissory note investment balances, and no gain or loss is expected to be recognized. Refer to Note 12. “Fair Value Measurement” for more information on the investments in this entity.
Fair Value Measurement of Assets and Liabilities
The Company accounts for certain assets and liabilities at fair value. The Company generally uses a market approach, when practicable, in valuing financial instruments. For certain assets the Company may also use a valuation technique consistent with the income approach whereby future cash flows are converted to a single discounted amount. The carrying value of the Company’s cash equivalents and restricted cash, accounts receivable, accounts payable and other payables and accrued expenses, approximate fair value due to their short-term nature.
Non-financial assets such as P&E, right of use (“ROU”) assets and intangible assets are subject to nonrecurring fair value measurements if impairment indicators are present. Factors we consider important that could trigger an impairment review include a significant under-performance compared to expected operating results, a significant or adverse change in customer business climate, and a significant negative industry or economic trend.
Refer to “Long-lived Asset Impairment” section below and Note 12. “Fair Value Measurement” for the Company’s recurring and non-recurring fair value measurements.
Deferred Financing Costs and Loan Discounts
Costs incurred in connection with long-term debt, which are paid directly to the Company’s lenders and to third parties, are presented as reductions to our long-term debt balance, except for the costs related to our revolving credit facility which are presented as assets. These costs are amortized over the term of the related financing agreement and included in Interest expense, net in the accompanying Consolidated Statements of Operations.
Self-Insurance Liabilities
We are primarily self-insured for workers’ compensation, associate health benefits and general liability claims. We record self-insurance liabilities based on claims filed, including the development of those claims and an estimate of claims incurred but not yet reported. Should a different amount of claims occur compared to what was estimated, or costs of the claims increase or decrease beyond what was anticipated, liabilities may need to be adjusted accordingly. We periodically update our estimates and record such adjustments in the period in which such determination is made. Self-insurance liabilities are recorded on an undiscounted basis in the accompanying Consolidated Balance Sheets. Refer to the following table and Note 3. “Details of Certain Balance Sheet Accounts” for further details.
We reinsure worker’s compensation and medical claims above our retention levels with a highly rated financial institution that can be expected to fully perform under the terms of the arrangement. Estimated recoveries from reinsurance as of fiscal year end 2025 and 2024 are shown in the following table.
| | | | | | | | | | | | | | | | | | | | |
| In thousands | Balance Sheet Classification | | As of January 3, 2026 | | As of December 28, 2024 |
| Current portion | Prepaid Expenses and Other Current Assets | | $ | 973 | | | $ | 854 | |
| Noncurrent portion | Other Assets | | 2,538 | | | 1,281 | |
| Total estimated recoveries from reinsurance | | $ | 3,511 | | | $ | 2,135 | |
Derivative Financial Instruments
The Company uses interest rate derivatives to manage the exposure of its Term Secured Overnight Financing Rate (“Term SOFR”)-based debt to fluctuations in interest rates. If our derivatives are designated as cash flow hedges, we formally document our hedge relationships, including identification of the hedging instruments and the hedged items, as well as our risk management objectives and strategies for undertaking the hedge transactions. We record all interest rate derivatives in our Consolidated Balance Sheets on a gross basis at fair value. Fair value represents estimated amounts we would receive or pay upon a termination of interest rate derivatives prior to their scheduled expiration dates. The fair value is based on information that is model-driven and whose inputs were observable (Level 2 inputs) such as Term SOFR forward rates. We do not hold or enter into financial instruments for trading or speculative purposes.
The gain or loss resulting from fair value adjustments for highly effective cash flow hedges is recorded in Accumulated other comprehensive loss (“AOCL”) in the accompanying Consolidated Balance Sheets until the hedged item is recognized as Interest expense, net in the Consolidated Statements of Operations. The gain or loss resulting from fair value adjustments of derivatives not deemed to be highly effective cash flow hedges is recognized in Interest expense, net immediately. We perform assessments of the effectiveness of our derivative contracts designated as hedges on a quarterly basis at a minimum and may perform the assessment more often, if deemed applicable.
To manage credit risk associated with our interest rate hedging program, we select as counterparties major financial institutions with investment grade credit ratings. The impact of credit risk, as well as the ability of each party to fulfill its obligations under our derivative financial instruments, is considered in determining the fair value of the contracts. We were party to an interest rate collar to offset the variability of cash flows in Term SOFR-indexed debt interest payments. The interest rate collar matured on July 18, 2024. On December 23, 2025, we entered into an interest rate swap that fixed the variable benchmark component (SOFR) on $100 million of variable rate debt through May 2027. See Note 13. “Interest Rate Derivatives” for further details.
Accumulated Other Comprehensive Loss
AOCL is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive loss, net of income tax, is entirely composed of the cumulative unrealized loss on our hedging instruments. See Note 16. “Accumulated Other Comprehensive Loss” for details of reclassifications out of AOCL.
Revenue Recognition
Net product sales include sales of prescription and non-prescription eyewear, contact lenses and related accessories to retail customers (including those covered by managed care). Net sales of services and plans include sales of eye exams, eye care club membership fees, product protection plans (i.e. warranties) and HMO vision plan fees.
The majority of our revenues are recognized at a point in time, either at the point of sale or upon delivery and customer acceptance. Consideration is generally paid at the time of sale in cash, credit card, or on account with managed care payors, which typically have payment terms between 14 and 120 days, with most paying within 60 days. Point in time revenues include retail sales of prescription and non-prescription eyewear, contact lenses, and related accessories to retail customers (including those covered by managed care), as well as stand-alone eye exams. Revenues recognized over time primarily include product protection plans (i.e. warranties) and eye care club memberships.
At our America’s Best brand, our signature offer is an eye exam plus two pairs of eyeglasses for one great price (“two-pair offer”). Since an eye exam is a key component in the ability for acceptable prescription eyewear to be delivered to a customer, we concluded that the eye exam service, while capable of being distinct from the eyeglass product delivery, was not distinct in the context of the two-pair offer. As a result, we do not allocate revenue to the eye exam associated with the two-pair offer, and we record all revenue associated with the offer in Owned & Host net product sales when the customer has received and accepted the merchandise.
Our retail customers generally make payments for prescription eyewear products at the time they place an order. Amounts we collect in advance for undelivered merchandise are reported as Unearned revenue in the accompanying Consolidated Balance Sheets. Unearned revenue at the end of a reporting period is estimated based on processing and delivery times throughout the current month which generally within two weeks; all unearned revenue at the end of a reporting period is recognized in the next fiscal period.
Revenue is recognized net of sales taxes and returns and includes amounts billed to customers related to shipping and handling costs. The returns allowance is based on historical return patterns. Provisions for estimated returns are established and the expected costs continue to be recognized as reductions to revenue when the products are sold. Shipping and handling costs are accounted for as fulfillment costs and are included in costs applicable to revenue.
An increasing percentage of our customers receive vision insurance coverage through managed care payors. The managed care business represents an increasingly significant portion of our overall revenues and our revenue growth and represented 42% of our revenues from continuing operations in fiscal 2025.
We record reductions in revenue for estimated price concessions granted to managed care providers. The Company considers its revenue from managed care customers to include variable consideration and estimates such amounts associated with managed care customer revenues using the history of concessions provided and cash receipts from managed care providers. We reduced our net revenue for variable considerations of $8.8 million, $17.7 million and $14.7 million during the fiscal years 2025, 2024 and 2023, respectively.
Refer to Note 8. “Revenue from Contracts with Customers” for further details of our revenues.
Costs Applicable to Revenue
Costs applicable to revenue consist primarily of cost of products sold and costs of administering services and plans. Costs of products sold include (i) costs to procure non-prescription eyewear, contacts and accessories which we purchase and sell in their finished form, (ii) costs to manufacture finished prescription eyeglasses, including direct materials, labor and overhead and (iii) remake costs, warehousing and distribution expenses and internal transfer costs. Costs of services and plans include costs associated with warranty programs, eye care club memberships, HMO vision plan fees, eye care practitioner and eye exam technician payroll, taxes and benefits and optometric and other service costs. Depreciation and amortization are excluded from costs applicable to revenue and are presented separately on the accompanying Consolidated Statements of Operations and Comprehensive (Loss) Income.
As a component of the Company’s procurement program, the Company frequently enters into contracts with its vendors that provide for payments of rebates or other allowances. These vendor payments are reflected when earned or as progress is made toward earning the rebate or allowance and, depending on the terms of the agreement with the vendor, are treated as a reduction of the carrying value of the inventory and a reduction of cost of products. Rebates that have been earned but not yet received are recognized as an increase to Accounts receivable, net or a reduction to Accounts payable, depending on the nature of the agreement with the vendor, until the payment has been received.
Selling, General and Administrative
SG&A includes store associate (including optician) payroll, taxes and benefits, occupancy and other store expenses, advertising and promotion, field services, and corporate support. Advertising and promotion costs, including online marketing arrangements, direct mail, television and radio, are recorded in SG&A and expensed at the time the advertising first occurs. Production costs of future media advertising and related promotional campaigns are deferred until the advertising events occur. Non-capital expenditures associated with opening new stores, including rent, marketing expenses, travel and relocation costs, and training costs, are recorded in SG&A as incurred. Certain vendor contracts provide for marketing co-op allowances; such allowances are reflected when earned or as progress is made toward earning the allowance and are treated as a reduction of SG&A.
Advertising expenses were $138.8 million, $138.6 million and $137.2 million for fiscal years 2025, 2024 and 2023, respectively.
Severance benefits
During fiscal years 2025, 2024 and 2023, we recognized $3.6 million, $0.1 million and $1.8 million, respectively, in SG&A in the Consolidated Statements of Operations and Comprehensive (Loss) Income, in the corporate and other category, related to termination benefits for certain associates; these charges were recognized in accordance with Financial Accounting Standards Board (“FASB”) guidance on employers’ accounting for post-employment benefits and guidance on accounting for costs associated with exit or disposal activities, as appropriate.
Leases
We lease our stores, distribution center, corporate offices, and most of our laboratories. These leases generally have noncancelable lease terms of between five and 10 years, with an option to renew for additional terms of one to 10 years or more. The lease term includes renewal option periods when the renewal is deemed reasonably certain after considering the value of the leasehold improvements at the end of the noncancelable lease period. Most leases for our stores provide for a minimum rent and typically include escalating rent over time with the exception of Military for which lease payments are variable and based on a percentage of sales. For Vista Optical locations in Fred Meyer stores, we pay the greater of fixed rent or a percentage of sales after certain minimum thresholds are achieved. The Company’s leases generally
require us to pay insurance, real estate taxes and common area maintenance expenses, substantially all of which are variable and not included in the measurement of the lease liability. Our lease arrangements frequently include tenant improvement allowances (“TIAs”), which are contractual amounts received or receivable from a lessor for improvements made to leased properties by the Company. For operating leases, TIAs are treated as a reduction of the lease payments used to measure the ROU assets in the accompanying Consolidated Balance Sheets and are amortized as a reduction in rental expense over the life of the respective leases. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.
The lease liability is measured at the present value of future lease payments over the lease term less TIAs receivable, and the ROU asset is measured at the lease liability amount, adjusted for prepaid lease payments, TIAs received and the lessee’s initial direct costs. As the rate implicit in the Company’s leases is not easily determinable, the Company’s incremental borrowing rate is used in calculating the present value of the sum of the lease payments. Factors incorporated into the calculation of the lease incremental borrowing rate include lease term, borrowing rates on the Company’s long-term debt, Term SOFR margins for issuers of similar credit rating to NVI and effect of collateralization.
For finance leases, the related ROU assets are recorded within Property and equipment, net on the Consolidated Balance Sheets. The corresponding finance lease obligations are recorded within Current maturities of long-term debt and finance lease obligations for the current portion and within Long-term debt and finance lease obligations, less current portion and debt discount for the noncurrent portion on the Consolidated Balance Sheets. Finance lease obligations are measured at the present value of lease payments due over the lease term at lease commencement.
Stock-Based Compensation
We measure stock-based compensation cost, which consists of grants of stock options, performance stock units (“PSUs”), and restricted stock units (“RSUs”), to associates and non-employee directors, based on the estimated grant date fair value of the awards. We recognize compensation expense for all awards containing a service requirement over the requisite service period using a straight-line recognition method. PSUs granted by the Company contain vesting conditions based on either performance or market conditions, in addition to a service requirement. For PSUs with performance conditions, we record compensation expense based on the portion of the award’s total fair value attributable to the service period already completed. The recognized expense is based on the number of units expected to vest, which is estimated by assessing expected performance against our defined metrics, which include Adjusted Operating Income and return on invested capital. These estimates may change over time and may result in reversals of previously recognized expense. For PSUs with market conditions, vesting is based on relative total shareholder return compared to a defined peer group. The fair value of these awards is estimated using the Monte Carlo simulation model and compensation expense is recognized based on the fair value on a straight-line basis over the requisite service period and is not adjusted for subsequent changes in actual or expected performance. We account for forfeitures as they occur. See Note 6. “Stock Incentive Plan” for further details related to our stock-based compensation plans.
Long-lived Asset Impairment
Non-financial assets such as P&E, ROU assets and intangible assets are subject to nonrecurring fair value measurements if impairment indicators are present. We evaluate impairment of long-lived tangible and ROU store assets at the store level, which is the lowest level at which independent cash flows can be identified, when events or conditions indicate the carrying values of such assets may not be recoverable. In making this evaluation, we may consider multiple factors including financial performance of the stores, regional and local business climates, industry or economic trends, future plans for the store operations and other qualitative factors. If the store’s projected undiscounted net cash flows expected to be generated by the related assets over the life of the primary asset within the asset group are less than the carrying value of the subject assets, we determine an estimate of the fair value of the asset group using an income approach based on discounted cash flows, which require estimates and assumptions related to forecasted store revenue growth rates and store profitability. If the fair value of the asset group is less than its carrying value, the loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the loss allocated to an individual long lived asset of the group shall not reduce the carrying amount of that asset below its fair value. We consider market-based indications of prevailing rental rates for retail space, market participant discount rates, and lease incentives when estimating the fair values of ROU assets.
We assess non-store, long-lived assets, including capitalized software costs in use or under development, for impairment if events or changes in circumstances indicate that the carrying value of those assets may not be recoverable.
Discontinued Operations
In accordance with ASC 205-20 “Presentation of Financial Statements: Discontinued Operations,” a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. In the period in which the component meets held-for-sale or discontinued operations criteria, the major current assets, non-
current assets, current liabilities, and non-current liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations.
Our operations related to Walmart Inc. (“Walmart”), including our former Legacy reportable segment (“Legacy”), as well as the majority of our AC Lens operations, met the requirements to be classified as discontinued operations. Accordingly, we classified the results of these operations as discontinued operations in the Consolidated Statements of Operations and Comprehensive (Loss) Income for all periods presented. The results of all discontinued operations, less applicable income taxes, are reported as components of net income separate from the net income of continuing operations, and certain assets and liabilities associated with these operations were classified as assets and liabilities of discontinued operations in the Consolidated Balance Sheets for the periods presented. There was no discontinued operations activity in fiscal year 2025. There were no discontinued operations assets or liabilities as of December 28, 2024 and January 3, 2026. Additionally, the cash flows and comprehensive (loss) income of discontinued operations have not been segregated and are included in the Consolidated Statements of Cash Flows and Consolidated Statements of Operations and Comprehensive (Loss) Income, respectively, for all periods presented. All amounts included in the notes to the consolidated financial statements relate to continuing operations unless otherwise noted. For additional information, see Note 2. “Discontinued Operations”
Income Taxes
We account for deferred income taxes based on the asset and liability method. The Company must make certain estimates and judgments in determining income tax expense. We are required to determine the aggregate amount of income tax expense to accrue and the amount which will be currently payable or refundable based upon tax statutes of each jurisdiction in which the Company does business. Deferred income taxes are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets also include future tax benefits to be derived from the utilization of tax loss carry-forwards and application of certain carry-forward credits. The net carrying amount of deferred income tax assets and liabilities is recorded in Noncurrent deferred income tax liabilities in the accompanying Consolidated Balance Sheets.
Deferred income taxes are measured using enacted tax rates in effect for the years in which those differences are expected to be recovered or settled. The effect on deferred taxes from a change in the tax rate is recognized through continuing operations in the period that includes the enactment of the change. Changes in tax laws and rates could affect recorded deferred tax assets and liabilities in the future.
A valuation allowance is recorded if it is more likely than not that some portion of a deferred tax asset will not be realized. Valuation allowances are released as positive evidence of future taxable income sufficient to realize the underlying deferred tax assets becomes available.
We establish a liability for tax positions for which there is uncertainty as to whether the position will ultimately be sustained. We assess our tax positions by determining whether it is more likely than not that the position will be sustained upon examination by the appropriate taxing authorities, including resolution of any related appeals or litigation, based solely on the technical merits of the position. These calculations and assessments involve estimates and judgments because the ultimate tax outcomes are uncertain and future events are unpredictable. See Note 7. “Income Taxes” for further details.
Adoption of New Accounting Pronouncements
Income taxes. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and for interim periods within fiscal years beginning after December 15, 2025. The Company adopted this guidance retrospectively in the fourth quarter of fiscal year 2025 and has provided the applicable disclosures in Note 7. “Income Taxes.”
Future Adoption of Accounting Pronouncements
Expense Disaggregation Disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive (Loss) Income (Topic 220-40): Expense Disaggregation Disclosures (“ASU 2024-03”). This update requires, among other things, more detailed disclosure about types of expenses in commonly presented expense captions such as cost of sales and SG&A, and is intended to improve the disclosures about an entity’s expenses including purchases of inventory, employee compensation, depreciation and amortization. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.
Credit Losses for Accounts Receivable and Contract Assets. In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This update provides a practical expedient which allows an entity to assume that, for purposes of estimating expected credit losses related to an asset, current conditions as of a balance sheet date do not change for the remaining life of the asset. This guidance is effective for fiscal years beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.
Derivatives and Hedging. In November 2025, the FASB issued ASU 2025-09, Derivatives and Hedging (Topic 815), to more closely align financial reporting with the economics of an entity’s risk management activities. The effective date for this standard is for fiscal years beginning after December 15, 2026 and interim periods within those fiscal years. Early adoption is permitted. The amendments in this ASU should be applied prospectively with an option to adopt the amendments for hedging relationships existing as of the date of adoption. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.
Intangibles - Internal-Use Software. In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40), which updates the accounting guidance for internal-use software costs. The amendments remove references to software development project stages and align the guidance with current software development practices. The standard is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.
Interim Reporting. In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (“ASU 2025-11”). The update provides clarifications intended to improve the consistency and usability of interim disclosure requirements, including a comprehensive listing of required interim disclosures and a new disclosure principle for reporting material events occurring after the most recent annual period. The amendments do not change the underlying objectives of interim reporting but are designed to enhance clarity in application. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.
The FASB issued other accounting guidance during fiscal year 2025 that is not currently applicable or expected to have a material impact on the Company’s financial statements, and therefore, is not described above.
2. Discontinued Operations
As a result of the termination of various agreements with Walmart and the wind down of AC Lens operations in fiscal year 2024, our former Legacy reportable segment and certain other results previously included in corporate and other as well as related effects of unearned and deferred revenue, met the criteria to be presented as discontinued operations. Accordingly, the assets and liabilities and results of operations of the discontinued operations have been presented in the tables below. There was no discontinued operations activity in fiscal year 2025. There were no discontinued operations assets or liabilities as of December 28, 2024 and January 3, 2026.
During fiscal years 2024 and 2023, we recorded $4.4 million and $5.2 million, respectively, of net expense associated with the aforementioned termination and consolidation activities, which consisted of employee compensation benefits, early termination fees, and other exit related costs. These charges were recorded in both Selling, general, and administrative expenses and Costs applicable to revenue for discontinued operations. The plan has been substantially completed and we do not anticipate additional material costs related to this plan.
The following table presents income (loss) from discontinued operations, net of tax:
| | | | | | | | | | | |
| In thousands | Fiscal Year 2024 | | Fiscal Year 2023 |
| Revenue: | | | |
| Net product sales | $ | 126,960 | | | $ | 320,907 | |
| Net sales of services and plans | 4,513 | | | 49,190 | |
| Total net revenue | 131,473 | | | 370,097 | |
| Costs applicable to revenue (exclusive of depreciation and amortization): | | | |
| Products | 109,637 | | | 240,578 | |
| Services and plans | 2,585 | | | 25,677 | |
| Total costs applicable to revenue | 112,222 | | | 266,255 | |
| Operating expenses: | | | |
| Selling, general and administrative expenses | 21,851 | | | 87,126 | |
| Depreciation and amortization | 1,331 | | | 8,378 | |
| Asset impairment | 248 | | | 79,714 | |
| Other expense (income), net | (87) | | | (60) | |
| Total operating expenses | 23,343 | | | 175,158 | |
| Earnings (loss) from discontinued operations before income taxes | (4,092) | | | (71,316) | |
| Income tax provision (benefit) from discontinued operations | (2,758) | | | (1,869) | |
| Income (loss) from discontinued operations, net of tax | $ | (1,334) | | | $ | (69,447) | |
The following table presents significant non-cash items and cash flows from investing activities related to discontinued operations:
| | | | | | | | | | | | | |
| | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | | | | |
| Depreciation and amortization | | | $ | 1,331 | | | $ | 8,378 | |
| Asset impairment | | | $ | 248 | | | $ | 79,714 | |
| | | | | |
| Stock-based compensation expense | | | $ | — | | | $ | 971 | |
| | | | | |
| Inventory adjustments | | | $ | 442 | | | $ | (177) | |
Other | | | $ | (1,647) | | | $ | — | |
| Cash flows from investing activities: | | | | | |
| Purchase of property and equipment | | | $ | — | | | $ | (1,781) | |
| Other | | | $ | 1,738 | | | $ | — | |
3. Details of Certain Balance Sheet Accounts
The following table provides a reconciliation of Cash and cash equivalents reported within the Consolidated Balance Sheets to the total of Cash, cash equivalents and restricted cash shown in the Consolidated Statement of Cash Flows:
| | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Cash, cash equivalents and restricted cash: | | | | | |
| Cash and cash equivalents | $ | 38,708 | | | $ | 73,948 | | | $ | 149,896 | |
Restricted cash included in Other assets | 1,594 | | | 1,289 | | | 1,131 | |
| $ | 40,302 | | | $ | 75,237 | | | $ | 151,027 | |
The following tables provide additional details of certain balance sheet accounts as of the dates shown below:
| | | | | | | | | | | |
| In thousands | As of January 3, 2026 | | As of December 28, 2024 |
| Accounts receivable, net: | | | |
| Trade receivables | $ | 42,563 | | | $ | 36,208 | |
| | | |
Other receivables (1) | 15,047 | | | 13,938 | |
| Allowance for credit losses | (288) | | | (208) | |
| $ | 57,322 | | | $ | 49,938 | |
(1) Includes CARES Act receivable in the amount of $9.0 million and $9.0 million as of January 3, 2026 and December 28, 2024, respectively. In January 2026, subsequent to the balance sheet date, the Company received the full payment of these receivables. |
| | | | | | | | | | | |
| In thousands | As of January 3, 2026 | | As of December 28, 2024 |
| Inventories: | | | |
Raw materials and work in process (1) | $ | 65,775 | | | $ | 66,056 | |
| Finished goods | 23,543 | | | 27,862 | |
| $ | 89,318 | | | $ | 93,918 | |
| (1) Due to the immaterial amount of estimated work in process and the short lead times for the conversion of raw materials to finished goods, the Company does not separately present raw materials and work in process. |
| | | | | | | | | | | |
| In thousands | As of January 3, 2026 | | As of December 28, 2024 |
| Property and equipment, net: | | | |
| Land and building | $ | 3,736 | | | $ | 3,736 | |
| Equipment | 315,231 | | | 299,823 | |
| Information technology hardware and software | 123,294 | | | 128,654 | |
| Furniture and fixtures | 88,514 | | | 85,061 | |
| Leasehold improvements | 386,329 | | | 360,927 | |
| Construction in progress | 34,711 | | | 31,620 | |
| Right of use assets under finance leases | 36,219 | | | 36,219 | |
| 988,034 | | | 946,040 | |
| Less: Accumulated depreciation | (643,415) | | | (583,865) | |
| $ | 344,619 | | | $ | 362,175 | |
| | | | | | | | | | | |
| In thousands | As of January 3, 2026 | | As of December 28, 2024 |
| Other payables and accrued expenses: | | | |
| Associate compensation and benefits | $ | 47,719 | | | $ | 42,752 | |
| Self-insurance liabilities | 9,696 | | | 9,087 | |
| Capital expenditures | 12,186 | | | 9,248 | |
| Advertising | 6,282 | | | 6,504 | |
| Reserves for customer returns and remakes | 5,489 | | | 4,840 | |
| | | |
| Income tax payable | 556 | | | 3,641 | |
| Supplies and other store support expenses | 4,373 | | | 5,038 | |
| Litigation settlements | 293 | | | 4,950 | |
| | | |
Other(1) | 23,080 | | | 22,976 | |
| $ | 109,674 | | | $ | 109,036 | |
(1) Primarily includes accrued patient liability refunds, professional fees, and cloud hosted software costs |
| | | | | | | | | | | |
| In thousands | As of January 3, 2026 | | As of December 28, 2024 |
| Other noncurrent liabilities: | | | |
| | | |
| Self-insurance liabilities | $ | 6,144 | | | $ | 5,577 | |
| Other | 2,800 | | | 2,651 | |
| $ | 8,944 | | | $ | 8,228 | |
4. Goodwill and Intangible Assets
The gross carrying amount and accumulated impairment of the Company’s goodwill balances for 2025 and 2024 are as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| As of January 3, 2026 | | As of December 28, 2024 |
| In thousands | Gross Carrying Amount | | Accumulated Impairment | | Gross Carrying Amount | | Accumulated Impairment |
Owned & Host Segment (1) | $ | 739,238 | | | $ | (38,596) | | | $ | 736,901 | | | $ | (38,596) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
(1)The Company acquired $2.3 million of additional goodwill during fiscal year 2025 upon transition of select Eyeglass World stores from a sublease model to a Company owned model.
The Owned & Host Segment’s goodwill contains $606.5 million related to America’s Best and $94.1 million related to Eyeglass World. Accumulated goodwill impairment relates to our Eyeglass World, Fred Meyer and Military reporting units. In fiscal year 2024, we tested Eyeglass World goodwill for recoverability due to reduced projections of future growth and profitability and we recognized an impairment of $19.2 million of Eyeglass World goodwill. Refer to Note 1. “Business and Significant Accounting Policies” and Note 12. “Fair Value Measurement” for more information on goodwill impairment.
Indefinite-lived intangible assets by major asset class are as follows:
| | | | | | | | | | | |
| In thousands | As of January 3, 2026 | | As of December 28, 2024 |
| Trademarks and trade names: | | | |
| America’s Best | $ | 200,547 | | | $ | 200,547 | |
| Eyeglass World | 40,000 | | | 40,000 | |
| $ | 240,547 | | | $ | 240,547 | |
We intend to maintain our trademarks; renewals will take place as needed.
Finite-lived, amortizing intangible assets by major asset class are as shown in the following table.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| As of January 3, 2026 | | As of December 28, 2024 |
| In thousands | Gross Carrying Amount | | Accumulated Amortization | | Remaining Life (Years) | | Gross Carrying Amount | | Accumulated Amortization | | Remaining Life (Years) |
| Contracts and relationships: | | | | | | | | | | | |
| | | | | | | | | | | |
Fred Meyer contracts and relationships | $ | 8,400 | | | $ | (846) | | | 11 | | $ | 8,400 | | | $ | (169) | | | 12 |
| Other | 151 | | | (151) | | | 0 | | 151 | | | (113) | | | 1 |
| $ | 8,551 | | | $ | (997) | | | | | $ | 8,551 | | | $ | (282) | | | |
In the third quarter of 2024, we recorded $10.5 million impairment related to the Fred Meyer contract and relationship intangible asset due to the decision to close certain Fred Meyer stores as part of our store fleet review in fiscal year 2024.
We intend to maintain our Fred Meyer contracts and relationships intangible asset. We amortized $0.7 million, $1.4 million, and $1.6 million in 2025, 2024, and 2023, respectively.
Aggregate amortization expense is included in Depreciation and amortization in the accompanying Consolidated Statements of Operations. Aggregate future estimated amortization expense is shown in the following table:
| | | | | | | | |
| Fiscal Year | | In thousands |
| 2026 | | $ | 677 | |
| 2027 | | 677 | |
| 2028 | | 677 | |
| 2029 | | 677 | |
| 2030 | | 677 | |
| Thereafter | | 4,169 | |
| | $ | 7,554 | |
5. Debt
Our debt consists of the following:
| | | | | | | | | | | |
| In thousands | As of January 3, 2026 | | As of December 28, 2024 |
| 2025 Notes, due May 15, 2025 | $ | — | | | $ | 84,774 | |
| Term Loan A, due June 13, 2028 | 237,625 | | | 254,188 | |
| | | |
| Debt before unamortized discount and issuance costs | 237,625 | | | 338,962 | |
| Unamortized discount and issuance costs - 2025 Notes | — | | | (191) | |
| Unamortized discount and issuance costs - Term Loan A | (1,137) | | | (1,602) | |
| Debt less debt discount and issuance costs | 236,488 | | | 337,169 | |
| Less current maturities | (13,250) | | | (98,024) | |
| Long-term debt - noncurrent portion | 223,238 | | | 239,145 | |
| Finance lease obligations | 9,422 | | | 12,833 | |
| Less current maturities | (3,333) | | | (3,368) | |
| Long-term debt and finance lease obligations, less current portion, discount, and issuance costs | $ | 229,327 | | | $ | 248,610 | |
2025 Notes
In May 2020, we completed the issuance of $402.5 million in aggregate principal amount of 2.50% convertible senior notes due on May 15, 2025 (the “2025 Notes”). The Company recognized an extinguishment loss of $0.6 million related to $100 million aggregate principal repurchases in fiscal year 2023. The Company recognized an extinguishment gain of $0.9 million related to $217.7 million aggregate principal repurchases in fiscal year 2024. During fiscal year 2025, the Company fully repaid the remaining outstanding balance.
We recognized the following in Interest expense, net related to the 2025 Notes:
| | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Contractual interest expense | $ | 802 | | | $ | 5,443 | | | $ | 9,747 | |
| Amortization of issuance costs | $ | 191 | | | $ | 1,282 | | | $ | 2,293 | |
Credit Agreement
On June 13, 2023, the Company entered into a second joinder and restatement agreement (“Second Restatement Agreement”) to amend and restate the original credit agreement, dated as of July 18, 2019 to, among other things, (i) establish new Term Loan A (“Term Loan A”) to repay all principal, interest, fees and other amounts outstanding (other than contingent obligations) under the original credit agreement, (ii) establish new Revolving Loans (the “Revolving Loans”), (iii) provide for a Secured Overnight Financing Rate, with a credit spread adjustment of 10 basis points for all interest periods and a SOFR floor of 0.00% per annum, and (iv) as set forth below, modify the applicable margins of Term Loan A and the revolving credit facility.
Term Loan A is amortized in equal calendar quarterly installments at a rate of 5.00% per calendar year since September 30, 2023.
Following the delivery of the financial statements for the period ending on September 30, 2023, the Applicable Margins for the Loans are based on NVI’s total leverage ratio as follows:
| | | | | | | | |
Consolidated Total Debt to Consolidated EBITDA Ratio | Term SOFR Rate | ABR Rate(1) |
> 2.50:1.00 | 2.25% | 1.25% |
≤ 2.50:1.00 but >1.75:1.00 | 2.00% | 1.00% |
≤ 1.75:1:00 but >0.75:1.00 | 1.75% | 0.75% |
≤ 0.75:1:00 | 1.50% | 0.50% |
(1) ABR = Alternate Base Rate |
In connection with the Second Restatement Agreement, we deferred $2.0 million of debt issuance costs related to the revolving credit facility in Other assets and $0.9 million of debt issuance costs related to the Term Loan A in Long-term debt and finance lease obligations, less current portion and debt discount on our Consolidated Balance Sheets. We will amortize these costs over the term of the amended credit agreement. We wrote off previously unamortized debt issuance costs of $0.2 million in Interest expense (income), net during fiscal year 2023 related to lenders who were parties to the original credit agreement but are not parties to the Second Restatement Agreement. We recognized $0.2 million of other refinancing fees in Interest expense (income), net during fiscal year 2023.
On August 9, 2024, NVI and certain other subsidiaries of the Company entered into a Joinder Agreement (the “Joinder Agreement”) to establish incremental term loans in an aggregate principal amount of $115.0 million, provided to NVI on August 9, 2024. These incremental term loans under the Joinder Agreement have the same terms as the existing term loans under the Credit Agreement. The additional borrowings resulted in $0.9 million of fees deferred on the Consolidated Balance Sheets during the fiscal year ended December 28, 2024.
The Second Restatement Agreement contains customary affirmative covenants, negative covenants, and events of default substantially comparable to the original credit agreement. The agreement includes covenants that, among other things, limit NVI’s ability to incur additional debt, create liens against assets, make acquisitions, pay dividends or distributions on its stock, merge or consolidate with another entity and transfer or sell assets. We were in compliance with all covenants related to our long-term debt as of January 3, 2026.
As of January 3, 2026, the Company had $293.3 million of availability under its $300.0 million revolving credit facility net of $6.7 million in outstanding letters of credit.
Scheduled annual maturities of debt are as follows: | | | | | | | | |
| Fiscal Year | | In thousands |
| 2026 | | $ | 13,250 | |
| 2027 | | 13,250 | |
| 2028 | | 211,125 | |
| | |
| | |
| | |
| | $ | 237,625 | |
6. Stock Incentive Plans
In connection with the initial public offering of our common stock (the “IPO”), on October 23, 2017, the Company’s Board of Directors adopted, and its stockholders approved, the National Vision Holdings, Inc. 2017 Omnibus Incentive Plan (the “2017 Omnibus Incentive Plan”). The total number of shares of common stock originally issuable under the 2017 Omnibus Incentive Plan was 4,000,000. On June 12, 2024, the Company’s stockholders approved the amendment and restatement of the 2017 Omnibus Incentive Plan, increasing the number of shares of common stock authorized for issuance by an additional 5,600,000 shares. The plan authorizes the grant of stock options, stock appreciation rights, restricted stock awards (“RSAs”), RSUs, PSUs, other equity-based awards and other cash-based awards to our associates, non-employee directors, officers, consultants and advisers. In 2014, our Board of Directors and stockholders of the Company approved the 2014 Stock Incentive Plan for Key Employees of National Vision Holdings, Inc. (formerly known as Nautilus Parent, Inc.) and its subsidiaries (the “2014 Stock Incentive Plan”). There were 10,988,827 stock options authorized for issuance pursuant to the 2014 Stock Incentive Plan. All stock awards under these plans vest through continued service. All options under these plans have a contractual life of 10 years.
The Company also provides associates the opportunity to purchase Company common shares through the Associate Stock Purchase Plan (the “ASPP”), which the Company’s Board of Directors adopted and its stockholders approved on June 6, 2018. The ASPP provides that up to 850,000 shares of common stock, at par value of $0.01 per share, may be offered and issued under the ASPP.
The following table summarizes stock compensation expense under the Company’s plans, which is included in SG&A in the accompanying Consolidated Statements of Operations:
| | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Stock options | $ | — | | | $ | 123 | | | $ | 740 | |
| RSUs and PSUs | 23,565 | | | 16,457 | | | 18,312 | |
| | | | | |
| Associate stock purchase plan | 121 | | | 128 | | | 151 | |
| Pre-tax stock-based compensation expense | $ | 23,686 | | | $ | 16,708 | | | $ | 19,203 | |
| Income tax benefit | (5,972) | | | (4,212) | | | (4,841) | |
| After-tax stock-based compensation expense | $ | 17,714 | | | $ | 12,496 | | | $ | 14,362 | |
| | | | | | | | | |
| | | RSUs and PSUs |
Unrecognized compensation cost (in thousands) | | | $ | 26,534 | |
| Expected remaining weighted-average period of expense recognition (in years) | | | 1.84 |
| | | |
| | | |
Service-based options
The following tables summarize service-based stock option activity. No service-based options were granted in fiscal years 2025, 2024, and 2023.
| | | | | | | | | | | | | | | | | | | | | | | |
| Number of Options Outstanding (In thousands) | | Weighted Average Exercise Price ($) | | Weighted Average Remaining Contractual Life (Years) | | Aggregate Intrinsic Value (In thousands) ($) |
| Outstanding options at December 28, 2024 | 549 | | | $ | 29.98 | | | 4.13 | | $ | — | |
| Exercised | (105) | | | $ | 21.19 | | | | | |
| Forfeited | (39) | | | $ | 37.29 | | | | | |
| Outstanding options at January 3, 2026 | 405 | | | $ | 31.54 | | | 3.36 | | $ | 1,057 | |
| Vested and exercisable at January 3, 2026 | 405 | | | $ | 31.54 | | | 3.36 | | $ | 1,057 | |
| | | | | | | | | | | | | | | | | |
| In thousands except per share values | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Fair value of options vested | $ | — | | | $ | 635 | | | $ | 1,251 | |
| Aggregate intrinsic value of options exercised | $ | 581 | | | $ | 76 | | | $ | 147 | |
Performance-based options
The following table summarizes performance-based stock option activity:
| | | | | | | | | | | | | | | | | | | | | | | |
| Number of Options Outstanding (In thousands) | | Weighted Average Exercise Price ($) | | Weighted Average Remaining Contractual Life (Years) | | Aggregate Intrinsic Value (In thousands) ($) |
| Outstanding options at December 28, 2024 | 49 | | | $ | 15.74 | | | 2.57 | | $ | — | |
| | | | | | | |
| | | | | | | |
| Outstanding options at January 3, 2026 | 49 | | | $ | 15.74 | | | 1.55 | | $ | 502 | |
| Vested and exercisable at January 3, 2026 | 49 | | | $ | 15.74 | | | 1.55 | | $ | 502 | |
There were no grants, no vests and no exercises of performance-based options during fiscal years 2025, 2024, and 2023.
The following tables summarize RSU and PSU awards activity:
| | | | | | | | | | | | | | | | | | | | |
| RSUs (In thousands) | Weighted average grant date fair value ($) | | PSUs (In thousands) | Weighted average grant date fair value ($) | | | |
| Outstanding at December 28, 2024 | 1,353 | | $ | 20.97 | | | 861 | | $ | 24.61 | | | | |
| Granted | 1,429 | | $ | 14.19 | | | 483 | | $ | 14.07 | | | | |
| Vested | (670) | | $ | 22.25 | | | — | | $ | — | | | | |
| Forfeited | (211) | | $ | 17.45 | | | (325) | | $ | 27.22 | | | | |
| Outstanding at January 3, 2026 | 1,901 | | $ | 15.81 | | | 1,019 | | $ | 18.78 | | | | |
| | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| RSUs | | | | | |
| Weighted average grant date fair value of RSUs granted | $ | 14.19 | | | $ | 18.03 | | | $ | 22.65 | |
| Total fair value of RSUs vested (In thousands) | $ | 14,914 | | | $ | 12,755 | | | $ | 12,084 | |
| PSUs | | | | | |
| Weighted average grant date fair value of PSUs granted | $ | 14.07 | | | $ | 22.19 | | | $ | 22.35 | |
| Total fair value of PSUs vested (In thousands) | $ | — | | | $ | 4,070 | | | $ | 3,852 | |
| | | | | |
| | | | | |
| | | | | |
Restricted stock units (RSUs)
Most RSUs vest in three equal annual installments on the first, second and third anniversary of the grant date. The RSUs outstanding as of January 3, 2026 have $49.3 million intrinsic value. Non-employee directors were granted RSUs in fiscal year 2025 that fully vest on the first anniversary of the grant date.
Performance stock units (PSUs)
PSUs are settled after the end of a three-year performance period (i.e., cliff vesting), which begins on the first day of the grant year and are based on the Company’s achievement of certain performance targets. The performance stock units outstanding as of January 3, 2026 have $26.4 million intrinsic value. While the PSU amounts shown in the tables above reflect achievement at target, the number of PSUs ultimately vested will be based on a comparison of certified performance results to predefined performance criteria that include threshold, target and maximum attainment levels.
In 2025, the Company granted PSUs that vest based on the Company’s relative total shareholder return (“TSR”) compared to a defined peer group over a three‑year performance period. The grant‑date fair value of PSUs based on TSR is estimated using a Monte Carlo simulation model. The key assumptions used in the Monte Carlo valuation include: (i) expected volatility of 57.1%, based on the Company’s three‑year daily historical volatility as of the grant date; (ii) a risk‑free interest rate of 3.97%, derived from U.S. Treasury constant‑maturity yields on the grant date; (iii) a correlation assumption calculated using three years of daily share price data for the Company and the peer group as of the grant date; and (iv) an expected dividend yield of zero.
Associate Stock Purchase Plan
Under the ASPP, eligible associates receive a 10% discount from the market trading value of common stock of the Company at the time of purchase. Participants may contribute to the ASPP, not to exceed $25,000 under the ASPP in any calendar year. During fiscal year 2025, the amount of shares issued to eligible participants through the ASPP was not material.
7. Income taxes
The income tax provision (benefit) consists of:
| | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Current income tax: | | | | | |
| Federal | $ | 3,190 | | | $ | 9,333 | | | $ | 8,278 | |
| State | 2,502 | | | 2,123 | | | 3,717 | |
| Deferred income tax: | | | | | |
| Federal | 5,839 | | | (8,869) | | | (3,878) | |
| State | 550 | | | (1,106) | | | (2,111) | |
| Income tax provision (benefit) from continuing operations | $ | 12,081 | | | $ | 1,481 | | | $ | 6,006 | |
| | | | | |
| | | | | |
Our income tax provision (benefit) differs from the amounts computed by multiplying earnings (loss) before income taxes by the statutory federal income tax rate.
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Earnings (loss) from continuing operations before income taxes | $ | 41,681 | | | $ | (25,684) | | | $ | 9,552 | |
| Federal income tax provision at statutory rate | 8,753 | 21.0 | % | | (5,394) | 21.0 | % | | 2,006 | 21.0 | % |
State income tax provision, net of federal income tax (a) | 2,422 | 5.8 | % | | 895 | (3.5) | % | | 1,686 | 17.7 | % |
Tax credits: | | | | | | | | |
Work opportunity tax credit | (899) | (2.2) | % | | (747) | | 2.9 | % | | (1,143) | (12.0) | % |
| Increase (decrease) in deferred tax asset valuation allowance | (912) | (2.2) | % | | (1,272) | 5.0 | % | | 2,238 | 23.4 | % |
Nontaxable or nondeductible items: | | | | | | | | |
| Executive compensation limitation | 623 | 1.5 | % | | 994 | (3.9) | % | | 354 | 3.7 | % |
| Goodwill impairment | — | — | % | | 3,539 | (13.8) | % | | — | — | % |
| Tax provision (benefit) of equity-based compensation deductions | 876 | 2.1 | % | | 1,240 | (4.8) | % | | 1,133 | 11.9 | % |
| Meals and entertainment | 327 | 0.8 | % | | 369 | (1.4) | % | | 433 | 4.5 | % |
| Other | 14 | — | % | | (22) | 0.1 | % | | (64) | (0.7) | % |
| | | | | | | | |
Other adjustments: | | | | | | | | |
| Net operating loss limitation | 467 | 1.1 | % | | — | — | % | | — | — | % |
| Other, net | 410 | 1.1 | % | | 1,879 | (7.4) | % | | (637) | (6.6) | % |
Net income tax provision (benefit) from continuing operations / Effective tax rate | $ | 12,081 | 29.0 | % | | $ | 1,481 | (5.8) | % | | $ | 6,006 | 62.9 | % |
| | | | | | | | |
Note: Percentages reflect line item as a percentage of earnings (loss) from continuing operations before income taxes, adjusted for rounding. |
(a) State taxes in Texas, Florida, California, New Jersey and Illinois made up the majority (greater than 50 percent) of the tax effect in this category. |
Incomes taxes paid (net of refunds) are as follows:
| | | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 | |
| Federal | $ | 17,844 | | | $ | 4,200 | | | $ | 2,795 | | |
State | 3,302 | | | 2,132 | | | 4,776 | | |
Total income taxes paid | $ | 21,146 | | | $ | 6,332 | | | $ | 7,571 | | |
| | | | | | |
| | | | | | |
Income taxes paid (net of refunds) exceeded 5 percent of total income taxes paid (net of refunds) in the following jurisdictions:
| | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| | | | | |
| | | | | |
| | | | | |
| Texas | * | | $ | 606 | | | 578 | |
* Jurisdiction below the threshold for the period presented. |
| | | | | |
| | | | | |
The sources of the differences between the financial accounting and tax bases of our assets and liabilities that give rise to the deferred tax assets and deferred tax liabilities and the tax effects of each are as follows:
| | | | | | | | | | | |
| In thousands | As of January 3, 2026 | | As of December 28, 2024 |
| Deferred tax assets: | | | |
| NOL carry-forwards | $ | 6,454 | | | $ | 8,017 | |
| | | |
| Credit carryforwards | 289 | | | 274 | |
| Deferred revenue | 6,126 | | | 5,999 | |
| Accrued expenses and reserves | 12,425 | | | 13,811 | |
| Loss on equity and other investments | 878 | | | 886 | |
| Stock-based compensation | 7,936 | | | 6,191 | |
| | | |
| Operating lease liabilities | 114,237 | | | 120,990 | |
| | | |
| Subtotal | 148,345 | | | 156,168 | |
| Valuation allowances | (5,458) | | | (5,961) | |
| Total net deferred tax assets | 142,887 | | | 150,207 | |
| Deferred tax liabilities: | | | |
| Depreciation of property and equipment | (58,634) | | | (57,150) | |
| Amortization of intangible assets | (65,051) | | | (65,168) | |
| | | |
| Right of use asset | (98,716) | | | (102,446) | |
| Other | (3,058) | | | (3,352) | |
| Total deferred tax liabilities | (225,459) | | | (228,116) | |
| Net deferred tax liabilities | $ | (82,572) | | | $ | (77,909) | |
As of fiscal year-end 2025, our consolidated VIEs had $9.8 million of U.S. federal NOL carry-forwards available to reduce future federal income taxes, all of which have no expiration date. $6.7 million of these NOL carry-forwards ($1.4 million tax-effected) carry a full valuation allowance because it is more likely than not that a future tax benefit will not be realized. In addition, we have NOL carry-forwards in varying amounts and with differing expiration dates in multiple states in which we operate.
For the fiscal year end 2025, we carry various state tax credits totaling $0.3 million that are available to offset certain future taxes. These state credits carry a valuation allowance of $0.1 million for the portion that we do not expect to be able to utilize in future periods.
We have a $0.9 million deferred income tax asset for capital losses associated with the losses realized on the sale of our equity method non-consolidated investee. We do not expect to generate significant capital gains in the near future. Therefore, we believe it is more likely than not that we will not realize a tax benefit for the majority of these deferred income tax assets. Accordingly, we have established a full valuation allowance against this deferred asset.
As a result of our utilization of NOL carry-forwards to reduce or eliminate subsequent years’ tax obligations, our federal and a substantial number of our state income tax returns for fiscal years 2001 through 2025 remain open for examination by the tax authorities.
The Company evaluates uncertain tax positions using a “more-likely-than-not” threshold and recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by tax authorities. The Company evaluates uncertain tax positions on a quarterly basis and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in-process audit activities and changes in facts or circumstances related to a tax position.
In July 2025 the One Big Beautiful Bill Act (the "Tax Act") was enacted, introducing a series of corporate tax changes in the U.S. including 100% bonus depreciation on qualified property. The impacts of the Tax Act are reflected in our results for the fiscal year 2025, and there was no material impact to our income tax expense or effective tax rate. Certain provisions decreased cash taxes paid in the current fiscal year and may change the timing of cash tax payments in future periods.
8. Revenue from Contracts with Customers
Revenues Recognized at a Point in Time
Owned & Host
Within our Owned & Host segment, product revenues include sales of prescription and non-prescription eyewear, contact lenses and related accessories to retail customers.
For sales of in-store non-prescription eyewear and related accessories, we recognize revenue at the point of sale. For sales of prescription eyewear, we recognize revenue when the performance obligations are satisfied, which generally occurs upon delivery and customer acceptance of the product. Within our Owned & Host segment services and plans revenues, eye exam services sold on a stand-alone basis are also recognized at the point of sale which occurs immediately after the exam is performed.
Other revenues
Our dedicated e-commerce website sells contact lenses and optical accessory products to retail customers, and recognizes revenue when products have been delivered to the customer. FirstSight issues individual vision plans in connection with our America’s Best operations in California.
Revenues Recognized Over Time
Within our Owned & Host segment, services and plans revenues include revenues from product protection plans (i.e. warranties), eye care club memberships and HMO vision plan fees. We offer extended warranty plans in our Owned & Host segment that generally provide repair and replacement of eyeglasses for primarily a one-year term after purchase. We recognize service revenue under these programs on a straight-line basis over the warranty or service period which is consistent with our efforts expended to satisfy the obligation. We offer three-year eyecare club memberships in our Owned & Host segment to our contact lens customers. For these programs we apply the portfolio approach of recognizing revenues of contracts with similar characteristics and use estimates and assumptions that reflect the size and composition of the portfolio of contracts. We selected the portfolio approach because our historical club membership data demonstrate that our club customers behave similarly, such that the difference between the portfolio approach and calculating revenue of each individual contract is not material. We recognize revenue across the contract portfolio based on the value delivered to the customers relative to the remaining services promised under the programs. We determine the value delivered based on the expected timing and amount of customer usage of benefits over the terms of the contracts. The unamortized portion of amounts we collect in advance for these services and plans are reported as Deferred revenue (current and noncurrent portions) in the accompanying Consolidated Balance Sheets.
The following disaggregation of revenues depicts our revenues based on the timing of revenue recognition:
| | | | | | | | | | | | | | | | | | | | |
| In thousands | | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Revenues recognized at a point in time | | $ | 1,859,291 | | | $ | 1,696,735 | | | $ | 1,631,030 | |
| Revenues recognized over time | | 128,197 | | | 126,585 | | | 125,341 | |
| Total net revenue | | $ | 1,987,488 | | | $ | 1,823,320 | | | $ | 1,756,371 | |
Refer to Note 15. “Segment Reporting” for the Company’s disaggregation of net revenue by reportable segment/category and by product type. As our operating segments are aligned by similar economic factors, trends and customers, the reportable segment view best depicts how the nature, amount and uncertainty of revenue and cash flows are affected by economic factors.
9. Deferred Revenue
The following depicts a roll-forward of deferred revenue:
| | | | | | | | | | | | | | | | | |
| Fiscal Year 2025 |
| In thousands | Product Protection Plans | | Eye Care Clubs | | Total |
| Beginning of the year | $ | 35,700 | | | $ | 48,889 | | | $ | 84,589 | |
| Sold | 75,120 | | | 55,565 | | | 130,685 | |
| Revenue recognized | (73,565) | | | (54,632) | | | (128,197) | |
| End of year | $ | 37,255 | | | $ | 49,822 | | | $ | 87,077 | |
| | | | | |
| Current | $ | 36,948 | | | $ | 27,612 | | | $ | 64,560 | |
| Noncurrent | 307 | | | 22,210 | | | 22,517 | |
| $ | 37,255 | | | $ | 49,822 | | | $ | 87,077 | |
| | | | | | | | | | | | | | | | | | |
| Fiscal Year 2024 |
| In thousands | Product Protection Plans | | Eye Care Clubs | | | Total |
| Beginning of the year | $ | 36,419 | | | $ | 47,907 | | | | $ | 84,326 | |
| Sold | 72,135 | | | 54,713 | | | | 126,848 | |
| Revenue recognized | (72,854) | | | (53,731) | | | | (126,585) | |
| End of year | $ | 35,700 | | | $ | 48,889 | | | | $ | 84,589 | |
| | | | | | |
| Current | $ | 35,409 | | | $ | 27,098 | | | | $ | 62,507 | |
| Noncurrent | 291 | | | 21,791 | | | | 22,082 | |
| $ | 35,700 | | | $ | 48,889 | | | | $ | 84,589 | |
Unsatisfied Performance Obligations (Contract Liabilities)
During fiscal years 2025 and 2024, we recognized $62.7 million and $62.8 million, respectively, of deferred revenues outstanding at the beginning of each respective period.
Deferred revenue recorded as of the end of fiscal year 2025 is expected to be reflected in future operating results as follows:
| | | | | | | | |
| Fiscal Year | | In thousands |
| 2026 | | $ | 64,560 | |
| 2027 | | 17,156 | |
| 2028 | | 5,361 | |
| | |
| | $ | 87,077 | |
10. Leases
Information related to our leases is presented below:
| | | | | | | | | | | | | | | | | |
| In thousands | | As of January 3, 2026 | | As of December 28, 2024 |
| Type | Classification | | | | |
| ASSETS | | | | |
| Finance | Property and equipment, net (a) | | $ | 5,956 | | | $ | 8,258 | |
| Operating | Right of use assets (b) | | 394,896 | | | 408,589 | |
| Total leased assets | | $ | 400,852 | | | $ | 416,847 | |
| LIABILITIES | | | | |
| Current Liabilities: | | | | |
| Finance | Current maturities of long-term debt and finance lease obligations | | $ | 3,333 | | | $ | 3,368 | |
| Operating | Current operating lease obligations (c) | | 90,313 | | | 99,694 | |
| Other noncurrent liabilities: | | | | |
| Finance | Long-term debt and finance lease obligations, less current portion and debt discount | | 6,089 | | | 9,465 | |
| Operating | Noncurrent operating lease obligations | | 358,377 | | | 366,335 | |
| Total lease liabilities | | $ | 458,112 | | | $ | 478,862 | |
As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the net present value of minimum lease payments. We used the incremental borrowing rate on December 30, 2018 for operating leases that commenced prior to that date. |
_________
(a) Finance lease assets are recorded net of accumulated amortization of $30.3 million and $28.0 million as of January 3, 2026 and December 28, 2024, respectively.
(b) TIA and deferred rent are treated as reductions of lease payments used to measure ROU assets in the accompanying Consolidated Balance Sheets as of January 3, 2026 and December 28, 2024.
(c) Current operating lease liabilities are measured net of TIA receivables of $6.5 million and $4.6 million as of January 3, 2026 and December 28, 2024, respectively.
| | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Operating lease cost | | | | | |
Fixed lease cost (a) | $ | 109,463 | | | $ | 103,547 | | | $ | 96,215 | |
Variable lease cost (b) | 40,104 | | | 37,733 | | | 36,133 | |
Sublease income(c) | (1,255) | | | (1,410) | | | (1,263) | |
| Finance lease cost | | | | | |
| Amortization of finance lease assets | 2,194 | | | 2,370 | | | 3,061 | |
| Interest on finance lease liabilities | 982 | | | 1,233 | | | 1,675 | |
| Net lease cost | $ | 151,488 | | | $ | 143,473 | | | $ | 135,821 | |
(a)Includes short-term leases, which are immaterial. (b)Includes costs for insurance, real estate taxes and common area maintenance expenses, which are variable as well as lease costs above minimum thresholds for Fred Meyer stores and lease costs for Military stores. (c)Income from sub-leasing of stores includes rental income from operating lease properties to independent optometrists. |
| | | | | | | | | | | | | | |
| Lease Term and Discount Rate | | As of January 3, 2026 | | As of December 28, 2024 |
| Weighted average remaining lease term (months) | | | | |
| Operating leases | | 70 | | 71 |
| Finance leases | | 37 | | 48 |
Weighted average discount rate (a) | | | | |
| Operating leases | | 5.4 | % | | 5.1 | % |
Finance leases (b) | | 10.2 | % | | 10.4 | % |
(a)The discount rate used to determine the lease assets and lease liabilities was derived upon considering (i) incremental borrowing rates on our term loan and revolving credit facility; (ii) Term SOFR margins for issuers of similar credit rating; and (iii) effect of collateralization. As a majority of our leases are five-year and 10-year leases, we determined a lease discount rate for such tenors and determined this discount rate is reasonable for leases that were entered into during the period. (b)The discount rate on finance leases is higher than operating leases because the present value of minimum lease payments was higher than the fair value of leased properties for certain leases entered into prior to adoption of ASC 842. The discount rate differential for those leases is not material to our results of operations. |
| | | | | | | | | | | | | | | | | | | | |
| In thousands | | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Other Information | | |
| | | | | | |
| Operating cash outflows - operating leases | | $ | 128,268 | | | $ | 113,113 | | | $ | 103,562 | |
| | | | | | |
| Right of use assets acquired under operating leases | | $ | 80,740 | | | $ | 96,170 | | | $ | 111,792 | |
The following table summarizes the maturity of our lease liabilities as of January 3, 2026:
| | | | | | | | | | | | | | |
| In thousands | | Operating Leases (a) | | Finance Leases (b) |
| Fiscal Year |
| 2026 | | $ | 110,992 | | | $ | 4,249 | |
| 2027 | | 102,659 | | | 3,370 | |
| 2028 | | 80,021 | | | 1,959 | |
| 2029 | | 70,742 | | | 612 | |
| 2030 | | 53,573 | | | 273 | |
| Thereafter | | 111,690 | | | 136 | |
| Total lease liabilities | | 529,677 | | | 10,599 | |
| Less: Interest | | 80,987 | | | 1,177 | |
Present value of lease liabilities(c) | | $ | 448,690 | | | $ | 9,422 | |
_________
(a) Operating lease payments include $19.7 million related to options to extend lease terms that are reasonably certain of being exercised.
(b) Finance lease payments include no options to extend lease terms that are reasonably certain of being exercised.
(c) The present value of lease liabilities excludes $21.0 million of legally binding minimum lease payments for leases signed but not yet commenced.
11. Commitments and Contingencies
Contractual Commitments
As of January 3, 2026, the Company had contractual commitments of approximately $174.3 million consisting of agreements for merchandise purchases, technology, and advertising.
Warranty Costs
The Company records an allowance for the estimated amount of future warranty costs when the related revenue is recognized, which is recorded in Other payables and accrued expenses on the accompanying Consolidated Balance Sheets. Expense associated with warranty costs is presented in Cost of services and plans in the accompanying Consolidated Statements of Operations and Comprehensive (Loss) Income. Estimated future warranty costs are primarily based on historical experience of identified warranty claims. However, there can be no assurance that future warranty costs will not exceed historical amounts. The following details the activity in our product warranty liability accounts:
| | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 |
| Beginning of year balance | $ | 2,565 | | | $ | 2,463 | |
| Accrued obligation | 38,378 | | | 35,325 | |
| Claims paid | (38,076) | | | (35,223) | |
| End of year balance | $ | 2,867 | | | $ | 2,565 | |
401(k) Plan
The Company sponsors a 401(k) plan into which associates may defer a portion of their wages. In fiscal 2025, the Company increased its employer matching contribution from 50% of the first 3% of participant contributions to 50% of the first 4% of participant contributions. The expense for the plan was $9.9 million, $7.5 million, and $7.2 million in fiscal years 2025, 2024, and 2023, respectively. Expense associated with our 401(k) plan is presented in SG&A in the Consolidated Statements of Operations and Comprehensive (Loss) Income.
Legal Proceedings
From time to time, the Company is involved in various legal proceedings incidental to its business. Because of the nature and inherent uncertainties of litigation, we cannot predict with certainty the ultimate resolution of these actions and, should the outcome of these actions be unfavorable, the Company’s business, financial position, results of operations or cash flows could be materially and adversely affected.
The Company reviews the status of its legal proceedings and records a provision for a liability when it is considered probable that a liability has been incurred and the amount of the loss can be reasonably estimated. This review is updated periodically as additional information becomes available. If either or both of the criteria are not met, we reassess whether there is at least a reasonable possibility that a loss, or additional losses, may be incurred. If there is a reasonable possibility that a loss may be incurred, we disclose the estimate of the amount of the loss or range of losses, or that an estimate of loss cannot be made. The Company expenses its legal fees as incurred.
We are currently and may in the future become subject to various claims and pending or threatened lawsuits in the ordinary course of our business.
On September 23, 2022, we were served with notice of a lawsuit filed by a former employee in California state court alleging, on behalf of a proposed class of employees, several violations of California wage and hour laws. On December 9, 2022, the case was removed to the federal District Court for the Northern District of California. On January 18, 2023, we were served with a related representative action filed in California state court pursuant to California’s Private Attorneys General Act (“PAGA”). We filed an answer to this action on February 17, 2023. On September 29, 2023, the state court set the PAGA action for trial on October 7, 2024. The parties attended mediation on March 11, 2024, but a resolution of the matter was not reached at that time. Following mediation, the parties agreed to a settlement of all claims alleged by the named plaintiff on behalf of himself and all putative class members and other aggrieved employees. The parties agreed to move the federal and state court actions to state court for review of the settlement terms agreed to by the parties. The Sacramento County state court entered preliminary approval of the settlement on March 21, 2025, and on July 29, 2025, the Court filed its order granting final approval of the settlement and entering judgment in accordance with the settlement agreement. The deadline for any appeal of the final approval and judgment expired on September 27, 2025 and the settlement agreement became effective at that time. On October 10, 2025, the Company paid a total of $4.6 million as the gross settlement fund in accordance with the settlement agreement.
On January 27, 2023, a purported class action complaint was filed in federal court in the Northern District of Georgia against the Company and two of the Company’s officers (the “Securities Class Action”). The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 10b-5 thereunder, for materially false and misleading statements made between May 2021 and May 2022. The complaint seeks unspecified damages as well as equitable relief. On March 28, 2023, the original plaintiff, City of Southfield General Employees Retirement System, and a new plaintiff, International Union of Operating Engineers, Local No. 793, Members Pension Benefit Trust of Ontario, filed a lead plaintiff motion, seeking to be appointed co-lead plaintiffs. On April 3, 2023, the Company along with its named officers filed a motion to dismiss the complaint. On May 19, 2023, the court granted the lead plaintiff motion. On June 30, 2023, the plaintiffs filed an amended complaint, which added a claim under Section 20A of the Exchange Act and extended the alleged class period to February 28, 2023. On August 21, 2023, the Company filed a motion to dismiss the amended complaint. The plaintiffs filed their response in opposition to this motion on October 5, 2023. On March 30, 2024, the court granted the Company’s motion and dismissed the amended complaint with prejudice. On April 29, 2024, the plaintiffs filed a motion for reconsideration of the order granting the motion to dismiss. The Company and named officers filed a response in opposition to the plaintiffs’ motion for reconsideration on May 13, 2024, and the plaintiffs then filed a reply in support of their motion on May 28, 2024. The court entered an order denying the motion for reconsideration on March 24, 2025, and no appeal was filed by the plaintiff.
On May 23, 2024, a stockholder derivative complaint was filed by a stockholder in the Delaware Court of Chancery, purportedly on behalf of the Company (the “Derivative Action”). The Derivative Action is based on the same alleged facts and circumstances as the Securities Class Action and names certain of the Company’s officers, including our Chief Executive Officer and former Chief Operating Officer, and the Company’s directors who were members of the Company’s Board of Directors during the relevant time period as defendants. The Derivative Action alleges claims for breach of fiduciary duty, unjust enrichment, and violations of the Exchange Act and seeks to recover damages on behalf of the Company. On July 24, 2024, the Company along with the named defendants, filed a motion to dismiss the complaint. On September 9, 2024, the plaintiff filed an amended complaint. Defendants filed a motion to dismiss the amended complaint on October 31, 2024. The plaintiff filed an opposition to the motion to dismiss on December 16, 2024, and the defendants filed a reply brief on January 15, 2025. Oral argument on the motion to dismiss was held on October 28, 2025. On February 11, 2026, the court granted the motion to dismiss. The plaintiff has 30 days from the date of the order to file an appeal. The defendants dispute the allegations made by the plaintiff and intend to vigorously defend the litigation should an appeal be pursued.
On September 26, 2025, the Company attended a pre-trial mediation in a lawsuit filed in Alabama state court by a patient who claims to have been injured due to medical negligence during eye exams performed by an optometrist employed by the Company. The parties failed to reach an agreement at mediation. On October 3, 2025, the parties reached a post-mediation agreement for the Company to pay $1.8 million, net of anticipated recoveries from professional liability insurance, in consideration for plaintiff dismissing the lawsuit and releasing all claims against the Company. The parties executed a settlement agreement on October 21, 2025, after which the Company and its professional liability insurance carrier issued payment according to the terms of the agreement, and the case was dismissed by the court on December 1, 2025. The litigation settlement is recognized in Other payables and accrued expenses in the Condensed Consolidated Balance Sheets as of January 3, 2026 and in SG&A in the Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended January 3, 2026.
12. Fair Value Measurement
General
The Company uses a fair value hierarchy that is intended to increase consistency and comparability in fair value measurements and related disclosures. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity’s own market assumptions.
The Company is required to measure certain assets and liabilities at fair value or disclose the fair values of certain assets and liabilities recorded at cost. Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated assuming the transaction occurs in the principal or most advantageous market for the asset or liability and includes consideration of non-performance risk and credit risk of both parties. A three-tier fair value hierarchy prioritizes the inputs used in measuring fair value. These tiers include:
•Level 1 - Valuation inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.
•Level 2 - Valuation inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in inactive markets, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the instruments.
•Level 3 - Valuation inputs are unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are determined using model-based techniques that include discounted cash flow models and similar techniques.
The fair value estimates of financial instruments are not necessarily indicative of the amounts we might pay or receive in actual market transactions. The use of different market assumptions and/or estimation methodologies may have a material impact on the estimated fair value amounts.
Recurring fair value measurements
Interest Rate Derivatives
We recognize as assets or liabilities at fair value the estimated amounts we would receive or pay upon a termination of interest rate derivatives prior to their scheduled expiration dates. The fair value is based on information that is model-driven based on regression analysis and whose inputs were observable (Level 2 inputs) such as Term SOFR forward rates. See Note 13. “Interest Rate Derivatives” for further details.
Convertible Promissory Note
On December 17, 2024, the Company purchased $1.3 million principal amount of a convertible promissory note issued by a private company. During fiscal year 2025, the Company purchased an additional $1.2 million in the same instrument. The convertible promissory note is an investment that will convert to an equity stake in the private company upon a predetermined conversion event and is also convertible by us under certain circumstances. The Company elected the fair value option in accordance with accounting guidance for financial instruments to record the convertible promissory note. The fair value option allows an entity to account for the entire financial instrument at fair value with subsequent changes in fair value recognized in earnings through the consolidated statements of operations at each reporting date. The Company elected the fair value option to account for the convertible promissory note because the Company believes it reflects the fair value of the note receivable and embedded features. As of January 3, 2026, the Company estimated the fair value of the convertible promissory note to be $2.5 million; this investment is included in Other assets on the Consolidated Balance Sheets and in Other in the investing section of the Consolidated Statements of Cash Flows. Refer to Note 1. “Business and Significant Accounting Policies” for information on equity investments in this entity.
Non-recurring fair value measurements
These non-recurring fair value measurements are classified as Level 3 measurements in the fair value hierarchy. A decrease in the estimated cash flows would lead to a lower fair value measurement, as would an increase in the discount rate. Asset impairment charges are reflected in Asset impairment in the Consolidated Statements of Operations and Comprehensive (Loss) Income.
Long-lived and Right of Use Store Assets
We recognized impairments of $2.0 million, $10.1 million and $2.7 million in fiscal years 2025, 2024, and 2023, respectively, related to our store assets. The store asset impairment charges is related to our Owned & Host segment and is driven by lower than projected customer sales volume in certain stores. The cash flows used in estimating the fair value of ROU and store assets were discounted using market rates from 10% to 10.5%. The estimated remaining fair value of the long-lived and ROU assets impaired during fiscal years 2025, and 2024, was $1.3 million, and $5.6 million, respectively; the estimated remaining fair values include amounts estimated at various dates during the related fiscal years. Substantially all of the remaining fair value of the impaired store assets in fiscal years 2025 and 2024 represents the fair value of ROU assets.
Refer to Note 1. “Business and Significant Accounting Policies” and Note 4. “Goodwill and Intangible Assets” for more details on impairment charges.
Additional fair value information
Cash Equivalents and Restricted Cash
The carrying amount of cash equivalents and restricted cash approximates fair value due to the short-term maturity of the instruments. All cash and cash equivalents are denominated in U.S. currency.
Accounts Receivable, Net
The carrying amount of accounts receivable approximates fair value due to the short-term nature of those items and the effect of credit losses.
Accounts Payable and Other Payables and Accrued Expenses
The carrying amounts of accounts payable and other payables and accrued expenses approximate fair value due to the short-term nature of those items.
Term Loan A and Revolving Loans
Since the borrowings under the $237.6 million outstanding principal Term Loan A and $300.0 million aggregate principal Revolving Loans utilize variable interest rate setting mechanisms such as Term SOFR, the fair values of these borrowings are deemed to approximate the carrying values. We also considered the effect of our own credit risk on the fair values of our Term Loan A and Revolving Loans. Refer to Note 5. “Debt” for more information on these borrowings.
13. Interest Rate Derivatives
In December 2025, we entered into an interest rate swap agreement to help manage interest rate exposure by economically converting a portion of our variable-rate debt to fixed-rate debt. Under the interest rate swap agreement, we receive a floating interest rate of the one-month SOFR and pay a fixed interest rate of 3.43% on $100 million of notional amount. We designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship.
We recognized (gains) losses on the change in fair value of the interest rate swap of $0.2 million in Other comprehensive income (loss) during fiscal year 2025. An immaterial amount of net gain was reclassified from Accumulated other comprehensive income (loss) into Interest expense, net during fiscal year 2025.
We were party to an interest rate collar to offset the variability of cash flows in Term SOFR-indexed debt interest payments. The interest rate collar matured on July 18, 2024.
We recognized (gains) losses on the change in fair value of the interest rate collar of $(0.5) million and $(2.3) million in Interest expense, net during fiscal years 2024 and 2023, respectively.
Cash flows related to derivatives are included in the operating section of the Consolidated Statements of Cash Flows and were immaterial.
As of January 3, 2026, the Company expects to reclassify an immaterial amount of unrealized losses on the derivative instruments, net of tax, from AOCL into earnings in the next 12 months. See Note 16. “Accumulated Other Comprehensive Income” for further details.
Our cash flow hedge position related to derivatives designated as hedging instruments under ASC 815 is as follows:
| | | | | | | | | | | | | | | | |
In thousands | | Balance Sheet Classification | | As of January 3, 2026 | | |
| | | | | | |
Current portion | | Other Payables and Accrued Expenses | | $ | 45 | | | |
Non-current portion | | Other Liabilities | | 116 | | | |
Total derivative liabilities designated as hedging instruments | | | | $ | 161 | | | |
14. Earnings Per Share
Basic earnings per share (“EPS”) is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS is computed by dividing net income by the weighted average shares outstanding for the period and includes the dilutive impact of potential new shares issuable upon vesting and exercise of stock options, vesting of restricted stock units, and assumed conversion of the 2025 Notes. Potential shares of common stock are excluded from the computation of diluted EPS if their effect is anti-dilutive.
The 2025 Notes were fully settled in 2025. Diluted EPS for fiscal year 2024 and 2023 included the potential impact of the 2025 Notes using the if-converted method; the number of dilutive shares is based on the initial conversion rate associated with the 2025 Notes. A reconciliation of the numerators and denominators of the basic and diluted EPS calculations is as follows:
| | | | | | | | | | | | | | | | | |
| In thousands, except EPS | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Numerator | | | | | |
| Income (loss) from continuing operations, net of tax | $ | 29,600 | | | $ | (27,165) | | | $ | 3,546 | |
| Income (loss) from discontinued operations, net of tax | — | | | (1,334) | | | (69,447) | |
| Net income (loss) | $ | 29,600 | | | $ | (28,499) | | | $ | (65,901) | |
| | | | | |
| Denominator | | | | | |
| Weighted average shares outstanding, Basic | 79,131 | | | 78,592 | | | 78,313 | |
Dilutive effect of share-based awards (1) | 1,445 | | | — | | | 283 | |
| | | | | |
| | | | | |
| | | | | |
| Weighted average shares outstanding, Diluted | 80,576 | | | 78,592 | | | 78,596 | |
| | | | | |
| Basic earnings (loss) per share | | | | | |
| Continuing operations | $ | 0.37 | | | $ | (0.35) | | | $ | 0.05 | |
| Discontinued operations | $ | — | | | $ | (0.02) | | | $ | (0.89) | |
| Total | $ | 0.37 | | | $ | (0.36) | | | $ | (0.84) | |
| | | | | |
| Diluted earnings (loss) per share | | | | | |
| Continuing operations | $ | 0.37 | | | $ | (0.35) | | | $ | 0.05 | |
| Discontinued operations | $ | — | | | $ | (0.02) | | | $ | (0.88) | |
| Total | $ | 0.37 | | | $ | (0.36) | | | $ | (0.84) | |
| Anti-dilutive securities excluded from diluted weighted average common shares | 712 | | | 8,771 | | | 12,513 | |
(1) Represents the dilutive impact of RSUs, PSUs and stock options |
| Some of the EPS totals in the table above may not foot due to rounding differences |
15. Segment Reporting
The Company’s operating segments were determined on the same basis as used by the Chief Operating Decision Maker (“CODM”) to evaluate performance internally. Our CODM is our chief executive officer. Our operations consist primarily of one reportable segment: the Owned & Host segment. Our owned brands consist of our America’s Best and Eyeglass World operating segments. In America’s Best stores, vision care services are provided by optometrists employed either by us or by independent professional corporations. Eyeglass World locations have on-site laboratories and offer eye exams, provided by optometrists employed either by us or independent professional corporations. Our Host operating segments consist of Military and Fred Meyer. These brands provide eye exams principally by independent optometrists in nearly all locations. We have aggregated our America’s Best, Eyeglass World, Military and Fred Meyer operating segments into a single reportable segment due to similar economic characteristics and similarity of the nature of products and services, production processes, class of customers, regulatory environment and distribution methods of those brands.
In addition to our single reportable segment, the results of our dedicated e-commerce website and FirstSight, which sells single-service health plans in connection with the operations of America’s Best operations in California, are presented in the “corporate and other” category. The Company concluded that our dedicated e-commerce website meets the criteria to be an operating segment but does not meet the quantitative thresholds for separate disclosure as a reportable segment. Further, in 2025, the Company concluded that FirstSight, does not meet the criteria to be an operating segment. Its results are not separately provided to the CODM, and therefore, they are also included in the “corporate and other” category. Prior-period information has been recast to reflect the segment presentation.
Our “corporate and other” category also includes corporate overhead support expenses as well certain non-cash charges, including asset impairment, stock-based compensation expense, and the impact of certain events, gains, or losses excluded from the assessment of segment performance.
Other adjustments to reportable segment results represent adjustments necessary for the presentation of consolidated financial results in accordance with U.S. GAAP, specifically effects of the change in unearned and deferred revenue during the period.
Our former Legacy reportable segment and the majority of our former AC Lens operations as well as related effects of unearned and deferred revenue are classified as discontinued operations. Refer to Note 2. “Discontinued Operations” for information related to our discontinued operations.
The operating segments identified above are the business activities of the Company for which discrete financial information is available and for which operating results are regularly provided to, and reviewed by, our CODM to allocate resources and assess performance. The Company considers each of our brands to be an operating segment and has further concluded that presenting the results of our reportable segment provides meaningful information consistent with the objectives of ASC 280, Segment Reporting.
The CODM uses segment EBITDA, calculated as net revenue, less costs applicable to revenue, less SG&A expenses, to evaluate the performance, and make decisions about the allocation of resources to segments predominantly in the annual budget and forecasting process. The CODM considers budget-to-actual variances on a monthly and quarterly basis when making decisions about the allocation of resources to each segment. Consistent with what the CODM reviews, depreciation and amortization and interest expense(income), net are excluded from segment EBITDA.
There are no differences between the measurement of our reportable segment’s assets and consolidated assets. There have been no changes from prior periods in the measurement methods used to determine reportable segment profit or loss, and there have been no asymmetrical allocations to segments.
Reportable segment information is presented on the same basis as our consolidated financial statements, except for net revenue and associated costs applicable to revenue, which exclude the effects of unearned and deferred revenue, consistent with what the CODM regularly reviews. Asset information is not included in the following summary since the CODM does not regularly review such information for the reportable segment.
The following table is a summary of certain financial data for our Owned & Host reportable segment, and other categories, and includes a reconciliation to the Company’s consolidated earnings (loss) from continuing operations before income taxes.
| | | | | | | | | | | | | | | | | |
| Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| In thousands | | | | | |
| Owned & Host revenue: | | | | | |
| Net product sales | $ | 1,593,503 | | | $ | 1,433,777 | | | $ | 1,396,355 | |
| Net sales of services and plans | 385,385 | | | 360,470 | | | 333,693 | |
| Total Owned & Host revenue | 1,978,888 | | | 1,794,247 | | | 1,730,048 | |
| Less: | | | | | |
| Owned & Host costs applicable to revenue (exclusive of depreciation and amortization) | | | | | |
| Cost of products | 445,146 | | | 410,527 | | | 401,385 | |
| Cost of services and plans | 358,191 | | | 330,801 | | | 310,643 | |
| | | | | |
| Owned & Host SG&A | 744,146 | | | 708,623 | | | 670,337 | |
| | | | | |
| | | | | |
| | | | | |
| Owned & Host segment EBITDA | 431,405 | | | 344,296 | | | 347,683 | |
| | | | | |
| Corporate and other | (271,608) | | | (263,496) | | | (228,746) | |
| Effects of unearned and deferred revenue | (9,816) | | | 1,049 | | | (5,172) | |
| Depreciation and amortization | (91,152) | | | (91,349) | | | (89,874) | |
| Interest expense, net | (17,148) | | | (16,184) | | | (14,339) | |
| Earnings (loss) from continuing operations before income taxes | $ | 41,681 | | | $ | (25,684) | | | $ | 9,552 | |
The following table presents a reconciliation of revenue:
| | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Revenue | | | | | |
| Owned & Host | $ | 1,978,888 | | | $ | 1,794,247 | | | $ | 1,730,048 | |
Corporate and other | 20,972 | | | 27,621 | | | 33,139 | |
| Effects of unearned and deferred revenue | (12,372) | | | 1,452 | | | (6,816) | |
| Total consolidated revenue | $ | 1,987,488 | | | $ | 1,823,320 | | | $ | 1,756,371 | |
Entity-wide Information
The following table presents our consolidated net revenue information:
| | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Net product sales | | | | | |
| Eyeglasses and sunglasses | $ | 1,269,126 | | | $ | 1,145,725 | | | $ | 1,115,000 | |
| Contact lenses | 324,196 | | | 307,314 | | | 301,268 | |
| Accessories and other | 11,270 | | | 10,100 | | | 6,961 | |
Total net product sales | 1,604,592 | | | 1,463,139 | | | 1,423,229 | |
| Net sales of services and plans | | | | | |
| Exams | 254,699 | | | 233,621 | | | 207,833 | |
| Product protection plans | 73,565 | | | 72,854 | | | 72,069 | |
| Eyecare clubs | 54,632 | | | 53,706 | | | 53,240 | |
Total net sales of services and plans | 382,896 | | | 360,181 | | | 333,142 | |
| Total net revenue | $ | 1,987,488 | | | $ | 1,823,320 | | | $ | 1,756,371 | |
16. Accumulated Other Comprehensive Loss
Changes in the fair value of the Company’s cash flow hedge derivative instruments from their inception are recorded in AOCL if the instruments are deemed to be highly effective as cash flow hedges. The following table presents the changes in AOCL, net of tax:
| | | | | | | | | | | | | | | | | |
| In thousands | Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Cash flow hedging activity | | | | | |
| Balance at beginning of fiscal year | $ | — | | | $ | (419) | | | $ | (1,179) | |
| Other comprehensive income (loss) before reclassification | (159) | | | — | | | — | |
| Tax effect of other comprehensive income (loss) before reclassification | 39 | | | — | | | — | |
Amount reclassified from AOCL | (2) | | | 548 | | | 1,019 | |
Tax effect of amount reclassified from AOCL | 1 | | | (129) | | | (259) | |
| | | | | |
| Net current period other comprehensive income (loss), net of tax | (121) | | | 419 | | | 760 | |
| Balance at end of fiscal year | $ | (121) | | | $ | — | | | $ | (419) | |
See Note 13. “Interest Rate Derivatives” for a description of the Company’s use of cash flow hedging derivatives.
Schedule I - Condensed Financial Information of Registrant
National Vision Holdings, Inc. and Subsidiaries (Parent Company Only)
Condensed Balance Sheets
In Thousands, Except Share Data
| | | | | | | | | | | |
| As of January 3, 2026 | | As of December 28, 2024 |
| ASSETS | | | |
| Current assets: | | | |
| Cash and cash equivalents | $ | 871 | | | $ | 974 | |
| | | |
| | | |
| Total current assets | 871 | | | 974 | |
| | | |
Noncurrent assets: | | | |
| Deferred income taxes, net | 11,892 | | | 11,618 | |
| Investment in subsidiary | 925,142 | | | 970,199 | |
| | | |
| Total noncurrent assets | 937,034 | | | 981,817 | |
| Total assets | $ | 937,905 | | | $ | 982,791 | |
| | | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | |
| Current liabilities: | | | |
| Other payables and accrued expenses | $ | — | | | $ | 249 | |
| Current maturities of long-term debt | — | | | 84,774 | |
| Total current liabilities | — | | | 85,023 | |
| | | |
| | | |
| Noncurrent liabilities: | | | |
| Other liabilities | 68,372 | | | 81,435 | |
| | | |
Total noncurrent liabilities | 68,372 | | | 81,435 | |
| | | |
| Stockholders’ equity: | | | |
Common stock, $0.01 par value; 200,000,000 shares authorized; 86,278,538 and 85,444,263 shares issued as of January 3, 2026 and December 28, 2024, respectively; 79,416,050 and 78,775,117 shares outstanding as of January 3, 2026 and December 28, 2024, respectively | 862 | | | 854 | |
| Additional paid-in capital | 834,000 | | | 807,048 | |
| Accumulated other comprehensive loss | (121) | | | — | |
| Retained earnings | 255,717 | | | 226,117 | |
Treasury stock, at cost; 6,862,488 and 6,669,146 shares as of January 3, 2026 and December 28, 2024, respectively | (220,925) | | | (217,686) | |
| Total stockholders’ equity | 869,533 | | | 816,333 | |
| Total liabilities and stockholders’ equity | $ | 937,905 | | | $ | 982,791 | |
Note: Fiscal year 2025 includes 53 weeks. Fiscal years 2024 and 2023 include 52 weeks.
The accompanying notes are an integral part of these condensed financial statements.
Schedule I - Condensed Financial Information of Registrant
National Vision Holdings, Inc. And Subsidiaries (Parent Company Only)
Condensed Statements of Operations and Comprehensive (Loss) Income
In Thousands
| | | | | | | | | | | | | | | | | |
| Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Total net revenue | $ | — | | | $ | — | | | $ | — | |
| Total costs applicable to revenue | — | | | — | | | — | |
| Total operating expenses | 256 | | | 256 | | | 214 | |
| Interest expense, net | 948 | | | 6,639 | | | 12,040 | |
| (Gain) loss on extinguishment of debt | — | | | (859) | | | 599 | |
| Earnings (loss) before income taxes | (1,204) | | | (6,036) | | | (12,853) | |
| Income tax provision (benefit) | (274) | | | (1,373) | | | (2,401) | |
| Earnings (loss) before equity in net income of subsidiaries | (930) | | | (4,663) | | | (10,452) | |
| Net income (loss) of subsidiaries | 30,530 | | | (23,836) | | | (55,449) | |
| Net income (loss) | $ | 29,600 | | | $ | (28,499) | | | $ | (65,901) | |
| | | | | |
| Comprehensive income (loss): | | | | | |
| Net income (loss) | $ | 29,600 | | | $ | (28,499) | | | $ | (65,901) | |
Unrealized gain (loss) on hedge instruments | (161) | | | 548 | | | 1,019 | |
| Tax provision of unrealized gain on hedge instruments | (40) | | | 129 | | | 259 | |
| Comprehensive income (loss) | $ | 29,479 | | | $ | (28,080) | | | $ | (65,141) | |
Note: Fiscal year 2025 includes 53 weeks. Fiscal years 2024 and 2023 include 52 weeks.
The accompanying notes are an integral part of these condensed financial statements.
Schedule I - Condensed Financial Information of Registrant
National Vision Holdings, Inc. and Subsidiaries (Parent Company Only)
Condensed Statements of Cash Flows
In Thousands
| | | | | | | | | | | | | | | | | |
| Fiscal Year 2025 | | Fiscal Year 2024 | | Fiscal Year 2023 |
| Cash flows from operating activities | | | | | |
| Net cash provided by (used for) operating activities | $ | (14,676) | | | $ | (6,082) | | | $ | (6,780) | |
| Cash flows from investing activities | | | | | |
| Dividend from (investment in) subsidiary | 99,157 | | | 224,245 | | | 132,443 | |
| Net cash provided by (used for) investing activities | 99,157 | | | 224,245 | | | 132,443 | |
| Cash flows from financing activities | | | | | |
| Repayments on long-term debt | (84,774) | | | (215,000) | | | (99,250) | |
| | | | | |
| Proceeds from issuance of common stock | 3,395 | | | 1,507 | | | 1,837 | |
| Purchase of treasury stock | (3,205) | | | (3,092) | | | (28,415) | |
| Payments of debt issuance costs | — | | | (837) | | | (443) | |
| Net cash provided by (used for) financing activities | (84,584) | | | (217,422) | | | (126,271) | |
| Net change in cash and cash equivalents | (103) | | | 741 | | | (608) | |
| Cash and cash equivalents, beginning of year | 974 | | | 233 | | | 841 | |
| Cash and cash equivalents, end of year | $ | 871 | | | $ | 974 | | | $ | 233 | |
Note: Fiscal year 2025 includes 53 weeks. Fiscal years 2024 and 2023 include 52 weeks.
The accompanying notes are an integral part of these condensed financial statements.
Schedule I - Condensed Financial Information of Registrant
National Vision Holdings, Inc. and Subsidiaries (Parent Company Only)
Notes to Condensed Financial Statements
1. Basis of Presentation
National Vision Holdings, Inc. (“NVHI,” or the “Company”) conducts substantially all of its activities through its indirect wholly owned subsidiary, National Vision, Inc. (“NVI”) and its subsidiaries. NVHI was incorporated in Delaware on February 14, 2014 under the name Nautilus Parent, Inc. There were no financial transactions between the inception date and March 13, 2014, the date the majority ownership of NVI was transferred from private equity funds managed by Berkshire Partners LLC (“Berkshire”) to affiliates of Kohlberg Kravis Roberts & Co. L.P (“KKR”). In October 2017, we completed the initial public offering of our common stock. By August 2019, each of KKR and Berkshire had sold their remaining holdings of our common stock. In the parent-company-only financial statements, NVHI’s investment in subsidiaries is stated at cost, plus equity in undistributed earnings of subsidiaries since the date of acquisition, less dividends. The parent-company-only financial statements should be read in conjunction with the NVHI consolidated financial statements.
In May 2020, the Company issued $402.5 million principal amount of 2.50% convertible senior notes due 2025. NVHI contributed the proceeds from the 2025 Notes to NVI as additional investments during the fiscal year 2020. The Company fully repaid the 2025 Notes during fiscal year 2025. See Note 5. “Debt” to the NVHI consolidated financial statements for more information.
2. Guarantees and Restrictions
As of January 3, 2026, NVI had $237.6 million of principal amount of long-term debt outstanding under its Term Loan A and no outstanding cash borrowings under its $300.0 million Revolving Loans, which includes $6.7 million in outstanding letters of credit.
Under the terms of NVI’s amended credit agreement, provided no event of default has occurred and is continuing, NVI is permitted to pay dividends to NVHI with certain restrictions.
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.
In accordance with Rule 13a-15(b) of the Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of its management, including its CEO and CFO, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of January 3, 2026. Based on that evaluation, the CEO and the CFO have concluded that, as of January 3, 2026, the Company’s disclosure controls and procedures are effective in ensuring that material information relating to the Company required to be disclosed in the Company’s periodic filings with the U.S. Securities and Exchange Commission (“SEC”) is made known to them in a timely manner.
Management’s Annual Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) for the Company. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements of the Company in accordance with U.S. generally accepted accounting principles. The Company’s internal control over financial reporting includes those policies and procedures that:
•pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
•provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles and that receipts and expenditures are being made only in accordance with authorizations of the Company's management and directors; and
•provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Management, with the participation of our CEO and CFO, has assessed the effectiveness of the Company’s internal control over financial reporting as of January 3, 2026 in accordance with the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on this assessment, management concluded that the Company maintained effective internal control over financial reporting as of January 3, 2026. The Company’s independent registered public accounting firm, Deloitte & Touche LLP, as auditors of our consolidated financial statements as of and for the year ended January 3, 2026, has issued their attestation report on management’s internal control over financial reporting which is set forth below.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as that term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of National Vision Holdings, Inc. and Subsidiaries
Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of National Vision Holdings, Inc. and subsidiaries (the “Company”) as of January 3, 2026, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of January 3, 2026, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended January 3, 2026, of the Company and our report dated March 4, 2026, expressed an unqualified opinion on those financial statements.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal Control over financial reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Deloitte & Touche LLP
Atlanta, GA
March 4, 2026
Item 9B. Other Information
Except as set forth below, during the twelve months ended January 3, 2026, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, terminated or modified a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as such terms are defined in Item 408(a) of Regulation S-K).
On December 4, 2025, L. Reade Fahs, the Company’s Executive Chairman, adopted a trading arrangement for the sale of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of the Exchange Act Rule 10b5-1(c). Mr. Fahs’ Rule 10b5-1 Trading Plan provides for the sale of up to 352,000 shares of common stock pursuant to one or more limit orders from March 6, 2026, until December 31, 2026.
On December 5, 2025, Alex Wilkes, the Company’s Chief Executive Officer, adopted a trading arrangement for the sale of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of the Exchange Act Rule 10b5-1(c). Mr. Wilkes’ Rule 10b5-1 Trading Plan provides for the sale of up to 35,000 shares of common stock and expires on March 13, 2026.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
PART III
Item 10. Directors, Executive Officers and Corporate Governance
Executive Officers of the Company
The following table sets forth the names, ages and positions of our executive officers as of March 4, 2026.
| | | | | | | | | | | | | | |
| Name | | Age | | Position |
| Alex Wilkes | | 47 | | Chief Executive Officer and Director |
Chris Laden | | 39 | | Chief Financial Officer |
| Mark Banner | | 51 | | President of America’s Best |
| Jared Brandman | | 49 | | Chief Legal & Strategy Officer, Corporate Secretary |
| Bill Clark | | 51 | | Chief People Officer |
David Cutler | | 55 | | Chief Technology Officer |
Ana Moeddel | | 45 | | Chief Merchandising and Managed Care Officer |
| Priti Patel | | 49 | | Head of Emerging Brands |
| Joe VanDette | | 48 | | Chief Brand and Marketing Officer |
Alex Wilkes has served as our Chief Executive Officer since August 2025, having joined National Vision as President in August 2024. Previously, Mr. Wilkes served as President, Americas at CooperVision, a global leader in contact lenses. Prior to this, he spent more than a decade at EssilorLuxottica, a leading global eyewear company, most recently as Senior Vice President and General Manager of Pearle Vision, where he spearheaded the expansion of one of the largest franchises in the vision care industry, and as Vice President of Vision Care for LensCrafters. Mr. Wilkes’ early career as a management consultant included roles with Accenture and Deloitte. Mr. Wilkes holds a B.A. in Economics from the University of Iowa.
Chris Laden has served as our Chief Financial Officer since March 2025. Before joining National Vision, Mr. Laden was Chief Financial Officer at Community Veterinary Partners, a community of veterinary hospitals, from January 2023 to March 2025. Prior to that, he served as the Chief Financial Officer of Women's Care, a leading women’s healthcare group in the U.S., from 2021 to 2022, and MD Now Urgent Care, the largest provider of urgent care services in Florida, from 2020-2021. Mr. Laden also brings extensive experience in the optical industry, having held key leadership roles at Pearle Vision, a division of EssilorLuxottica. Mr. Laden hold a B.S. in Business Administration from the University of Florida.
Mark Banner has served as President of America's Best since January 2025, and previously served as our Chief Stores Officer since July 2024. Prior to joining National Vision, Mr. Banner served as the Senior Vice President, Retail and Real Estate, of Sleep Number Corporation, where he led all sales, stores, operations, promotions & credit, digitally assisted retail, real estate and maintenance teams, and as Vice President of Strategic Integration at Signet Jewelers, in addition to various operations and managerial roles during his 18 years with Signet and its subsidiary, Sterling Jewelers. He holds a bachelor's degree in organizational studies from Saint Louis University and an M.B.A. from the Sloan School of Management at Massachusetts Institute of Technology.
Jared Brandman has served as our Chief Legal & Strategy Officer, and Corporate Secretary, since January 2025, having previously served as our Senior Vice President, General Counsel and Secretary since February 2019. Mr. Brandman joined National Vision in 2017 as Vice President, Assistant General Counsel and Assistant Secretary. Prior to joining the Company, Mr. Brandman was Securities Counsel for The Coca-Cola Company from 2010 to 2017. Mr. Brandman holds a B.A. degree in organizational studies from the University of Michigan and a J.D. degree from Emory University School of Law.
Bill Clark has served as our Chief People Officer since June 2019. Prior to joining National Vision, he served as Senior Vice President, Human Resources at Five Below, Inc. from October 2014 until May 2019. Prior to Five Below, Mr. Clark served as Vice President of Retail HR at Dollar General Corporation from April 2012 until October 2014 and spent 10 years in key executive leadership roles at Walmart and Sam’s Club, including as Vice President of Field Human Resources, Vice President of Talent Management and Vice President of HR Administration and Strategy. Mr. Clark holds both a B.S. degree in Biology and a Master of Science degree in College Teaching from Northeastern State University in Oklahoma.
David Cutler has served as our Chief Technology Officer since September 2025. Prior to joining National Vision, Mr. Cutler spent nearly two decades at Slalom, a business and technology consulting firm, where he most recently served as General Manager and Global Lead for Technology Enablement from 2016 to 2025. Prior to that, he was a Managing Director for Slalom from 2008 to 2016. From 2012-2016, Mr. Cutler co-founded and served as CEO of mLevel, a Slalom corporate learning company later acquired by Axonify. Mr. Cutler holds a B.S. in Computer Science and Electrical Engineering from Northwestern University.
Ana Moeddel has served as our Chief Merchandising and Managed Care Officer since September 2025. Prior to joining National Vision, she served as Chief Growth Officer of Community Veterinary Partners, a network of veterinary hospitals, from January 2022 to August 2025. From 2012 to 2022, Ms. Moeddel held various leadership roles at EssilorLuxottica, including Vice President of Operations and General Manager for TeamVision, where she helped define, design and implement a new business unit for the organization. She also held Vice President roles in Product, Pricing, Managed Care, Strategy, Real Estate, Ecommerce, Customer Experience and Business Development, across multiple Luxottica Retail Brands like Lenscrafters, Target Optical and others. Ms. Moeddel holds a bachelor’s degree in Economics and Computers from Academia de Studii Economice in Bucharest, Romania and an M.B.A. in Corporate Strategy from Stephen M. Ross School of Business at the University of Michigan.
Priti Patel, O.D. has served as Head of Emerging Brands, since August 2025. Having joined National Vision in 2010, Dr. Patel previously served as General Manager of Eyeglass World, Fred Meyer and Military Stores, from January 2025 to August 2025; Senior Vice President, Chief Medical Officer from June 2024 to January 2025; Senior Vice President, Healthcare Strategy and Development from February 2024 to June 2024; and Vice President of Physician Practice Management from March 2018 to June 2024. Dr. Patel also serves as President and CEO of our wholly-owned subsidiary, FirstSight Vision Services. Prior to joining National Vision, Dr. Patel was responsible for leading Walmart’s U.S. professional affairs and business relationships with over 3,000 optometrists. Dr. Patel holds a Bachelor of Science degree in Biology and Chemistry from the University of Alabama and a Doctor of Optometry degree from Nova Southeastern College of Optometry. Her residency was in Primary Care and Ocular Disease from Salus University.
Joe VanDette has served as our Chief Brand and Marketing Officer since January 2025, having joined National Vision in April 2022 as our Senior Vice President, Chief Marketing Officer. Previously, Mr. VanDette served as Chief Marketing & Digital Officer for Smart & Final in Commerce, California from May 2018 until March 2022. Prior to that, he served as Vice President of CRM, Analytics and Digital for Smart & Final from September 2014 until May 2018. From February 2005 until September 2014, he served in various management roles for Toys “R” Us in Wayne, New Jersey. Mr. VanDette holds a Bachelor of Science in Management Science & Information Systems from Pennsylvania State University.
Insider Trading Policy
We have adopted the National Vision Holdings, Inc. Securities Trading Policy governing the purchase, sale and/or other dispositions of our securities by our directors, officers, employees or us, that we believe is reasonably designed to promote compliance with insider trading laws, rules and regulations and the Nasdaq listing standards. The foregoing summary of the Securities Holding and Trading Policy does not purport to be complete and is qualified in its entirety by reference to the full text of the Securities Trading Policy attached to this Annual Report as Exhibit 19.1 and incorporated herein by reference.
Other
The additional information required by this item will be included in our definitive proxy statement for the 2026 Annual Meeting of Stockholders and is incorporated herein by reference.
Item 11. Executive Compensation
The information required by this item will be included in our definitive proxy statement for the 2026 Annual Meeting of Stockholders and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this item will be included in our definitive proxy statement for the 2026 Annual Meeting of Stockholders and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this item will be included in our definitive proxy statement for the 2026 Annual Meeting of Stockholders and is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services
The information required by this item will be included in our definitive proxy statement for the 2026 Annual Meeting of Stockholders and is incorporated herein by reference.
PART IV
Item 15. Exhibits and Financial Statement Schedules
The following documents are filed as a part of this report:
| | | | | | | | | | | | | | |
| (1) Consolidated financial statements |
| | | | |
| | For the following consolidated financial information included herein, see Part II. Item 8.on Page 61 |
| | | | |
| | | | Page |
| | |
Consolidated Balance Sheets as of January 3, 2026 and December 28, 2024 | | 63 |
Consolidated Statements of Operations and Comprehensive (loss) income for the Fiscal years ended January 3, 2026, December 28, 2024, and December 30, 2023 | | 64 |
Consolidated Statements of Stockholders’ Equity for the Fiscal years ended January 3, 2026, December 28, 2024 and December 30, 2023 | | 65 |
Consolidated Statements of Cash Flows for the Fiscal years ended January 3, 2026, December 28, 2024 and December 30, 2023 | | 66 |
Notes to Consolidated Financial Statements | | 67 |
Schedule I – Condensed Financial Information of Registrant | | 98 |
| | | | |
| (2) Financial statement Schedule I as filed in Part II. Item 8. of this Form 10-K: |
| | | | |
| | Schedule I - Condensed financial information of the Registrant | | |
| | All other financial schedules have been omitted because the required information is not presented in amounts sufficient to require submission of the schedule, or because the information required is included in the Consolidated Financial Statements, including notes thereto. | | |
| | | | |
| (3) Exhibits: |
| | | | |
| | The exhibits listed in the accompanying Exhibit Index attached hereto are filed or incorporated by reference into this Form 10-K. |
Exhibit Index
| | | | | | | | |
| Exhibit No. | | Exhibit Description |
3.1 | | Third Amended and Restated Certificate of Incorporation of National Vision Holdings, Inc. - incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 10, 2021 |
3.2 | | Fourth Amended and Restated Bylaws of National Vision Holdings, Inc. - incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on December 12, 2023 |
4.1 | | Description of Securities of the Registrant - incorporated herein by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K filed on February 28, 2022 |
10.1 | | Second Joinder and Restatement Agreement, dated as of June 13, 2023, including as Exhibit A thereto, to the Second Amended and Restated Credit Agreement, by and among Nautilus Acquisition Holdings, Inc., National Vision, Inc., certain subsidiaries of National Vision, Inc., as guarantors, Bank of America, N.A., as Administrative Agent and the Collateral Agent, and the lenders from time to time party thereto - incorporated therein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 20, 2023 |
10.2 | | Joinder Agreement, dated as of August 9, 2024, among Nautilus Acquisition Holdings, Inc., National Vision, Inc., the other credit parties party thereto, the lenders party thereto and Bank of America, N.A., as administrative agent and collateral agent- incorporated therein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 9, 2024 |
10.3 | | First Lien Guarantee, dated as of March 13, 2014, by the guarantors party thereto - incorporated herein by reference to Exhibit 10.6 to the Company’s Form S-1 Registration Statement filed on September 29, 2017 |
10.4 | | First Lien Security Agreement, dated as of March 13, 2014, among Nautilus Acquisition Holdings, Inc., Nautilus Merger Sub, Inc., Vision Holdings Corp., National Vision, Inc., subsidiary grantors party thereto, Goldman Sachs Bank USA, as collateral agent - incorporated herein by reference to Exhibit 10.7 to the Company’s Form S-1 Registration Statement filed on September 29, 2017 |
10.5 | | First Lien Pledge Agreement, dated as of March 13, 2014, among Nautilus Acquisition Holdings, Inc., Nautilus Merger Sub, Inc., Vision Holdings Corp., National Vision, Inc. subsidiary pledgors party thereto, Goldman Sachs Bank USA, as collateral agent - incorporated herein by reference to Exhibit 10.8 to the Company’s Form S-1 Registration Statement filed on September 29, 2017 |
10.6† | | National Vision Holdings, Inc. Amended and Restated 2017 Omnibus Incentive Plan - incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on June 13, 2024 |
10.7† | | Form of Stock Option Agreement under the 2017 Omnibus Incentive Plan, as adopted February 2019 - incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on May 9, 2019 |
10.8† | | Form of Restricted Stock Unit Agreement for Non-Employee Directors under the 2017 Omnibus Incentive Plan, as adopted June 15, 2022 – incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on August 11, 2022 |
10.9† | | Form of Restricted Stock Unit Agreement under the 2017 Omnibus Incentive Plan, as adopted February 12, 2024 – incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on May 8, 2024 |
10.10† | | Form of Performance Stock Unit Agreement under the 2017 Omnibus Incentive Plan, as adopted February 12, 2024– incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on May 8, 2024 |
10.11† | | 2014 Stock Incentive Plan for Key Employees of National Vision Holdings, Inc. (formerly known as Nautilus Parent, Inc.) and its Subsidiaries - incorporated herein by reference to Exhibit 10.16 to the Company’s Form S-1 Registration Statement filed on September 29, 2017 |
10.12† | | Amendment No. 1 to the 2014 Stock Incentive Plan for Key Employees of National Vision Holdings, Inc. (formerly known as Nautilus Parent, Inc.) and its Subsidiaries - incorporated herein by reference to Exhibit 10.17 to the Company’s Form S-1 Registration Statement filed on September 29, 2017 |
10.13† | | Amendment No. 2 to the 2014 Stock Incentive Plan for Key Employees of National Vision Holdings, Inc. (formerly known as Nautilus Parent, Inc.) and its Subsidiaries - incorporated herein by reference to Exhibit 10.18 to the Company’s Form S-1 Registration Statement filed on September 29, 2017 |
10.14† | | Form of Stock Option Agreement under the 2014 Stock Incentive Plan for Key Employees of National Vision Holdings, Inc. (formerly known as Nautilus Parent, Inc.) and its Subsidiaries - incorporated herein by reference to Exhibit 10.19 to the Company’s Form S-1 Registration Statement filed on September 29, 2017 |
10.15† | | Form of Director Indemnification Agreement - incorporated herein by reference to Exhibit 10.36 to the Company’s Amendment No. 2 to Form S-1 Registration Statement filed on October 16, 2017 |
10.16† | | Form of Management Stockholder’s Agreement - incorporated herein by reference to Exhibit 10.20 to the Company’s Form S-1 Registration Statement filed on September 29, 2017 |
| | | | | | | | |
10.17† | | National Vision Holdings, Inc. Executive Severance Plan - incorporated by reference to Exhibit 10.1 filed to the Company’s Current Report on Form 8-K filed on December 18, 2018 |
10.18‡ | | Letter Agreement between National Vision, Inc. and Essilor of America, Inc., dated as of November 12, 2018 - incorporated herein by reference to Exhibit 10.36 to the Company’s Form 10-K filed on February 27, 2019 |
10.19‡ | | First Amendment to the Direct Lens Letter Agreement, dated July 19, 2022, by and between Essilor of America, Inc. and National Vision, Inc. - incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 25, 2022 |
10.20‡ | | Second Amendment to the Direct Lens Letter Agreement, dated November 8, 2023, by and between Essilor of America, Inc. and National Vision, Inc. |
10.21‡ | | Third Amendment to the Direct Lens Letter Agreement, dated December 13, 2025, by and between Essilor of America, Inc. and National Vision, Inc. - incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 16, 2025 |
10.22‡ | | Cooperation Agreement, dated March 17, 2025, by and between National Vision Holdings, Inc. and Engine Capital, L.P. - incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 17, 2025 |
10.23† | | Transition and Separation Agreement, dated February 25, 2025, by and between National Vision, Inc. and Melissa Rasmussen - incorporated herein by reference to Exhibit 10.2 to the Company’s Form 10-Q filed on May 8, 2025 |
10.24† | | Form of Performance Stock Unit Agreement under the 2017 Omnibus Incentive Plan, as adopted March 5, 2025 - incorporated herein by reference to Exhibit 10.3 to the Company’s Form 10-Q filed on May 8, 2025 |
10.25† | | Executive Chair Agreement, dated April 28, 2025, by and between National Vision Holdings, Inc. and L. Reade Fahs - incorporated herein by reference to Exhibit 10.1 to the Company’s Form 10-Q filed on August 7, 2025 |
19.1 | | National Vision Holdings, Inc. Securities Trading Policy – incorporated herein by reference to Exhibit 19.1 to the Company’s Annual Report on Form 10-K filed on February 26, 2025. |
21.1 | | Subsidiaries of National Vision Holdings, Inc. |
23.1 | | Consent of Deloitte & Touche LLP |
31.1 | | Certification of Periodic Report by Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2 | | Certification of Periodic Report by Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002 |
32.1 | | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith) |
32.2 | | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith) |
97.1 | | Incentive Compensation Clawback Policy – incorporated herein by reference to Exhibit 97.1 to the Company’s Annual Report on Form 10-K filed February 27, 2024 |
| 101.INS | | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within Inline XBRL document |
| 101.SCH | | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | | The cover page of the Company’s Annual Report on Form 10-K for the year ended January 3, 2026, formatted in Inline XBRL (included within the Exhibit 101 attachments) |
____________
(†)Identifies exhibits that consist of a management contract or compensatory plan or arrangement.
(‡) Portions of this exhibit have been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because such information is (i) not material and (ii) the type of information that the registrant treats as private or confidential.
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | | | |
| | National Vision Holdings, Inc. |
| (Registrant) |
| |
| By: | /s/ Alex Wilkes |
| | Alex Wilkes |
| | Chief Executive Officer |
| | (Principal Executive Officer) |
| | |
| Date: | March 4, 2026 |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:
| | | | | | | | |
| Signature | Title | Date |
| | |
/s/ Alex Wilkes | Chief Executive Officer and Director | March 4, 2026 |
Alex Wilkes | (Principal Executive Officer) | |
| | |
/s/ Christopher Laden | Chief Financial Officer | March 4, 2026 |
| Christopher Laden | (Principal Financial and Accounting Officer) | |
| | |
| /s/ Jose Armario | Director | March 4, 2026 |
| Jose Armario | | |
| | |
/s/ L. Reade Fahs | Executive Chairman | March 4, 2026 |
L. Reade Fahs | | |
| | |
| /s/ Virginia A. Hepner | Director | March 4, 2026 |
| Virginia A. Hepner | | |
| | |
| /s/ Susan S. Johnson | Director | March 4, 2026 |
| Susan S. Johnson | | |
| | |
| /s/ Naomi Kelman | Director | March 4, 2026 |
| Naomi Kelman | | |
| | |
/s/ James M. McGrann | Director | March 4, 2026 |
James M. McGrann | | |
| | |
/s/ Michael J. Nicholson | Director | March 4, 2026 |
Michael J. Nicholson | | |
| | |
| /s/ Susan O’Farrell | Director | March 4, 2026 |
| Susan O’Farrell | | |
| | |
| /s/ D. Randolph Peeler | Lead Independent Director | March 4, 2026 |
| D. Randolph Peeler | | |
| | |
| /s/ Caitlin Zulla | Director | March 4, 2026 |
| Caitlin Zulla | | |